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Summary
The development of efficient biocatalysts for industry remains a challenge. Over the past
decade, the group of Professor Thomas R. Ward (University of Basel, Switzerland) has de-
veloped various artificial metalloenzymes for enantioselective catalysis. For this purpose, a
biotinylated organometallic catalyst is incorporated in (Strept)avidin, thereby providing a
hybrid catalyst that displays attractive features, reminiscent of both chemo- and biocatalysts.
Relying on knowledge acquired within the group, the main objective of my reasearch
was to rationally design and study a novel class of artificial metalloenzymes centered on an
alternative biomolecular scaffold: human Carbonic Anhydrase II (hCA II). The interest in
hCA II is motivated by the possibility to use this protein as a target, because it is overex-
pressed in various forms of cancers. This feature may be exploited to accumulate a catalytic
drug in cells requiring therapeutic action. A library of ruthenium piano-stool complex bear-
ing a sulfonamide anchor was designed in silico, synthesized and tested as organometallic
hCA II inhibitor.
An additional second recognition motif was subsequently introduced to further fine-tune
the binding affinity of the metal complex for the hCA II. In parallel with these synthetic
efforts, we developed widely applicable force field parameters amenable to molecular dynamics
simulations of hCA II-inhibitor interactions. These were experimentaly validated and used to
predict the affinity of fluorinated arylsulfonamide inhibitors for hCA II.
Based on computational results, a second generation of inhibitors with improved binding
affinities for wild-type hCA II (10 nM) were designed in silico. Coupled to a second recognition
element, which ensured precise localization of catalytic metals within the hCA II binding
pocket, a well-defined chiral environment was tailored to provide a favourable environment for
enantioselective catalysis. A chemogenetic optimization strategy (i.e. genetic variation of the
hCA II combined with chemical fine-tuning of the piano-stool moiety) allowed for improving
the catalytic performance of the artificial metalloenzyme for the reduction of prochiral imines.
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Summary
During my PhD thesis, I gained expertize in the in-silico design, synthesis and biophysi-
cal characterization of organometallic inhibitors and their interaction with a model protein:
human Carbonic Anhydrase II. The multidisciplinary environment provided in the group of
Professor Thomas R. Ward gave me a unique opportunity to collaborate on a daily basis with
molecular biologists, computational chemists, protein crystallographers etc.
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Generalities
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Il est bon de savoir que l’utopie n’est jamais rien
d’autre que la réalité de demain et que la réalité
d’aujourd’hui était l’utopie d’hier.
Le Corbusier 1
Introduction
1.1 Preamble
Enzymes are involved in most chemical transformations in Nature. [1] Due to their high ar-
chitectural complexity, folded polypeptides are able to perform a variety of complex tasks.
Moreover, enzymes containing metallic ion cofactors in their active sites possess the ability
to perform complex biological transformations (e.g. photosynthesis, respiration, water oxi-
dation, molecular oxygen reduction and nitrogen fixation, etc.). Such natural biocatalysts
have been studied and improved for the purpose of industrial synthesis over the past 30 years.
Nowadays, biocatalytic steps using fine-tuned biological scaffolds are implemented in indus-
try in order to synthesize complex molecules, e.g. advanced pharmaceutical or insecticide
intermediates. [2–4] For this purpose, (bio)chemists have worked on genetic optimization of
enzymes in order to reach high chemo-, regio- and stereoselective biotransformations under
environmentally friendly conditions. [5,6]
1.2 Introduction to catalysis
Catalysis plays an important role in green technologies and is one of the most important
chemical tools. Its continued development will certainly contribute in the future to solve
important energy and environmental challenges. [7] Historically, in 1836, Berzelius and other
3
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scientists observed that certain substances added to (or coming into contact with) other com-
pounds were able to accelerate the transformation of those compounds. In 1909, Ostwald
was awarded the Nobel Prize in Chemistry for his work on catalysis. His search led him to a
contemporary definition of catalysis: [8] catalysis (from Greek katalusis: dissolution) is a phe-
nomenon by which a substance, called a catalyst, modifies the reaction profile of a reaction
without itself undergoing any permanent chemical change, i.e. it must be regenerated at the
end of the reaction. It should be noted that the catalyst participates in a reaction by pro-
viding an alternative reaction mechanism involving various transition states (Figure 1.1, red
line) and decreasing the energy of activation (∆G ‡
cat
<∆G ‡
uncat
), although the thermodynamic
equilibrium (∆G
r
) of the reaction is not altered. [9]
E
ne
rg
y
Reactants
+ Catalyst
Reaction coordinate
Products
+ Catalyst
∆G ‡
uncat
∆G ‡
cat
∆G
r
Figure 1.1. Reaction profile of a catalyzed (red line) and uncatalyzed (black line) reaction.
In the early 20th century, the emphasis was placed on heterogeneous catalysis for the pro-
duction of ammonia. Since 1909, the Haber-Bosch process has been based on an inexpensive
iron catalyst and has been used by BASF for large scale production of ammonia. Chemists
have also focused on the synthesis of hydrocarbons from carbon monoxide (Fischer-Tropsch
process) which was used on a large scale during World War II to produce petrol. [7] In 1965,
Wilkinson revolutionized the world of catalysis presenting the first homogeneous catalyst used
for the hydrogenation of alkenes. [10] Since the 1970s, Rachel Carson’s book "Silent Spring"
4
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changed the perception of the chemical industry in the general population, and sparked an
environmental movement, which had a significant impact on government policies requiring
stricter regulation of produced chemical substances, especially pesticides. As a result, chemi-
cal companies have had to develop environmentally sustainable solutions, leading in Europe
to the REACH legislation in 2006 (Registration, Evaluation, Authorization and Restriction
of Chemicals) managed by the European Chemicals Agency. [11]
Finally, to illustrate the importance of catalysis in chemistry in recent years, several Nobel
Prizes have been awarded for breakthroughs in this field, e.g. for metal catalyzed asymmet-
ric transformations (2001), [12–14] the development of the metathesis reaction (2005), [15–17]
the studies of chemical processes on solid surfaces (2007), [18] and for metal-catalyzed cross
coupling reactions (2010). [19–21]
1.2.1 Catalyst performance
The successful application of a catalytic transformation depends on several key parameters
such as temperature, pH, solvents, etc. The activity of a catalyst is defined as the amount
of product produced per mole of catalyst in a defined time (TOF), while for biocatalysts the
specific activity is defined as the amount of product transformed per unit mass of enzyme per
unit of time. [7] For the study of artificial metalloenzymes, the theory developed by Michaelis-
Menten for enzyme kinetics was applied. The catalytic reactions were divided into two steps
(equation 1.1). First, the enzyme (E) and the substrate (S) associate in a rapid and reversible
step to form a complex ES (dissociation constant KS in equation 1.1). Then, the chemical
processes take place during the second step when the ES complex is converted into the product
(P ) and the enzyme (E) is recovered (rate constant k2). [22]
E + S
k1−−⇀↽−
k-1
ES
k2−→ E + P (1.1)
The simple Michaelis-Menten kinetic is described by equation 1.2, where KM can be
treated as the overall dissociation constant of all enzyme-bound species (if k2 << k-1). [23] In
5
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this model, it is also assumed that the binding steps are fast, thus k2 can be assimilated to
the overall catalytic rate constant kcat.
v =
[E]0 · kcat · [S]
KM + [S]
(1.2)
The catalytic rate constant of the enzyme kcat [1/s] and the dissociation constant KM
[1/M] can be determined experimentally (section 2.4.2). The kcat/KM constant determines
the specificity of the enzyme for competing substrates. In the ideal case for catalysis, an
enzyme shows high specific activity and should be subject to minimal substrate inhibition.
1.2.2 Chirality and the importance of enantioselectivity
A chiral (from Greek kheir : Hand) object is defined as an object that is not superposable
with its mirror image. [24] Chirality is an intrinsic propriety of matter. Nature contains many
different types of chiral molecules such as amino acids, carbohydrates, lipids or DNA, which
are essential building blocks for all organisms.
Chiral technology has taken an important place in the fine chemicals and therapeutic in-
dustries, and it is expected that biocatalysts able to transform prochiral substrates to highly
enantiopure pharmaceutical intermediates will reach $354 million in 2013 ($198 million in
2006). [4] The two enantiomers present the same physical and chemical properties in an achi-
ral environment. However, because living systems are chiral, each of the enantiomers of a
chiral drug can behave very differently in vivo, and thus display different pharmacological
activities. [25] The importance of controlling drug chirality can be illustrated by thalidomide.
Thalidomide was used in racemic form for the treatment of morning sickness in pregnant
women in the 60s. While (R)-thalidomide (19) acts as a sedative, (S )-thalidomide (20)
induced fetus deformations because of its teratogenic properties (Scheme 1.1). [26]
Therefore, control of the enantioselectivity of catalytic reaction is crucial to enable the
production of the desired enantiomer. In addition, the synthesis of enantiopure compounds
catalysts reduces chemical waste produced during the production process. An enantiopure
6
1.2. Introduction to catalysis
Scheme 1.1. Structure of thalidomide. The two enantiomers of thalidomide display different biological ac-
tivites: the (R)-thalidomide is a sedative, while the (S)-thalidomide has teratogenic properties.
(R)-thalidomide (S)-thalidomide
mirror
NH
O
O
O
O
HN
O
O
O
O
N N
19 20
compound is in opposition to a racemate, which consists of equimolar amounts of both enan-
tiomers. The degree of enantiomeric enrichment of a non racemic mixture can be determined
by polarimetry, spectroscopy (NMR) or chromatographic techniques (GC, or HPLC). Enan-
tiomeric excess (ee) is defined as:
ee =
|([R]− [S])|
([R] + [S])
· 100 (1.3)
1.2.3 Homogeneous asymmetric catalysis
In 1966, Wilkinson and Osborn reported the first generation of homogeneous hydrogena-
tion catalysts based on a rhodium complex (21, Scheme 1.2). [10] To induce a higher degree
of stereoselectivity in asymmetric catalysis, Kagan and Dang proposed to use a bidentate
ligand. This ligand was accessible from the natural product, l-(+)-tartaric acid. [27] This
pioneering work was extended by Knowles and co-workers, [28] whereby a rhodium complex
bearing enantiopure phosphorus ligands was reported for the asymmetric hydrogenation of
dehydro amino acids. The synthesis of l-DOPA was achieved in high ee (94 %) with the
enantiopure biphosphane ligand DIPAMP (22, Scheme 1.2). [12] l-DOPA is used as drug for
the treatment of Parkinson’s disease.
During the past decade, asymmetric catalysis has been one of the most active research
fields in chemistry. [29] Numerous enantiopure catalysts have been reported in literature, but
only a few of them, the so-called “privileged chiral catalysts”, present good enantioselectivity
over a wide range of transformations and bear ligands presented in Scheme 1.3. [30] However,
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Scheme 1.2. Wilkinson’s catalyst 21 ([RhCl(PPh3)]) for hydrogenation of functionalized olefins and DIPAMP
enantiopure ligand (22) used for asymmetric hydrogenation of dehydro amino acids.
P
PH3CO
OCH3Rh
Cl
Ph3P
PPh3
PPh3
21 22
rational modifications of these ligands (i.e. the first coordination sphere) in order to improve
the reaction selectivity remain a very challenging task for chemists. Indeed numerous inter-
actions such as weak and non-bonding contacts with solvent, buffer, salts can influence the
selectivity of the reaction. [31] It is noteworthy that a difference in energy of 2 kcal/mol in the
transition state energies results in an enantiomeric excess of 95%.
Scheme 1.3. Examples of ligands used for the synthesis of “privileged chiral catalysts”.
X
X
X=OH, BINOL
X=PPh2, BINAP
P P
MeDuPhos
PPh2Fe
PCy2
Josiphos
N
O
Me Me
t-Bu
N
O
t-Bu
Bis(oxazoline)
OH
N
t-Bu
t-Bu
N
HO
H H
t-Bu
t-Bu
Salen
PPh2 N
O
iPr
Phosphinooxazoline 
(PHOX)
1.2.4 Enzymatic catalysis
Compared to homogeneous catalysts, enzymes provide an environmentally friendly route to
synthesize enantiopure chemicals. To illustrate the advantages of enzyme catalysis over classi-
cal synthetic methods, development of the industrial synthesis of sitagliptin, which is used for
the treatment of type 2 diabetes, is of particular interest. [32] Indeed, using traditional cata-
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lysts for the industrial synthesis of pharmaceuticals, many problems arise such as the removal
of metal traces from the product or the high hydrogen pressure required for the asymmetric
hydrogenation of the enamine intermediate product 23 (Scheme 1.4, Solvias-Merck path-
way). [33] Therefore synthesis of pharmaceuticals using “fine-tuned” enzymes presents many
advantages. Coupled to in silico design, a directed evolution strategy used by Codexis and
Merck led to the development of an (R)-selective transaminase for the synthesis of compound
24. [34] The enzymatic process can be achieved at high substrate concentration (220 g · L−1,
substrate/catalyst 2600 mol/mol, and TOF 163 h−1) and in the presence of DMSO (50%).
β-Ketoamide (25) was converted to sitagliptin in 92% yield and >99.95% ee (Scheme 1.4)
under mild conditions (40 ◦C). Compared to the rhodium catalyzed reaction, sitagliptin was
obtained in a 13% increased overall yield and with an improved enantiomeric excess.
Scheme 1.4. Synthesis of enantiopure sitagliptin (24) using an homogeneous (Solvias-Merck) or an enzymatic
(Codexis-Merck) route.
N
NN
N
O O
F3C
F
F
F
Mutant Transaminase
NH4OAc
N
NN
N
O NH3
F3C
F
F
F
N
NN
N
O NH2
F3C
F
F
F
N
NN
N
O NH2
F3C
F
F
F
Solvias - M
erck
Co
de
xi
s 
- M
er
ck
2. carbon treatmant
    to remove Rh
1. Rh(t-Bu-Josiphos)
    H2 (250 psi)
i-PrNH2
> 99.95 % ee
95 % ee
25
23
24
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1.2.5 Artificial metalloenzymes
Considering the number of chemical transformations catalyzed by transition metals which
have not been observed to occur enzymatically and the ability of macromolecules to selec-
tively discriminate substrates, the Ward group and others reasoned that a hybrid catalyst may
combine some of the most attractive features of homogeneous and enzymatic catalysts previ-
ously presented. [32,35] Since the 70’s, chemists have designed many hybrid catalyst, so called
“artificial metalloenzymes“, that exhibit high selectivity for the synthesis of enantiomerically
enriched compounds in aqueous media (Section 1.3). The artificial metalloenzyme concept
dates back to 1978 when Whitesides and Wilson postulated:
“A globular protein modified by introduction of a catalytically active metal at an
appropriate site could, in principle, provide an exceptionally well-defined steric en-
vironment around that metal, and should do so for considerably smaller effort than
would be required to construct a synthetic substance of comparable stereochemical
complexity.” [36]
They proved this theory by incorporation of biotinylated metal catalysts into avidin,
achieving conversion of α-acetamidoacrylic acid in 44% ee. Whitesides and co-workers also
proposed a hybrid catalyst based on hCA II for the hydrogenation of α-acetamidoacrylic
acid. However, only a small amount of hydrogenated product was observed (without any
enantiomeric excess) and it was concluded that hCA II was a severe poison for the catalytic
reaction. [37]
10
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1.3 Artificial metalloenzymes: Background
The pioneering work of Whitesides and Wilson was based on incorporating one biotinylated
phosphine-rhodium(I) complex within avidin, for the hydrogenation of α-acetamidoacrylic
acid, yielding a modest chiral induction (44% ee). [36] In more general terms, the development
of a hybrid catalyst results from the combination of a biomolecular scaffold (e.g. proteins, [38,39]
DNA [40] or peptides [41]) with an active catalytic moiety. To ensure the precise localization of
the organometallic catalyst precursor embedded within the biomolecular host, a very strong
guest⊂host interaction (e.g., a protein inhibitor) is required (anchor, Figure 1.2).
x
x
*
host protein
anchor
spacer
M
Figure 1.2. General scheme of an artificial metalloenzyme using supramolecular anchoring strategy to incor-
porate a catalytically active metal within the host protein. Chemical optimization can be achieved either
by modification of the spacer or the metal ligand scaffold (x). Site-directed mutagenesis allows a genetic
optimization of the protein near the catalytic metal center (*) to further optimize the enantioselectivity.
To create new artificial metalloenzymes, two different approaches can be envisaged:
a catalytically active metal center within a biomolecular scaffold can be created from scratch,
the so-called de novo design, [42,43] or, alternatively, by modification of an existing natural
enzyme or protein. [44] The design of an artificial metalloenzyme based on a wild-type protein
has many advantages compared to the de novo approach. [45] Indeed, our understanding of
protein folding is still lacunar for the purpose of designing complex proteins with well-defined
catalytic sites. This problem can be overcome with the recent advances in computational
protein design. [46] However, this approach requires extensive efforts and is limited to sim-
ple catalytic transformations. [47] Interestingly, Pecoraro and co-workers recently reported
a de novo designed metalloprotein (Figure 1.3a) able to hydrolyse p-nitrophenyl acetate
(kcat/Km ≈ 2500 M−1 s−1) with an efficiency only ∼100-fold lower than wild-type human
Carbonic Anhydrase II (Figure 1.3b and Section 1.3.3). [48]
11
Chapter 1. Introduction
(a) (b)
Figure 1.3. a) de novo-designed scaffold (PDB code 3PBJ) with a Zn binding site (gray) used as catalytic
metal and a Hg binding site (brown) for structural stabilization, b) native protein scaffold: human Carbonic
Anhydrase II (PDB code 1G54).
1.3.1 General anchoring strategies within macromolecular scaffolds
Currently, different strategies are exploited for the localization of an organometallic moiety
within macromolecular scaffolds: dative, covalent or supramolecular anchoring (Figure 1.4) [49]
or a combination of them. [50]
X M
(a)
MS
(b)
M
(c)
Figure 1.4. Anchoring strategies for the localization of a catalyst precursor within macromolecular scaffolds
(blue): a) dative, b) covalent, and c) supramolecular. M denotes the catalytically active transition metal and
the chemically synthesized first coordination sphere is highlighted in orange. [45]
The dative anchoring strategy relies on the coordination of a catalytic metal by chemical
functionalities present directly on the surface of the macromolecular scaffold or an inhibitor
which coordinate to the metal present within a protein pocket, e.g. sulfonamide ligands that
bind hCA II zinc (Section 1.3.4). [51–53] In the case of hCA II, this anchoring technique was
12
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previously used by Kazlauskas et al. to modify the catalytic activity of the protein. For this
purpose, Zn II was substituted by Mn II to obtain a novel peroxidase able to enantioselectively
epoxidize olefins conjugated to an aromatic or aliphatic carbon (Figure 1.5b). [54–56] Moreover,
metal ions can also be accommodated into specific binding sites of certain non-metalloproteins
to obtain catalytically active metalloproteins. [57,58] In the further development, as opposed to
simply exchanging the bound metal ion or binding metal at exposed coordinating residues,
Ward et al. identified through a PDB search, metal-free two-histidines one-carboxylate bind-
ing motifs in proteins amenable to facial coordination of metals. [59]
(a) (b)
Figure 1.5. a) Native hCA II with Zn II as active metal (PDB code 1G52) b) Modified hCA II with Mn II as
active metal (PDB code 1RZD).
The covalent approach [6,60–63] commonly uses a cysteine as an anchoring residue, a method
proposed by Kaiser et al. [64] This method allows for precise localization of a metal complex
within or on the surface of a biological scaffold. Recently, Häussinger et al. used this strategy
to localize lanthanide tags on protein surfaces for solution NMR studies (Section 1.3.4). [65]
The supramolecular anchoring method preferred in the Ward group and by others has
been investigated. [66,67] In this approach, a strong and highly specific non-covalent interac-
tion between a biomacromolecule and a small molecule derived from specific ligand/inhibitor
structures is observed (Section 1.3.2). This technique allows for easy chemical optimization
of metal ligand features (first coordination sphere) and avoids uncertainties concerning the
localization of the metal within the macromolecular scaffold. [68]
13
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1.3.2 Previous technology: Biotin-streptavidin
The first generation of metalloenzymes developed in the Ward group relied on the high affin-
ity of (+)-biotin (also known as vitamin H) towards two proteins, streptavidin and avidin.
To introduce the catalytic metal within the host protein, the biotin, used as anchor, is deriva-
tized through the valeric acid side chain. Despite the modifications brought to the valeric
acid side chain of biotin, the affinity towards the host protein remains high. [69] This artificial
metalloenzyme remains remarkably stable even under harsh catalytic conditions, e.g. 55 ◦C
and mixture of water and organic solvents. [70]
As previously mentioned, the first example of a hybrid catalyst based on biotin-avidin
technology was developed by Whitesides and Wilson in 1978. [36] A biotinylated Wilkinson’s
catalyst was embedded into avidin to obtain 44% ee for the reduction of α-acetamidoacrylic
acid. Subsequently, rational chemogenetic modifications of the hybrid catalyst enabled the
Ward group to improve the enantioselectivity of the reaction up to 91% ee (R) as well as re-
versed of the enantioselectivity 75% ee (S ) for the reduction of 4’-bromoacetophenone. [71,72]
In contrast to the rational design strategy proposed by the Ward group, an alternative ap-
proach focused on directed evolution of hybrid catalysts was implemented by Reetz and co-
workers. [73] They were able to enhance or invert the selectivity for the transfer hydrogenation
of α-acetamidoacrylate. This Darwinian approach to create novel artificial metalloenzymes
faced, however, screening problems due to e.g. low protein expression levels in miniaturized
systems (96 well plates). Moreover, the metals are extremely sensitive to cellular debris and
the activity of the catalysts decrease if the protein is not adequately purified. [74] Compared to
the results obtained by chemogenetic optimization for the reduction of α-acetamidoacrylate,
the directed evolution strategy yielded only 65% ee (R) or 7% ee (S ) under optimized condi-
tions.
Having demonstrated the potential of artificial metalloenzymes for enantioselective trans-
formations of prochiral substrates, other catalytic systems have been successfully investigated
within the Ward group. [71,72] They focused on reactions for which the substrate does not bind
to the catalytic metal center in the transition state. [38] In such cases, the second coordination
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sphere is expected to have a strong influence on the enantioselectivity of the reaction. For this
purpose, asymmetric transfer hydrogenation, dihydroxylation, and sulfoxidation were stud-
ied. A summary of the different artificial metalloenzymes developed within the Ward group
is reported in Table 1.1.
Table 1.1. Catalytic reactions using artificial metalloenzymes implemented in the Ward group. [38,49]
Entry Reaction Type General catalytic conditions
1 Hydrogenation [75] H2O buffer, H2 (5 bar), r.t., 15 h
2 Ketone reduction [76,77] H2O buffer/DMF, formic acid (pH 6.25), 55
◦C, 64 h
3 Alcohol oxidation [78] H2O/DMF/acetone (5/1), TBHP
a , r.t., 90 h
4 Allylic substitution [72] H2O/DMSO (10/1), DMB
b , K2CO3, r.t., 16 h
5 Imine reduction [22] H2O buffer, sodium formate (pH 7.5), 5
◦C, 48 h
6 Olefin metathesis [79] H2O/DMSO (5/1), pH 7 or 4, 40
◦C, 16 h
7 Enantioselective Sulfoxidation [57] H2O buffer/DMF/EtOH, pH 2.2, r.t., 48 h
8 Enantioselective cis-dihydroxylation [58] H2O, K2CO3, r.t., 24 h
9 C-H activation [80] H2O buffer/MeOH, 23
◦C, 72 h
a tert-butylhydroperoxide. b didodecyldimethylammonium bromide.
Nowadays, a major challenge in bioinorganic chemistry is the development of new artificial
metalloenzymes that catalyze in vivo the conversion of drug precursors into an active form to
treat diseases in a targeted manner. [32] Towards this goal, it may be possible to exploit proteins
that are overexpressed in certain forms of disease in order to accumulate active catalysts within
the cells that require therapeutic action. During our research, a biological scaffold candidate
with the required characteristics drew our attention: human Carbonic Anhydrase II. [53]
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1.3.3 Human Carbonic Anhydrase II, a protein scaffold for the creation of
artificial metalloenzymes
Carbonic Anhydrase isozymes are metalloenzymes that catalyze the reversible hydration of
carbon dioxide into bicarbonate with remarkable efficiency (kcat/KM ≈ 1.5 × 108 M−1 s−1,
Equation 1.4). These are critical enzymes and any deficiency or mutation can result in diseases
such glaucoma, ureagenesis and lipogenesis. [81] Additionally, overexpression of hCA IX and
hCA XII are found in certain forms of cancers [82] and inhibitors have been designed for
diagnosis and therapy. [83,84]
CO2 +H2O
hCA II
−−−−⇀↽ − HCO
−
3 +H
+ (1.4)
Wild-type human Carbonic Anhydrase II (hCA II, EC 4.2.1.1, M [g·mol−1] = 29227, pI 7.4,
259 amino acids) is a globular protein, see Table 2.1. [53] The active site of hCA II comprises
a catalytic ZnII ion coordinated tetrahedrally to three histidines (His94, His96 and His119,
Figure 1.6a) and a solvent molecule. The Zn-cofactor is located at the base of a funnel-
shaped cavity measuring roughly 15 Å in diameter at its mouth and 15 Å deep. [85] This
cavity is characterized by three major domains: (i) the primary coordination sphere around
the Zn-cofactor (gray, Figure 1.6b); (ii) the primary and secondary hydrophobic faces involved
in secondary recognition of inhibitors (yellow, Figure 1.6b); and (iii) the hydrophilic face that
is located around His64 responsible for the catalytic activity of the protein (blue, Figure 1.6b).
Table 1.2. hCA II structural stability parameters.
Parameters
Temperature [86,87] up to 55 ◦C
pH [53] 5.7—8.4
Metal [88] low exchange rate
Organic solvent [89] less than 20 % (DMSO)
Human Carbonic Anhydrase II is particularly attractive for the development of a new
artificial metalloenzyme for many reasons: (i) hCA II is a monomeric protein with a large
16
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(a) (b)
Figure 1.6. a) Zinc atom coordinated with three histidine residues (His94, His96 and His119) and the histidine
cluster involved in the proton-shutting process for reversible hydration of carbon dioxide (His64, His4, His3,
His17, His15 and His10) b) hCA II surface rendering showing hydrophobic residues (yellow), polar residues
(blue) and Zn-cofactor (gray). [81]
binding pocket able to accommodate metal complexes; (ii) it is possible to apply computa-
tional design for rational tailoring of the active site to accommodate inhibitors compatible
with soft transition metals; [90,91] (iii) this monomeric protein is easy to overexpress in E. coli
and to purify; [85] (iv) since hCA II also has promiscuous esterase activity, it is possible to mon-
itor the rate of p-nitrophenylacetate hydrolysis, allowing inhibition to be monitored (Section
1.3.4); (v) the X-ray determination of hCA II structure is well established (Section 2.3.3) [53]
and NMR may provide the structure of the protein-inhibitor complex in solution (Section
2.3.4). [65]
1.3.4 Human Carbonic Anhydrase II anchoring strategy
In the spirit of Fischer’s lock-and-key model, [92] molecules analogous to the transition state
of carbon dioxide (CO2) hydration (Figure 1.7a and c) should be effective hCA II ligands.
[93]
Based on this consideration, sulfonamide derivatives were proposed in 1940 by Keilen et al.
as specific inhibitors of human Carbonic Anhydrase isozymes. [94]
The sulfonamide nitrogen anion coordinates to the Zn II cofactor (Figure 1.7b), and two
hydrogen bonds are established with the protein scaffold. The first of those is between the Oγ
of Thr199 and the sulfonamide NH, and the second between the sulfonamide oxygen and the
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Figure 1.7. Diagram comparing a) carbon dioxide (putative interactions), b) an arylsulfonamide, and c)
bicarbonate bound to the active site of hCA II. The arylsulfonamide can be viewed as a transition state
analogue of the hydratase reaction. [53]
NH of the Thr199 backbone. Moreover, the second sulfonamide oxygen coordinates weakly
to Zn II. To complete this sulfonamide interaction, aromatic moieties were found to interact
significantly with the primary hydrophobic faces inside the funnel-shaped cavity (Figure 1.6b,
yellow surface). [95] In the case of benzenesulfonamide (Table 1.3 entry 1, Kd = 200–1500 nM)
the bonds to the Zn II cofactor represent approximatively 65% of the free energy of binding,
while hydrogen bonds and hydrophobic interaction represent approximatively 10% and 25%,
respectively. [96] To further increase the binding affinity between ligands and protein, secondary
recognition elements may be exploited.
Jain et al. reported that para-substituted benzenesulfonamides bearing benzyl moieties
(Table 1.3, entries 2 to 4) can interact with the hydrophobic upper rim of the funnel-shaped
cavity of hCA II. Indeed N -(4-sulfamylbenzoyl)benzylamine establishes an edge-to-face con-
tact with Phe131, and the affinity observed for hCA II is approximatively 100-fold higher
(Kd = 2.1 nM) [97] than for the corresponding non-substitued para-carboxybenzensulfonamide
(Kd = 270 nM). [98] In the same spirit, Whitesides and co-workers computationally designed
para-benzenesulfonamide derivatives able to interact bivalently with the protein scaffold (Fig-
ure 1.8b). In 2002, they reported an inhibitor with the highest known affinity for hCA II
(Kd ≈ 30 pM, Table 1.3 entry 4). [99] To further increase the affinity of inhibitors, Fierke
introduced fluorine substituents on the molecular scaffold. Another benefit of fluorine is the
metabolic stabilization of inhibitors when used as drugs. (Table 1.3, entry 2). [100,101]
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Table 1.3. hCA II dissociation constants (Kd) of selected ligands.
Entry Structure Dissociation
constant (nM)
1 200-1500 [102,103]
2 2.1 [104]
3 0.29 [100]
4 0.03 [99]
S
O O
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H
H
N
OH
O
O
O
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∆GiZn-N= -9 to -8
∆GiH-bonds= -2 to -1
∆Giring= -4 to -3
Glu106
Thr199
(a) (b)
Figure 1.8. a) Estimated free energies between the benzenesulfonamide anion and hCA II (in kcal·mol−1) [96]
b) hCA II complexed with (R)-N -(3-indol-1-yl-2-methyl-propyl)-4-sulfamoyl-benzamide, the strongest in-
hibitor reported to date (PDB: 1IF7). [99] Pro202, Val135, and Phe131 of the hydrophobic surface as second
recognition element.
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There are several convenient assays to quantify interactions (Kd orKi) between hCA II and
inhibitors. An exhaustive review was published by Whitesides and co-workers [53] and the
four most popular are reported in Table 1.4. Two of the most commonly used methods
to determine affinities (Section 2.3.2 for results) between hCA II and inhibitors are: i) the
hydrolysis of p-nitrophenylacetate, which can be determined by measuring the appearance of
nitrophenolate (λmax 348 nm). This method is most appropriate for weak inhibitors, whereby
the hydrolysis can still be measured over a reasonable time frame; ii) competition experiments
with dansylamide (DNSA). This is best achieved by determining the fluorescence signal caused
by bound DNSA (unbound DNSA does not fluoresce). This method is most appropriate for
strong inhibitors.
ITC offers perhaps the widest Kd window (Kd = 10−3− 10−9 M) between hCA II and its
inhibitors. Unfortunately, the use of metal complexes as inhibitors leads to the observation of
multiple events, which we assumed to be caused by interactions with residues on the surface
of the protein. This renders the interpretation of measurements difficult. [105]
Table 1.4. Techniques used to determine affinities of inhibitors for hCA II.
Technique Observable Detectable Kd (M)
Dansylamide competition [106–108] bound dansylamide 10−4 − 10−8
Spectrophotometry [85,109] hydrolysis of p-nitrophenylacetate 10−4 − 10−7
CD [110] aromatic residues 10−3 − 10−5
ITC [53] heat change during binding 10−3 − 10−9
In 1996 Spicer et al. reported the first 2D NMR assignment of hCA II but the three-
dimensional (3D) hCA II structure determination in solution remains challenging because of
the size of hCA II (29 kD). [53,111] Nevertheless, recent advances in NMR spectroscopy show
that pseudocontact chemical shift provide information about long distance influences due
to their 1/r3 dependences (up to ∼50 Å, hCA II dimension 46 · 56 Å). For this purpose,
methylated DOTA (DOTA-M8, Figure 1.9) is complexed with a lanthanide, and this macro-
20
1.3. Artificial metalloenzymes: Background
molecule is covalently linked to the surface of a protein, as demonstrated by Häussinger and
co-workers. [65] Moreover, this technique allows the precise location of the inhibitors/complexes
inside the funnel-shaped cavity, in solution.
M
N
N
N
N
H
NO
O
O
OO
O
O
S
Figure 1.9. Structure of DOTA-M8. [65] M denotes a lanthanide ion.
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1.4 Catalytic system: imine reduction by transfer hydrogenation
Asymmetric reduction of compounds with C=N bonds is relatively underdeveloped although
enantiomerically pure amines play an important role in the pharmaceutical, agrochemical,
and chemical industries. [112] In the last 30 years, organometallic catalysts were developed
to address this problem. Imine reduction by transfer hydrogenation is commonly carried
out using isopropanol, formic acid or formate salts as the hydrogen source and most widely
employed catalytic metals are ruthenium, rhodium, and iridium. [113,114]
The first examples of asymmetric transfer hydrogenation were reported in the 1970s from
the groups of Ohkubo [115] and Sinou [116] who used Wilkinson’s based catalyst for the reduc-
tion of prochiral ketones. They were able to induce enantioselectivity relying on enantiopure
ligands (monosaccharides) bound to catalytically active metals. In 1981, Grigg et al. proposed
C=N transfer hydrogenation, using Wilkinson’s catalyst, [RhCl[P(C6H5)3]3], in isopropanol
to reduce aldimines into secondary amines. [117] Six years later, in 1987, a ruthenium cata-
lyst, Ru3(CO)12, for transfer hydrogenation of imines was reported by Jones et al.
[118] who
successfully used it for the reduction of benzylideneaniline. Nevertheless, the efficiency (con-
version and enantioselectivity) of such catalysts remained generally low. The 1990’s brought
improved catalysts including Shvo’s diruthenium catalyst (26) [119] and Noyori’s ruthenium
(II) based catalyst (27, Scheme 1.5). [120]
Scheme 1.5. Shvo (26) and Noyori (27) complexes used for transfer hydrogenation.
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The Shvo diruthenium complex has been extensively investigated by Bäckvall [121,122] and
Casey [123] as a transfer hydrogenation catalyst. Shvo’s catalyst was found to have high
turnover frequencies even at low loadings (0.3%) for the transfer hydrogenation of imines. Noy-
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ori’s ruthenium (II) based catalyst uses the N -p-tosyl-1,2-diphenylethylenediamine
(TsDPEN) enantiopure ligand previously developed for ketone reduction. [120] In addition, cat-
alysts bearing TsDPEN derivative ligands have been used for the reduction of a wide range of
substrates, such as C=O and C=N bonds, under mild conditions, i.e. room temperature and
no hydrogen gas, and provide excellent ee’s (up to 99%). [124] By using Noyori’s catalyst, cyclic
imines bearing alkyl or benzyl groups were enantioselectively reduced, and applied for the syn-
thesis of isoquinoline or β-carboline alkaloids. In 1996, Noyori published, as a model for the
asymmetric transfer hydrogenation of imines, the synthesis of salsolidine (quant., 95% (R),
(S,S )-Ru catalyst, Scheme 1.6). [125] For this purpose, formic acid/triethylamine azeotrope
was used as hydrogen source. The reactivity of the catalyst was much higher (>1000-fold)
for the imine reduction when compared to the ketone reduction. Moreover, Noyori high-
lighted the structural importance of the Ru(II) arene cap along with the sulfonamide moiety
(Scheme 1.6) for the successful enantioselective reduction of imines. [113] Carreira et al. recently
demonstrated that the iridium catalyst containing TsDPEN ligands bearing strongly electron
deficient sulfonamides (e.g. perfluorosulfonamide) have enhanced selectivity and reactivity
for the ketone reduction. [126] The first industrial application for imine reduction using an irid-
ium ferrocenyl diphosphine catalyst was announced in 1996 for the synthesis of the herbicide
(S )-metolachlor. [127]
Scheme 1.6. Asymmetric transfer hydrogenation of a cyclic imine.
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In the interest of developing environmentally friendly water soluble organometallic com-
plexes, Noyori’s ruthenium (II) based catalyst was modified to be water soluble. In 2006,
Deng et al. reported the first asymmetric transfer hydrogenation of cyclic imines and imini-
ums in water. Catalysis was performed with a water-soluble Ru(II)-catalyst and NaHCO2
as hydrogen source (Scheme 1.7). The observed ee’s were improved by addition of CTAB
(cetyltrimethylammonium), a surfactant which increased the solubility of the substrate, prod-
uct, and catalyst. [128,129] At the same time, different systems for transfer hydrogenation of
ketones and imines in water were reported from the labs of Ogo, [130,131] Renaud [132] and
Süss-Fink. [133] Many routes to increase the water solubility of organometallic complexes have
been reported (Scheme 1.7): i) by increasing the TsDPEN hydrophilicity (ligand 30); [128]
ii) the use of polymer-supported catalyst (ligand 31); [134] iii) incorporation of the catalyst
in a biomolecular scaffold; [135] and iv) use of other types of ligand, e.g. based on a pyridine
moiety (ligands 32, 33, 34 and 35). [130–133]
Scheme 1.7. Selected ligands for imine transfer hydrogenation.
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In 2005, Xiao et al. reported that, for asymmetric transfer hydrogenation, the pH of the
reaction solution affects the catalyst performance in the aqueous-phase. [134] The observed
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variations of enantioselectivity according to the pH may be explained by the protonation
of TsDPEN ligand under acidic conditions. [124] Depending on the nature of the aromatic
sulfonamide moieties, the pKa of the corresponding N-H group varies between 4.5 (Ar = C6F5)
and 7.6 (Ar = p-toluene). [136] The change in the sulfonamide protonation leads to an “on-
and-off” catalyst state observed by Xiao, as illustrated in Scheme 1.8. [137]
Scheme 1.8. Metal-TsDPEN ligand proposed states under acid (complex 36) or basic (complex 37) condi-
tions. L may be a water molecule. [124]
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Combining the fields of homogeneous and enzymatic catalysis, Ward et al. were able to
integrate known catalysts within a protein scaffold in order to render them water-soluble.
A novel artificial transfer hydrogenase for the enantioselective reduction of cyclic imines was
reported in 2011. [22] Imines were reduced under mild conditions (Scheme 1.9) using formate
as hydrogen source. Chemogenetic optimization of the hybrid catalyst resulted in a system
that yielded both enantiomers (S, 78% and R, 96 % ee) of salsolidine (38).
Scheme 1.9. Artificial transfer hydrogenase for the reduction of 1-methyl-6,7-dimethoxy-3,4-
dihydroisoquinoline into salsolidine based on biotin-streptavidin technology. [22]
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1.5 Catalyst optimization: biological and chemical diversity
To further enhance the activity and selectivity of hybrid catalysts, several methods have been
developed. [73,138–140] Directed evolution is one of the most powerful, and it involves the intro-
duction of random mutations into the genes, thus creating a library of mutant proteins. These
enzymes variants are screened for catalytic activity and selectivity, and the best candidates
taken forward to another round of random mutagenesis. In the case of hybrid catalysts, this
process turns out to be complicated as for the need to use purified (or semi-purified) protein
for screening.
Rational catalyst 
design
Catalyst 
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Analysis &
Optimization
Choice of
active catalyst
Choice of
chiral host
parallel synthesis 
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structure-activity
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X-ray & NMR
Computational 
chemistry
ee quantification
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Figure 1.10. Optimization of artificial metalloenzymes. [1]
To address this problem and to optimize hybrid catalysts, the chemogenetic approach, pre-
viously described by Ward and co-workers, was found to be the most suitable solution. [141,142]
As the name indicates, the chemogenetic approach relies on two distinct optimizations: i) ge-
netic modification of the protein scaffold, based on computational calculations and X-ray
structures. Particular attention is given to the active site of enzyme (<10 Å around the
catalytic metal center); [143,144] and ii) chemical fine-tuning of the catalytic moiety, to adjust
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the localization of the catalytic moiety inside the funnel-shaped cavity of the protein. These
combined techniques allow the design of a small collection of hybrid catalysts with improved
activity and selectivity. One advantage of this approach is that the chemogenetically opti-
mized library of hybrid catalysts is produced and screened on a relatively short time frame.
This operation can also be performed iteratively as shown in Figure 1.10 resulting in a
process which has been called “designed evolution”. [145]
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1.6 Research project
The objectives of this thesis are to strengthen and expand the concept of artificial metal-
loenzymes in the direction of developing new hybrid catalysts. Relying on the knowledge
acquired within the Ward group, human Carbonic Anhydrase II has been selected as a po-
tential biomolecular scaffold for the creation of artificial metalloenzymes.
With this goal in mind, three challenges were identified:
1. based on in silico docking and X-ray information, hCA II inhibitors that could poten-
tially act as bidentate ligands for piano stool complexes were designed, synthesized, and
characterized.
2. the most promising ligands were used to create and optimize an artificial transfer hy-
drogenase (ATHase) for the enantioselective reduction of imines.
3. these ATHases were characterized both structurally and in terms of catalytic perfor-
mances.
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La première vertu d’une pensée active sera donc de s’attacher
aux problèmes qui se posent et non pas à ceux que l’on sup-
pose.
D. de Rougemont
2
Results and discussion
The framework of the second chapter of this thesis is built around the development of a new,
artificial metalloenzyme capable of enantioselective catalysis, and based on human Carbonic
Anhydrase II scaffold (hCA II). For this purpose, several scientific fields, represented by
chemists, biologists and protein crystallographers, have joined forces. The discussion that
follows focuses particularly on issues related to the chemistry (i.e. synthesis, catalysis, ...) of
the project.
In the first section, the choice of a suitable catalytic system for the new protein is briefly
discussed (section 2.1). The preparation of different ligands and complexes previously designed
using computational tools are presented in sections 2.2.2, 2.2.5 and 2.2.1, respectively. Section
2.3 focuses on the interaction of the protein and the different inhibitors previously synthesized.
This is then followed by the analysis of the interaction between inhibitor and hCA II using
X-ray (section 2.3.3) and NMR (section 2.3.4) imaging. Finally, as an illustrative example
of an enantioselective catalytic reaction, the transfer hydrogenation of cyclic imines using
artificial metalloenzymes is presented and discussed in section 2.4.
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2.1 Suitable catalytic systems for hCA II
A number of recent reviews have introduced preparative methods for new artificial metal-
loenzymes. [1–3] In this context, and with the experience gained by the research group of Prof.
Ward in the field of hybrid catalysts, the first point to be addressed is the selection of potential
catalytic systems compatible with the new biomolecular scaffold, human Carbonic Anhydrase
II (hCA II).
Having chosen human Carbonic Anhydrase II as a biomolecular scaffold for the develop-
ment of a new, enantioselective artificial metalloenzyme, it is important to recall the various
constraints imposed by the protein scaffold, as summarized in Table 2.1.
Table 2.1. hCA II structural stability parameters.
Parameters
Temperature [4,5] up to 55 ◦C
pH [6] 5.7—8.4
Metal [7] low exchange rate
Organic solvent [8] less than 20 % (DMSO)
With these constraining parameters in mind, different catalytic systems suitable for the
host protein were selected: 1,4-addition, [9,10] imine reduction [11] (and/or reductive amina-
tion) and metathesis. [12] The advantage of using a bioorthogonal chemical reaction, such
as metathesis cross-coupling, is that it avoids any interfering reaction with the plethora of
functions present on the surface of hCA II. [12–14] Indeed, the 26 lysine residues found in
hCA II makes the use of ketone substrates difficult, due to the formation of imines by Schiff
base.
Having defined the different catalytic systems that can be used with hCA II, the develop-
ment of a specific ligand and -inhibitor combination for each type of catalytic reactions was
planned. Such ligands are based on a bipyridine pattern for the 1,4-addition, and, in our case,
it was completed by 2-picolylamine derivative ligands for the transfer hydrogenation of cyclic
imines. Carbene ligands were synthesized for the preparation of metathesis catalysts.
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2.2 Design and Synthesis
2.2.1 Introduction to rational ligand design
With the lock-and-key model in mind, many different approaches have been envisaged for the
identification of new, potent hCA II ligands. [15] In our case, a rational approach involving
computational tools was envisaged by exploiting the arylsulfonamide moiety as a transition-
state analogue for the hydratase reaction (section 1.3.4). The first aim of this investigation
was to parameterize zinc-sulfonamide interactions in order to predict the binding free energy
between hCA II and model ligands. [16] This calculation method was validated by studying
the influence of protein mutations on the inhibitor affinity (section 2.3.2). Subsequently, a
library of fluorinated inhibitors was studied in order to assess the influence of fluorine atoms
on protein-inhibitor interactions. Results are presented in the following sections 2.2.2 and
2.3.2.
Figure 2.1. Close up view of the structure of [(cp∗)Ir(5)Cl]Cl (16) ⊂ WT hCA II (PDB code 1G54). Position
F131 is highlighted and can interact with the complex (orange dashes). (Maurus Schmid calculations)
Furthermore, catalytic centers were parameterized and the first calculation results for
hCA II hybrid catalyst are presented in Figure 2.1. In the absence of crystallographic infor-
mation on the exact location of the catalytic center, computational tools provided a qualita-
tive model of the hybrid catalyst. This theoretical model was used to predict the amino acid
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residues to be mutated. Mutations at positions I91 and K170 were found to be relevant for
genetic optimization.
Because our computational resources were limited, information gained from existing crys-
tal structures as well as published affinity constants for specific ligands were exploited to
successfully create new in silico designed inhibitors. To validate the designed structures, in-
hibitors were manually docked into the funnel-shaped cavity of hCA II. The advantage of this
technique was to rapidly provide an overview of the interactions between the protein scaffold
and the potential inhibitor-ligands. For this purpose, computer tools including Maestro, and
VMD [17] were used.
The first generation of ligands was based on a report by Fierke et al. [18] They provided a
tight-binding (down to nM, see Table 1.3) library of fluorinated compounds that come into
contact with the protein scaffold at multiple points, including a CH/π bond between the
upper part of the inhibitor and the residue F131 (highlighted in orange, Figure 2.2a). The
first generation of ligands bearing pyridine residues that can interact with the F131 residue
was thus conceived. As an illustrative example, Figure 2.2b shows the ligand 4 docked into
the hCA II pocket with a possible interaction with residue F131 as anticipated. The newly
designed inhibitor-ligands are shown in Scheme 2.1.
(a) (b)
Figure 2.2. a) Close up view of the structure of N -(2,3-difluorobenzyl)-4-sulfamoylbenzamide ⊂ WT
hCA II (PDB code 1G52). CH/pi interaction between F131 and the ligand phenyl ring is highlighted in
orange. b) From the same point of view, N -(di(2-pyridyl)methyl)-amidobenzene-4-sulfonamide (4) was man-
ually docked into wild type hCA II (PDB code 1G52).
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The first generation of ligands was based on bipyridine type ligands, such as 2, 3 and 4.
The shorter ligand 1 was also part of this library. With ligand 1, the metal is located more
deeply in the hCA II funnel-shaped cavity, leading to a greater number of interactions between
the first and second coordination sphere and the substrate. This may induce higher enan-
tioselectivity during catalytic reactions. Inhibitor 40 and its derivatives have been designed
for the study of interactions between inhibitors and protein. Ligands 6 and 41 complement
the library and have been specifically conceived for the transfer hydrogenation reactions. The
carbene ligand 7 was designed for metathesis reactions.
In section 2.2.2 and following, the various syntheses required to obtain the inhibitor-ligands
presented in Scheme 2.1 are reported in detail.
Scheme 2.1. Structure of sulfonamide ligand-inhibitors used in this study.
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2.2.2 First ligand generation: bipyridine derivatives
2,2’-Bipyridine-5-sulfonamide (1)
For the synthesis of 2,2’-bipyridine-5-sulfonamide (1), the proposed two step synthesis is pre-
sented in Scheme 2.2. Access to compound 46 was gained by sulfonation of the
2,2’-bipyridine (33). The subsequent activation of the sulfonic acid bipyridine 46 with
PCl5, followed by treatment with aqueous NH3, resulted in the substitution reaction to
2,2’-bipyridine-5-sulfonamide (1).
Scheme 2.2. Synthesis of ligand 1.
N
N
N N
N N
S OO
NH2
S OO
OH
a b
5
33 46 1
Reagents and conditions: a) HgSO4, oleum, 220
◦C, 24 h b) i) PCl5, toluene, 120
◦C, 30 min ii) conc. aqueous
NH3, r.t., overnight.
The standard ligand synthesis procedure to obtain sulfonic acid derivative 46 from com-
mercially available 2,2’-bipyridine (33) was previously described by Kuchler et al. [19] Trans-
formation of 33 into 46 was achieved in the presence of a catalytic amount of mercury(II),
which allows for the activation of position 5 of bipyridine ring (Scheme 2.2). Two purification
methods were proposed in the literature in order to obtain the compound 46. Pilling et al. [20]
proposed an easy, rapid method for purification by crystallization of the product after remov-
ing mercury traces using activated charcoal; however, this method could not be reproduced.
Kuschler and co-workers were able to isolate the product by ion exchange extraction of the
tetra(N -butyl)ammonium salt in CH2Cl2. The synthesis of 2,2’-bipyridine-5-sulfonamide (1)
was achieved using PCl5, leading to a sulfuryl chloride intermediate followed by sulfonamide
group formation in concentrated NH3 aqueous solution. Due to the low overall yield (11 %),
the last step synthesis was carried out on a gram scale.
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4-(Di-2-pyridinylamino)-benzenesulfonamide (2)
The ligand 2 was prepared according to Scheme 2.3. Preparation of ligands containing sul-
fonamide moieties remains a major challenge to synthetic chemists because it is not always
possible to obtain a sulfonamide group from a sulfonic acid intermediate, as demonstrated
for the synthesis of compound 1. To circumvent the use of sulfonic acids, the route shown in
Scheme 2.3, using a thiomethyl group, was envisioned. The advantage of this route over the
sulfonic acid method is that a cross-coupling reaction, such as Buchwald-Hartwig amination,
can be applied (Scheme 2.3, reaction a).
Scheme 2.3. Synthesis of ligand 2.
N
Br
S
NH2
2 +
S
N
N N
a b
S
N
N N
S
N
N N
S
N
N N
OO
OO
NH2
Si
O O
dc
47 48 49
50
50
51 2
Reagents and conditions: a) tris(dibenzylideneacetone)dipalladium, 1,1’-bis(diphenylphosphino)ferrocene,
sodium tert-butoxide, toluene, under N2, 100 ◦C, 24 h b) KMnO4/MnO2 (1/1), CH2Cl2, r.t., 3 d
c) i) BuLi, THF, -78 ◦C, 1 h ii) chloromethyltrimethylsilane, THF, r.t., 2 d d) i) TBAF, THF, r.t., 1 h
ii) hydroxylamine-O-sulfonic acid, sodium acetate, THF, H2O, r.t., overnight.
A four-step synthesis was envisioned: Buchwald-Hartwig amination [21] leading to com-
pound 49, followed by sulfonamide group preparation as demonstrated by Zhang et al. [22]
Commercially available compounds 47 and 48 were reacted under Buchwald-Hartwig [21] con-
ditions in the presence of a palladium catalyst. This cross coupling reaction generated the key
intermediate product, 49, after flash chromatography. The thiomethyl group had to be fully
43
Chapter 2. Results and discussion
oxidized using a mixture of KMnO4/MnO2 that was removed by filtration to obtain product
50 according to Lee. [23] Product 2 was obtained in a two-step synthesis, first compound 50
was protected with chloromethyltrimethylsilane to obtain compound 51, which can be reduced
to the corresponding sulfone using TBAF. Sulfonamide formation using hydroxylamine-O-
sulfonic acid results in the formation of product 2 (overall yield 12%).
(4-((2,2’-Bipyridine)4-yl)benzenesulfonamide (3)
A class of bipyridine ligand containing longer spacers was also envisaged. The synthesis of
(4-((2,2’-bipyridine)4-yl)benzenesulfonamide (3) was achieved by minor modification of the
procedure published by Bergman and co-workers [24] to first obtain (4-(4-(methylthio)phenyl)-
2,2’-bipyridine (52). A synthetic pathway described in the previous section (Scheme 2.3) was
applied to transform the thiomethyl to sulfonamide, resulting in ligand 3 (Scheme 2.4).
Scheme 2.4. Synthesis of ligand 3.
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Reagents and conditions: a) NaOH aq. solution, MeOH, r.t., 3 h b) ethyl vinyl ether,
yttrium hexafluoroacetylacetonate, 4 Å molecular sieves, THF, under N2, r.t., 3 d c)
H2NOH ·HCl, ACN, reflux, 6 h d) KMnO4/MnO2 (1:1), CH2Cl2, r.t., 3 d e) i) BuLi, THF,
-78 ◦C, 1 h ii) chloromethyltrimethylsilane, THF, r.t., 2 d f) i) TBAF, THF, r.t., 1 h
ii) Hydroxylamine-O-sulfonic acid, sodium acetate, THF, H2O, r.t., overnight.
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Following the route published by Bergman and co-workers [24] with only minor modifica-
tions, commercially available 2-acetylpyridine (53) was reacted with
4-(methylthio)benzaldehyde (54) under Michael conditions to obtain the heterodiene product
55, which was purified by crystallization from a saturated MeOH solution. The synthesis
of 56 was achieved by aldol condensation of 55 with ethyl vinyl ether, using yttrium hexaflu-
oroacetylacetonate instead of the typical copper catalyst. [25] Following the work of Ciufolini
and co-workers, who developed the synthetic pathway to obtain pyridine from dihydropyrans,
the intermediate compound 52 was synthesized using H2NO ·HCl as the nitrogen source.
[25]
Subsequently, thioether 52 was oxidized to the sulfone 57 under heterogeneous conditions
with KMnO4/MnO2.
[23] The synthesis of (4-((2,2’-bipyridine)4-yl)benzenesulfonamide was
completed by transformations of precursors 57 to the corresponding sulfonamide 3 using the
standard method illustrated in the previous section (overall yield 8%).
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N -(Di(2-pyridyl)methyl)-amidobenzene-4-sulfonamide (4)
The synthesis of 4 relies on two key steps, comprising oxime reduction followed by amide
bond formation. The oxime reduction was previously described by Meunier using zinc as
the reducing agent. [26] 4-Carboxybenzenesulfonamide (59) activation was achieved using the
method described by Whitesides and co-workers. [27] Compound 60 was directly reacted with
61 without purification to avoid any decomposition of the primary amine. Ligand 4 was
isolated as a white powder (overall yield 59%). Following the same strategy, a library of
inhibitors (40, 42, 43, 44 and 45) was prepared (overall yield 15-44%).
Scheme 2.5. Synthesis of inhibitors 4, 40, 42, 43, 44 and 45.
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Reagents and conditions: a) ammonium acetate, Zn, H2O/MeOH/NH3, 80
◦C, 5 h b) NHS, DCC, DMF, r.t.,
overnight c) 60 or benzylamine derivatives, H2KPO4, H2O/acetone, r.t., overnight.
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2.2.3 Second ligand generation: picolylamine derivatives
4-(2-(Aminomethyl)pyridin-4-yl)benzenesulfonamide (5)
A second generation of ligand-inhibitors was envisaged based on the 2-picolylamine class of
ligands. As previously reported, this type of ligand was successfully applied for reduction
of ketones in water. [28,29] A three-step synthesis of 6 was proposed according to Scheme 2.6.
First, commercially available 4-(tert-butylaminosulphonyl)benzeneboronic acid (63) was cou-
pled to 4-chloropyridine-2-carbonitrile (64) by the Suzuki method, followed by two depro-
tection steps; the nitrile was reduced with (AlCl3) ·LiAlH4
[30] and tert-butylaminosulfonyl
was cleaved using TFA. [31] This three-step synthesis led to 4-(2-(aminomethyl)pyridin-4-
yl)benzenesulfonamide (5).
Scheme 2.6. Synthesis of ligand 5.
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Reagents and conditions: a) [Pd(PPh3)4], Na2CO3, THF, reflux, 3 h b) i) LiAlH4, AlCl3, THF, r.t., 5 h ii)
Boc2O, CH2Cl2, r.t., overnight c) TFA, anisole, r.t., overnight.
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The synthesis presented in Scheme 2.6 was centered on the coupling of 63 and 64 under
Suzuki-Miyaura conditions to obtain compound 65. Subsequently, the nitrile group was re-
duced with (AlCl3) ·LiAlH4. Reduction of the nitrile followed by precipitation of the amine
from diethyl ether did not generate a clean product but, by generating the Boc protected
amine 66, the product could be purified by column chromatography. The ligand 5 was ob-
tained by double deprotection with TFA to produce 6 as a colorless solid (overall yield 39%).
Considering the promise held by ligand 5 as a scaffold for new catalysts, [29,32] an investiga-
tion in the direction of a new approach to the synthesis of 6 (Scheme 2.7) was proposed in order
to avoid purification problems encountered during the preparation of 5. Moreover this second
methodology allowed for large scale synthesis. The synthesis started with commercially avail-
able 4-bromo-2-methylpyridine (67), which was readily oxidized with
3-chloroperoxybenzoic acid to compound 68. Treatment of molecule 68 with trifluoroacetic
anhydride (Boekelheid reaction) led to the alcohol function present in molecule 69. [33,34] The
alcohol function was oxidized to the corresponding aldehyde with MnO2.
[35] The aldehyde
function was transformed into oxime [36] and reduced to amine using TFA and Zn, and the ob-
tained primary amine was reacted with sulfonylchloride derivatives, leading to picolylamine
ligand 70 and 71. [37] Finally, 4-sulfamoylphenylboronic acid, pinacol ester was coupled to
the different bromo pyridine derivatives under microwave irradiation [38] to obtain inhibitor
ligands 6 and 41.
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Scheme 2.7. Synthesis of ligands 6 and derivatives.
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Reagents and conditions: a) 3-chloroperoxybenzoic acid, CH2Cl2, r.t., overnight b) trifluoroacetic anhydride,
reflux, 30 min c) MnO2, chloroform, reflux, 2 h d) hydroxylamine hydrochloride, NaHCO3, MeOH, r.t.,
overnight. e) i) TFA, zinc dust, r.t., 1 h ii) arylsulfonylchloride derivatives, DIPEA, CH2Cl2, r.t., overnight
f) [Pd(PPh3)4], Na2CO3, water/dioxane (1/1), microwave (150
◦C), 15 min.
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2.2.4 Carbene ligand
The synthesis of the carbene ligand 74 (Scheme 2.9) was also envisioned. Following the
work published by Hoveyda and Grubbs, who reported the synthesis of a carbene ligand that
could be bound to a solid support. [39,40] The strategy was also applied by Ward et al. [12] to
synthesize a biotinylated carbene complex (Scheme 2.8). In our case this synthetic strategy
did not work, as the activated para-carboxysulfonamide will not react with the deprotected
carbene 75. Therefore, a multi-step synthesis was proposed to first prepare the sulfonamide
protected ligand 74 (Scheme 2.9), which can react with the 1st generation Hoveyda-Grubbs
catalyst. Finally, as previously discussed in section 2.2.3, the sulfonamide group can be
deprotected under acid conditions.
Scheme 2.8. Proposed synthesis of carbene complex.
N N
Ru
NHBoc
Cl
Cl
O
N N
Ru
NH
Cl
Cl
O
a - b
O
S
O
O NH2
75 76
Reagents and conditions: a) HCl (g), CH2Cl2 b) 61, NEt3, DMF, r.t. or reflux, overnight.
A five-step synthesis was envisaged for the preparation of the carbene precursor (74,
Scheme 2.9). The two building blocks 77 and 78 were prepared separately.
First, tert-butylamine was reacted with 4-(chlorosulfonyl)benzoic acid to obtain the
tert-butyl protected sulfonamide 79. At the end of the synthesis, this protecting group is
easily removed under acidic conditions, i.e. conc. HCl. The use of HCl is important to
prevent chloride ligand displacement on the carbene Ru complex. [31] Compound 79 was sub-
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sequently activated with N -hydroxysuccinimide in order to obtain intermediate compound
78. The second building block, 77, was prepared by a slightly modified procedure published
by Ward et al. [12] Compound 80 was reacted with 2,4,6-trimethylaniline (81), leading to
molecule 77 without Boc protection; compound 77 was directly coupled to compound 78.
The synthesis of ligand 74 was finally achieved using triethylorthoformate (overall yield 23%).
Unfortunately, after many attempts it was not possible to obtain the carbene precursor 76.
The hygroscopicity of the imidazolium salt is one possible explanation for the non-reactivity
(the deprotonation does not occur under basic conditions). This may be avoided by modifying
the counterion and choosing, for example, PF –6 , which is less hygroscopic than chloride.
Scheme 2.9. Synthesis of carbene ligand 74.
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Reagents and conditions: a) 120 ◦C, overnight b) tert-butylamine, MeOH, r.t., overnight c) NHS, DCC,
DMF, r.t., overnight. d) 77, DMF, r.t., 72 h e) triethylorthoformate, NH4Cl, 120
◦C, 48 h.
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2.2.5 Complex synthesis
Ruthenium, rhodium and iridium complexes
Two strategies were used for the synthesis of complexes. First, ruthenium, rhodium and
iridium dimers were coupled with bipyridine-type ligands in acetonitrile (Scheme 2.10). Ace-
tonitrile was used due to its characteristic lability when used as a ligand. Bipyridine type
complexes were insoluble in acetonitrile and could be purified by filtration followed by a re-
peated washes. Most metal dimers used for this study were commercially available except for
[(η6-C6Me6)RuCl2]2, which was synthesized according to the procedure by Mann et al. [41]
Scheme 2.10. Synthesis of bipyridine-type complexes.
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Reagents and conditions: a) [(η6-C6H6)RuCl2]2, ACN, reflux, 4 h.
For the synthesis of complexes based on the 2-picolylamine pattern, the protocol described
by Oro and co-worker was followed. [42] The reaction was performed in ethanol and the product
was purified by precipitation with diethyl ether (Scheme 2.11). NMR analysis of complexes
[(cp∗)Ir(6)Cl]Cl (17) and [(cp∗)Ir(41)Cl]Cl (18) indicated the presence of two states of co-
ordination in solution according to the pH. The sulfonamide amine binds to the metal, as
previously described by Xiao , Section 1.4.
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Scheme 2.11. Synthesis of 2-picolylamine-type complexes.
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Reagents and conditions: a) [(cp*)IrCl2]2, EtOH, reflux, 2 h.
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2.3 Protein inhibitor interactions
2.3.1 Circular dichroism
The circular dichroism (CD) spectrum of wild type hCA II in the near-UV region (from 240
nm to 350 nm) is diagnostic of its tertiary structure, as previously reported by Carlsson et
al. [43] The spectrum contains a characteristic, large, positive band at 246 nm and a deep,
broad negative band in the region between 260 and 300 nm, which displays a fine structure.
The observed signal can be attributed to the seven tryptophan residues (Trp 97, 123, 192,
209 and 245) located in the central β-sheet region of hCA II scaffold (see Figure 2.3).
Figure 2.3. Human Carbonic Anhydrase II with the seven Trp residues highlighted in green (PDB code 1G54).
Trp residues are mainly localized in the funnel-shaped cavity and the presence of a catalyst inside the pocket
alters the three-dimensional structure of the protein, resulting in CD spectra modification.
As catalytic conditions required small amounts of organic solvent to dissolve complexes
and/or substrates, hCA II structural stability was investigated by circular dichroism in the
presence of varying DMSO concentrations (0 to 50%, v/v) in phosphate buffer solution. The
asymmetric environment around the various aromatic amino acid residues of WT hCA II was
slowly disrupted, upon unfolding, when the DMSO concentration in the phosphate buffer
exceeded 50% (Figure 2.4).
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Figure 2.4. The near-UV CD spectrum of WT hCA II. WT hCA II was dissolved in 50 mM phosphate buffer,
pH 7.4. Cell path lengths and protein concentration were 1 cm and 1 mg/mL, respectively. Percentage of
DMSO: 0% (•), 10% (•), 20% (•), 30% (•), 40% (•), 50% (•). [44]
The presence of complex [(cp∗)Ir(6)Cl]Cl (17) inside the hCA II the funnel-shaped cavity
induced a rise in the signal in the first part of the CD spectra (240 to 300 nm, Figure 2.5). The
change in the spectra indicated a change in the asymmetric environment of the hCA II scaffold,
due to an inhibitor located inside the funnel-shape of the protein that disturbed Trp residues.
The increasing signal reached a maximum at 0.8 equivalents of added complex. An inhibitor-
protein ratio of 0.8 was therefore used for the catalytic reaction.
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Figure 2.5. Near-UV CD spectrum of WT hCA II (•) and [(cp∗)Ir(6)Cl]Cl (17) ⊂ WT hCA II (0.1 equiv.
(•), 0.2 equiv. (•), 0.3 equiv. (•), 0.4 equiv. (•), 0.5 equiv. (•), 0.6 equiv. (•), 0.7 equiv. (•), 0.8 equiv. (•),
0.9 equiv. (•), 1.0 equiv. (•)). The protein was dissolved under imine catalytic condition of 1.2 M MOPS
buffer containing 3 M sodium formate, pH 7.5, 22 ◦C. Cell path lengths and protein concentration were 0.1
cm and 1 mg/100µL, respectively.
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2.3.2 Thermodynamics of hCA II-inhibitor binding
To determine the thermodynamics of protein-inhibitor binding in solution, two popular tech-
niques were used based on ease of observation, as explained in Section 1.3.4. The inhibition
constant (Ki) and the equilibrium dissociation constant (Kd) are introduced in the following
sections. It should be noted that the lowercase letter, i.e. i and d, refers to the type of
experimental approach used to determine the equilibrium dissociation constant K, and thus
are directly comparable. [45]
Esterase activity screening assay
Steady-state kinetic experiments were used to determine the inhibition constant Ki. Ligands
or complexes with inhibition constants on the order of mM were titrated against hCA II (exper-
imental details in Section 4.4). Binding experiments were performed in HEPES buffer (pH 8)
containing 10% DMSO to solubilize the inhibitors as well as the substrate (p-nitrophenyl
acetate).
For easy comparison of hydrolysis of p-nitrophenyl acetate (constant concentration), data
were presented as % activity of the enzyme as a function of inhibitor concentration. The
results were fitted to the function defined by equation 2.1 to determine the inhibition constant
Ki. [16,46,47]
v =
vo ·Ki
Ki + ([I]t − 0.5{([I]t + [E]t +Ki)−
√
([I]t + [E]t +Ki)2 − 4 · [I]t · [E]t})
(2.1)
Parameters used in the steady-state kinetics equation 2.1 are vo for the initial velocity of
the hCA II catalyzed reaction in the absence of inhibitor, Ki for the binding affinity constant,
[I]t for the total concentration of the inhibitor, and [E]t for the total concentration of enzyme.
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Competitive displacement assay
Competitive displacement of fluorescent hCA II inhibitor, dansylamide (DNSA), was used to
determine the dissociation constant Kd. Inhibitors with dissociation constants on the order of
nM (experimental details in Section 4.4.2) were titrated using this method. DNSA is a “non-
fluorescent” molecule in aqueous solution but, in the presence of hCA II, the fluorescence
signal at 470 nm increases (excitation at 280 nm, see Figure 2.6).
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Figure 2.6. Fluorescence spectra of dansylamide (DNSA) ⊂ hCA II. [Enzyme] = 0.1 µM, [DNSA] = 2.25 µM.
hCA II (•), DNSA (•), DNSA ⊂ hCA II (•), 470 nm (❙).
The dissociation constants (Kd) of screened hits were determined using a slightly modified
method proposed by Tripp and coworkers. [48–50] Screening using a black, flat-bottom 96-well
plate (NUNC F96 MicroWell Plates) was realized with excitation at 280 nm and detection at
470 nm. The dissociation constant Kd for DNSA was determined by titrating hCA II with
different DNSA concentrations (data reported in Figure 2.7). The equilibrium dissociation
constant for DNSA (KDNSA) was determined by fitting the data to equation 2.2
Ftot =
Fobs − Fini
Fend − Fini
=
1
1 + (KDNSA/[DNSA])
(2.2)
where Ftot is the total fluorescence, Fini the initial fluorescence of hCA II in the absence
of DNSA, and Fend is the end point fluorescence.
Equilibrium dissociation constants for inhibitors were determined by competitive binding
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Figure 2.7. Fluorescence titration of dansylamide (DNSA) against hCA II. The increase in the fluorescence
emission intensity at 470 nm (•) for a fixed concentration of hCA II ([Enzyme] = 0.1 µM). The solid, smooth
line is the best fit of the data according to equation 2.3 for the DNSA dissociation constant (Kd) determination.
with DNSA. A fixed concentration of DNSA (2.25 µM) and hCA II (100 nM) was titrated
against inhibitors (from 100 µM to 25 nM). The Kd value for each inhibitor was determined
by fitting the equation 2.3
Ftot =
Fobs − Fini
Fend − Fini
=
1
1 + (KDNSA/[DNSA])(1 + [I]/Kd)
(2.3)
where Ftot is the fraction of total fluorescence, Fobs the fluorescence signal at any concen-
tration of inhibitor, Fini the initial fluorescence of hCA II without DNSA, and Fend the end
point fluorescence.
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First generation inhibitor-ligands
After synthesis of the first generation inhibitors (Scheme 2.12), their respective inhibition
constants (K i, Section 2.3.2) were determined (Figure 2.8) and, as expected, inhibitors 3 and
4 exhibited inhibition constants on the order of nM. (Table 2.2, entry 5 and 6). However, it
was noted that inhibitor 2 was characterized by a low inhibition constant (2900 ± 200 nM),
which was probably due to the large size relative to the hCA II cavity. The inhibitor 2 was
therefore removed from selection for the synthesis of complexes. Indeed, for the development
of a hybrid catalyst, an inhibition constant on the order of magnitude of nM is required.
Measurements were validated by comparing the value obtained by titration of inhibitors 84
and 59 with the published values (Table 2.2, entry 1 and 2).
Scheme 2.12. Structure of arylsulfonamide ligand-inhibitors.
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Table 2.2. Final set of parameters for Ki with asymptotic standard error. [47]
Entry Inhibitor Dissociation
constant (nM)
Published dissociation
constant (nM)
1 84 780 ± 45 200-1500 [6]
2 59 570 ± 30 270 [6]
3 1 160 ± 15 -
4 2 2900 ± 200 -
5 3 60 ± 16 -
6 4 45 ± 7 -
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Figure 2.8. Steady-state kinetic data for the inhibition of hCA II first generation ligand-inhibitors. The initial
rates of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate substrate were measured as a function of
inhibitor concentration. [Enzyme] = 1 µM, [p-nitrophenyl acetate] = 0.5 mM. The solid, smooth lines are the
best fits of the data according to equation 2.1 for the Ki of 84 (•), 59 (•), 1 (•), 2 (•), 3 (•), 4 (•).
To investigate more precisely the interactions between hCA II and metal complexes, a
collection of ruthenium complexes was synthesized (Section 2.2.5). The first step was to deter-
mine the inhibition constant for each complex-inhibitor before moving to the crystallographic
analysis (Section 2.3.3). Compared to the parent carboxylic acid 4-carboxybenzenesulfonamide
(59), all complexes bearing ligands 3 and 4 display increased affinity. Interestingly,
[(η6-biphenyl)Ru(4)Cl]Cl (12) displays the highest affinity towards hCA II, whereas
[(η6-C6H6)Ru(4)Cl]Cl (9) displays a significantly reduced affinity. These data illustrate the
subtle complementarity between the piano-stool moiety and the funnel-shaped cavity. Com-
plexes bearing bipyridine ligand 1 were also studied. Titration results of
[(η6-C6H6)Ru(1)Cl]Cl (8) against hCA II are reported in Figure 2.9 (•). No reasonable
value could be obtained by fitting, due to the linearity of obtained points. This suggests that
there was no interaction between the inhibitor-complex 8 and the protein. It is proposed
that the metal complex is too big to fit inside the funnel-shaped cavity of the protein; there-
fore, complex 8 was removed from the library that was used during catalyst implementation.
Summary of complex inhibition constants is presented in Table 2.3.
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Figure 2.9. Steady-state kinetic data for the inhibition of hCA II ruthenium metal complexes. The initial
rates of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate substrate were measured as a function of
inhibitor concentration. [Enzyme] = 1 µM, [p-nitrophenyl acetate] = 0.5 mM. The solid, smooth lines are the
best fits of the data according to equation 2.1 for the Ki of 8 (•), 9 (•), 10 (•), 11 (•), 12 (•), 15 (•).
Table 2.3. Final set of parameters for Ki with asymptotic standard error.
Entry Inhibitor Dissociation
constant (nM)
PDB
1 [(η6-C6H6)Ru(1)Cl]Cl (8) n.d. -
2 [(η6-C6H6)Ru(4)Cl]Cl (9) 194 ± 19 -
3 [(η6-p-cymene)Ru(4)Cl]Cl (10) 275 ± 13 -
4 [(η6-C6Me6)Ru(4)Cl]Cl (11) 329 ± 16 3PYK
5 [(η6-biphenyl)Ru(4)Cl]Cl (12) 145 ± 12 -
6 [(cp∗)Ir(3)Cl]Cl (15) 270 ± 40 -
Second generation inhibitor-ligands
Based on a 2-picolylamine pattern, the affinities of the second generation ligand-inhibitors
were also determined (Table 2.4). Interestingly, the inhibitor 5 displays a relatively low
affinity (150 nM, entry 1) for the protein compared to inhibitor 6 (11 nM, entry 3). It should
be noted that it is preferable to use the dansylamide method to determine the affinity constant
on the nanomolar scale (Section 2.3.2). The determined dissociation constant of 11 nM for
ligand-inhibitor 6 suggests an anchoring not only at the level of the zinc-sulfonamide, but also
the presence of a secondary recognition element. The arylsulfonyl group can interact with the
upper part of the hCA II cavity, as suggested by computational simulation (Figure 2.1). Even
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the iridium complex did not significantly affect the observed dissociation constant (15 nM). As
the arylsulfonyl group was located near the catalytic center, the metal was located precisely
in the funnel-shaped cavity. This feature was used to localize potent mutation sites that could
influence the catalytic activity and/or selectivity.
Scheme 2.13. Structure of 2-picolylamine ligand-inhibitors.
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Figure 2.10. Steady-state kinetic data for the inhibition of hCA II second generation ligand-inhibitors. The
initial rates of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate substrate were measured as a function
of inhibitor concentration. [Enzyme] = 1 µM, [p-nitrophenyl acetate] = 0.5 mM. The solid, smooth lines are
the best fits of the data according to equation 2.1 for the Kd of 5 (•), 16 (•).
Table 2.4. Final set of parameters for Ki or Kd with asymptotic standard error.
Entry Inhibitor Dissociation
constant (nM)
Ki or Kd
1 5 150 ± 35 Ki
2 [(cp∗)Ir(5)Cl]Cl (16) 1280 ± 200 Ki
3 6 11 ± 1 Kd
4 [(cp∗)Ir(6)Cl]Cl (17) 15 ± 2 Kd
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Figure 2.11. Competitive displacement assay data for the inhibition of WT hCA II. The initial rates of
the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate substrate were measured as a function of inhibitor
concentration. [Enzyme] = 1 µM, [p-nitrophenyl acetate] = 0.5 mM. The solid, smooth lines are the best fits
of the data according to equation 2.3 for the Kd of 6 (•), 17 (•).
Inhibitors for physical chemistry studies
The computation identified position L198 as a critical site in terms of the thermodynamics
of binding for benzenesulfonamide (84, Scheme 2.14). Three hCA II mutants were designed
and produced recombinantly in E. coli : L198A, L198F and L198Q. [16] The corresponding
thermodynamics were determined using the esterase activity assay and fitted raw data are
presented in Figure 2.12. This assay yielded Ki = 1100 nM for WT hCA II. This value lies
well within the reported data ranging from 200–1500 nM. [6] The experimentally measured
inhibition constants of 84 for the L198X mutants are reported in Table 2.5.
Table 2.5. Final set of parameters for dissociation constant, Kd, for benzenesulfonamide 84 with asymptotic
standard error for hCA II mutants (see Figure 2.12). [16]
Entry Protein Dissociation
constant (nM)
Published dissociation
constant (nM)
1 WT 1100 ± 40 200-1500 [6]
2 L198A 5500 ± 270 -
3 L198F 1700 ± 130 -
4 L198Q 1800 ± 100 -
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Figure 2.12. Steady-state kinetic data for the inhibition of hCA II mutated proteins by benzenesulfonamide
(84). The initial rates of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate substrate were measured as
a function of inhibitor concentration. [Enzyme] = 1 µM, [p-nitrophenyl acetate] = 0.5 mM. The solid, smooth
lines are the best fits of the data according to equation 2.1 for the Ki of WT (•), L198A (•), L198F (•),
L198Q (•).
Scheme 2.14. Structure of arylsulfonamide inhibitors used for computational studies.
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In a second phase, five fluorinated inhibitors were studied (Scheme 2.14). The thermo-
dynamic binding constants were determined for inhibitors 84, 85, 86 and 87 using esterase
activity screening. A difference in Ki was observed (800–300 nM, Table 2.6) due to the inter-
action of the fluorine atoms with the funnel-shaped cavity of hCA II. The inhibitor 87, bearing
the trifluoromethyl group, binds to the protein with the lowest dissociation constant (30 nM),
as previously noted. This was probably due to enhanced hydrophobic interactions inside the
protein cavity. Due to the observed, high inhibition constant for 87 (nM range), a competitive
displacement test was employed to determine the Kd of inhibitors 87, 40, 42, 43, 44 and 45.
In this case, the analysis of the data shows little difference between the observed dissociation
constants Kd (Table Scheme 2.14, entry 6 to 9). Indeed, the modifications brought to the
inhibitors have little impact, because the fluorine atoms are located too far outside the cavity
of the protein. To validate these measurements, the obtained Kd for DNSA, 40, and 43 were
compared to published values and were in agreement (Table 2.6, entries 5, 7 and 10). [6]
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Figure 2.13. Steady-state kinetic data for the inhibition of WT hCA II. The initial rates of the enzyme-
catalyzed hydrolysis of p-nitrophenyl acetate substrate were measured as a function of inhibitor concentration.
[Enzyme] = 1 µM, [p-nitrophenyl acetate] = 0.5 mM. The solid, smooth lines are the best fits of the data
according to equation 2.1 for the Ki of 84 (•), 85 (•), 86 (•), 87 (•).
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Figure 2.14. Competitive displacement assay data for the inhibition of WT hCA II. The initial rates of
the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate substrate were measured as a function of inhibitor
concentration. [Enzyme] = 1 µM, [p-nitrophenyl acetate] = 0.5 mM. The solid, smooth lines are the best fits
of the data according to equation 2.3 for the Kd of 87 (•), 40 (•), 42 (•), 43 (•), 44 (•), 45 (•).
Table 2.6. Final set of parameters for Ki or Kd with asymptotic standard error.
Entry Inhibitor Dissociation
constant (nM)
Ki or Kd Published dissociation
constant (nM)
PDB
1 84 780 ± 45 Ki 200-1500 [51,52] -
2 85 330 ± 30 Ki 82 [52] -
3 86 490 ± 10 Ki 590 [53] 1IF4
4 87 30 ± 3 Ki - -
5 40 1.9 ± 0.2 Kd 1.1 [54] 1G4O
6 42 1.7 ± 0.2 Kd - -
7 43 2.2 ± 0.2 Kd 3.3 [55] -
8 44 2.3 ± 0.2 Kd - -
9 45 2.5 ± 0.2 Kd 0.29 [56] 1G52
10 DNSA 1600 ± 60 Kd 826 [57] 1OKL
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2.3.3 Crystallographic studies
(in collaboration with Tillmann Heinisch)
An X-ray structure analysis was used to gain insight on the host-guest interactions of ruthe-
nium complexes bearing the bispy 4 ligand. [47] Complementary NMR analysis of
[(η6-C6H6)Ru(4)Cl]Cl (9) indicated the existence of a single diastereomer, as evidenced by
an NOE cross-peak between the η6-benzene and HCbridge (Figure 2.15).
Ru
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Figure 2.15. Cross correlation (NOE) 6.21 ppm (η6-benzene) - 7.00 ppm (HCbridge) normalized integral 6.22
(1.35/H), confirming the assignment of diastereomer.
Human Carbonic Anhydrase II crystals were soaked in a solution of
[(η6-C6Me6)Ru(4)Cl]Cl (11) and diffraction data were collected at a synchrotron to 1.3 Å res-
olution. After refinement of the protein structure, strong residual positive- and anomalous
difference densities were apparent in the funnel-shaped sulfonamide-binding cavity. This was
modeled as [(η6-C6Me6)Ru(4)Cl]Cl (11). The various interactions between the anchoring
group (benzene-sulfonamide) and the protein are reminiscent of related hCA II-sulfonamide
complexes (Figure 2.16). As expected, by computational design, the upper part of complex
11 interacts with the upper edge of the funnel-shaped cavity (residues V121, F131, V135,
L141, L198, P202, and L204, Figure 2.16b).
The piano-stool moiety is localized at the entrance of the funnel-shaped cavity. The
chlorine atom is exposed to the solvent, as expected from the NMR, while the refinement of
the N -(di(2-pyridyl)methyl)-amidobenzene-4-sulfonamide (4) part of the Ru-ligand gave the
best results, with an occupancy of 100%. For ruthenium, hexamethylbenzene, and chlorine.
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(a) (b)
Figure 2.16. Crystal structure of complex [(η6-C6Me6)Ru(bispy 3)Cl]+ ⊂ hCA II (PDB code 3PYK). a)
Close-up view of the sulfonamide binding cavity. Interactions between the sulfonamide group and protein are
indicated. Residue F131 adopts two conformations, as explained in the text. The 2Fo-Fc map is shown in
blue at 1.0 Å, the anomalous difference density map in red at 3.0 Å. b) Interactions between the piano-stool
moiety and residues of the “hydrophobic wall“ at the entrance of the ligand binding site. [47] (Pictures Tillmann
Heinisch)
the occupancy was set to 50%. We assume that a partial dissociation of the metal from
bispy 4 and the 10-fold increased affinity of the latter fragment for hCA II may explain this
observation (Table 2.2 and Table 2.3). Interestingly, the phenyl group of residue F131, which is
also involved in the Fierke’s studies, [18] was found to adopt two conformations (Figure 2.16a).
The conformation with a dihedral angle χ2 = 93◦ is not compatible with ligand binding
(F131-R side chain contact indicated by a red arrow, Figure 2.16a), whereas the conformation
(χ2 = 16◦) is stabilized by a CH/π interaction between one methyl of the hexamethylbenzene
cap and the F131-T phenyl side chain (green dotted line, Figure 2.16a).
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2.3.4 NMR studies
(in collaboration with Kaspar Zimmermann and Prof. Dr Daniel Häussinger)
NMR spectroscopy was used to further investigate interactions in solution between the protein
host hCA II and the catalyst. For this purpose, pseudocontact chemical shift (pcs) were
recorded for fluorinated inhibitors. To validate the method developed by Häussinger [58] on a
30 kDa protein-like hCA II, N -(2,3-difluorobenzyl)-4-sulfamoylbenzamide (45) was used as a
test inhibitor (Scheme 2.15).
Scheme 2.15. Structure of ligand-inhibitors used for NMR studies.
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The complex 45 ⊂ hCA II S166C C206S was chosen as a model system because the
X-ray structure was previously reported by Christianson (PDB code 1G52). [18] The 1D
19F-NMR experiment was recorded (Figure 2.17) and observed pcs of 45 ⊂ hCA II S166C
C206S ([TmM8] labeled) were in good agreement with the published X-ray structure. Indeed,
initial calculations from the obtained pcs (Figure 2.17, red highlighted) indicate a 5 Å devia-
tion for the fluorine position.
At this stage of research, a fluorinated active catalyst (18, Scheme 2.15) was synthesized
(Section 2.2.3) to determine the position and the orientation of the catalyst inside the funnel-
shaped cavity of hCA II. Ultimately, this may lead to precious information about the solution
structure of the novel hybrid catalyst.
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Figure 2.17. 1D 19F spectra of inhibitor 45: a) without protein, b) with double mutant hCA II S166C
C206S, c) with labeled hCA II S166C C206S with [TmM8]. PCS are highlighted in red. (Picture Kaspar
Zimmermann)
70
2.4. Catalysis
2.4 Catalysis
This last section of this Chapter 2 aims to identify an active and selective artificial met-
alloenzyme using hCA II as a well-defined second coordination sphere. For this purpose,
different catalytic systems were envisaged (Section 2.1). In investigations using palladium
(II) complexes bearing bipyridine-derivative ligands for 1,4-addition, it was not possible to
reduce the reaction temperature below 45 ◦C, which corresponds to the denaturation tem-
perature of hCA II. [10,59] Additionally, in 2011 Cadierno et al. reported the instability of
Pd(II)/bipy complexes under aqueous catalytic conditions leading to the formation of palla-
dium (0) nanoparticles. [60] The results presented below focus on successful asymmetric transfer
hydrogenation of cyclic imines as a model reaction for hCA II. Chemical and genetic modi-
fications were implemented for the optimization of the system. Previous results concerning
activity and selectivity of hybrid catalysts are provided.
2.4.1 Imine transfer hydrogenation
Asymmetric transfer hydrogenation was chosen as a model reaction because of its compatibil-
ity with protein environments (Section 2.1). In 2008, efforts by Ward and co-workers identified
an artificial transfer hydrogenase for the enantioselective reduction of cyclic imines. [11] Hy-
brid catalysts used for this study were created by a combination of various arylsulfonamide
complexes with hCA II. For this purpose, two types of ligands were synthesized based on
bipyridine or aminopyridine patterns (Sections 2.2.2 and 2.2.3). Cyclic imine reduction was
tested under conditions previously described by the Ward group (Scheme 2.16). [11]
Scheme 2.16. Typical reaction conditions for the enantioselective reduction of cyclic amines. [11]
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First round of screening
Iridium protein hybrid catalysts were reported as the most active by Ward and co-workers. [11]
Screening results with different substrates (Scheme 2.17) are reported in Table 2.7. It is
noteworthy that after 20 h of reaction time, conversion of substrate was observed. An enan-
tiomeric excess of up to 30% (S ) was reached by the hybrid catalyst [(cp∗)Ir(6)Cl]Cl (17) ⊂
WT hCA II for the reduction of cyclic imine 39 (Table 2.7 entry 14). Complexes bearing
ligand 6 were therefore further investigated for the reduction of substrate 39. In the absence
of hCA II, all complexes presented in Table 2.7 catalyzed the aqueous transfer hydrogenation
of cyclic imines to yield racemic mixtures. Bulky substrate 88 was also tested in presence of
[(cp∗)Ir(5)Cl]Cl catalyst, but no conversion was observed, and we speculate that low water
solubility of 88 may be the cause.
Scheme 2.17. Substrate diversity for imine reduction.
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In order to obtain improved activity and enantiomeric excess, different strategies were
implemented. We focused our attention on modifications at the active catalytic site affecting
the reaction outcome by making use of: a chemical diversity (1st sphere of coordination,
e.g. ligands, Scheme 2.18), a genetic diversity (2nd sphere of coordination), and a substrate
diversity (Scheme 2.17). [61,62]
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Scheme 2.18. Ligand diversity for imine reduction.
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Table 2.7. Results obtained for co-catalyst screening.a
Entry Ligand
(Complex)
Metal ηn-(arene) Substrate Protein Conv.b TON ee (%)
1 91 (13) Ir η5-C5Me5 39 - 98 54 0
2 91 (13) Ir η5-C5Me5 39 WT 93 52 0
3 91 (13) Ir η5-C5Me5 89 - 99 55 0
4 91 (13) Ir η5-C5Me5 89 WT 99 55 0
5 91 (13) Ir η5-C5Me5 90 - quant. 55 0
6 91 (13) Ir η5-C5Me5 90 WT 85 47 0
7 5 (16) Ir η5-C5Me5 39 - quant. 55 0
8 5 (16) Ir η5-C5Me5 39 WT 20 11 5 (S)
9 5 (16) Ir η5-C5Me5 89 - 99 55 0
10 5 (16) Ir η5-C5Me5 89 WT 46 25 6 (S)
11 5 (16) Ir η5-C5Me5 90 - quant. 55 0
12 5 (16) Ir η5-C5Me5 90 WT 36 20 5 (S)
13 6 (17) Ir η5-C5Me5 39 - 61 34 1 (S)
14 6 (17) Ir η5-C5Me5 39 WT 41 23 30 (S)
15 6 (17) Ir η5-C5Me5 89 - 43 24 3 (S)
16 6 (17) Ir η5-C5Me5 89 WT 26 15 3 (S)
17 6 (17) Ir η5-C5Me5 90 - 40 22 2 (S)
18 6 (17) Ir η5-C5Me5 90 WT 22 12 24 (S)
19 - - - 39 WT 0 0 0
20 - - - 89 WT 0 0 0
21 - - - 90 WT 0 0 0
a Reaction conditions: The reaction was carried out at 40 ◦C for 20 h using 1.8 mol% complex (0.35 mM
final concentration), 20 mM substrate, 0.4 mM protein, in 0.4 M MOPS buffer (200 µL total volume, 5%
DMSO) containing 3 M formate, pH 7.5.
b Determined by normal phase HPLC after extraction; the relative response was corrected by the
experimentally determined response factor; amine [%] = (amine x 100)/(amine+imine).
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Having identified the most efficient hybrid catalyst [(cp∗)Ir(6)Cl]Cl (17)⊂ WT hCA II,
different metal complexes (Ru, Rh and Ir) bearing a bipyridine ligand (3 and 4) or picoly-
lamine derivative 6 were tested. Screening results for transfer hydrogenation of 6,7-diethoxy-
1-methyl-1,2,3,4-tetrahydroisoquinoline (39) are presented in Table 2.8. From this general
catalyst screening, the co-catalyst [(cp∗)Ir(6)Cl]Cl (17) emerged as the most active, at 39%
conversion (TON = 29, entry 10 in Table 2.8).
Table 2.8. Results obtained for the transfer hydrogenation of 6,7-diethoxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline with different hybrid catalysts bearing ligands 6, 3 or 4.a
Entry Ligand Metal ηn-(arene) Substrate Protein Conv.b TON
1 6c Ru η6-C6H6 39 - 48 27
2 6c Ru η6-C6H6 39 WT 4 2
3 6c Ru η6-p-cymene 39 - quant. 55
4 6c Ru η6-p-cymene 39 WT 11 6
5 6c Ru η6-C6Me6 39 - 99 52
6 6c Ru η6-C6Me6 39 WT 21 11
7 6c Rh η5-C5Me5 39 - 97 54
8 6c Rh η5-C5Me5 39 WT 36 20
9 6 Ir η5-C5Me5 39 - quant. 55
10 6 Ir η5-C5Me5 39 WT 39 29
13 3 Ir η5-C5Me5 39 - 14 8
14 3 Ir η5-C5Me5 39 WT 0 0
11 4 Ir η5-C5Me5 39 - 3 1
12 4 Ir η5-C5Me5 39 WT 1 1
a Reaction conditions: The reaction was carried out at 40 ◦C for 36 h using
1.8 mol% complex (0.35 mM final concentration), 20 mM substrate, 0.4 mM hCA II,
in 1.2 M MOPS buffer (200 µL) containing 3 M formate, pH 6.5.
b Determined by normal phase HPLC after extraction; the relative response was
corrected by the experimentally determined response factor; amine [%] = (amine x
100)/(amine+imine).
c Complex in situ prepared.
In the absence of crystallographic information on the exact localization of the catalytic
center inside the funnel-shaped cavity, docking studies were realized in collaboration with
Maurus Schmid to obtain a quantitative model of the hybrid catalyst (Figure 2.18). Based on
computational results, mutated proteins were produced and tested in combination with com-
plex 17. Results for the reduction of substrate 39 are presented in Table 2.9. WT hCA II as
well as isozymes K170A and I91A were found to be the most promising protein scaffolds. It is
noteworthy that artificial metalloenzyme activity was improved by a single point mutation at
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position 91 (full conversion and 29% ee), which showed the influence exerted by amino acid
localized close to the catalytic center (Figure 2.18). [61,62]
Table 2.9. Results obtained for the transfer hydrogenation of 6,7-diethoxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline (39) with hCA II variants.a
Entry Complex Substrate Proteinb Conv.c TON ee (%)
1 17 39 WT 33 18 27 (S)
2 17 39 H64A 11 6 0
3 17 39 I91A 99 55 29 (S)
4 17 39 K170A 59 33 30 (S)
5 17 39 E106Q - H64A 21 12 3 (S)
6 17 39 F131A 12 6 6 (S)
7 17 39 F131A-A2V 24 13 1 (S)
8 17 39 Q92G 15 8 3 (S)
9 17 39 Q92G - V121G 25 14 1 (S)
10 17 39 L198Q 11 6 23 (S)
11 17 39 L198A 6 3 6 (R)
12 17 39 L198F 13 7 23 (S)
13 17 39 L198H 13 7 23 (S)
a Reaction conditions: The reaction was carried out at 40 ◦C for 20 h using
1.8 mol% complex (0.35 mM final concentration), 20 mM substrate, 0.4 mM
protein, in 0.4 M MOPS buffer (200 µL total volume, 5% DMSO) containing 3 M
formate, pH 7.5.
b ESI-MS of hCA II isozymes are reported in Part III.
c Determined by normal phase HPLC after extraction; the relative response was
corrected by the experimentally determined response factor; amine [%] = (amine x
100)/(amine+imine).
General conclusions from this second optimization step were: i) genetic modification inside
the active pocket does not affect the catalytic reaction, ii) mutation near the catalytic moiety
(I91A and K170A) affects only the catalyst activity but with no significant enantiomeric excess
modification observed (always ∼ 30%). Based on information gained from computational
calculations, we speculated that replacing residue isoleucine at position 91 by alanine provides
a larger opening at the catalytic center (Figure 2.18). To confirm the location of the catalytic
center in the pocket of hCA II and the influences that different mutations can have on catalysis,
structural insights on the guest-host interactions need to be gained by X-ray diffraction.
Nevertheless, this demonstrates the importance of the environment around the active metal
catalyst on performance.
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Figure 2.18. Structure of complex [(cp∗)Ir(6)Cl]Cl (17) ⊂ hCA II (PDB code 1G52, Maurus Schmid calcu-
lations). Positions I91 and K170 are highlighted.
Complementary to the preliminary study related to the chemogenetic optimization, ad-
ditional investigations to improve catalyst selectivity by modifying reaction conditions were
undertaken.
Catalytic reaction parameter modifications
Reaction conditions were optimized in order to further improve the selectivity of the hybrid
catalyst [(cp∗)Ir(6)Cl]Cl (17) ⊂ I91A. Modification to the reaction temperature, catalyst
loading, as well as reaction time are presented in Tables 2.10 to 2.12. As previously shown in
section 2.3.1, the complex loading into WT hCA II reached a maximum around 0.8 equivalent.
For this purpose, different catalyst loadings were also tested. As shown in Table 2.10, it is
noteworthy that the conversion at 20 ◦C in the presence of protein was improved (entries 3 to
6) compared to the free protein catalysis (entries 1 and 2). A so-called “protein accelerated
catalysis” phenomenon was observed, and this is discussed in Section 2.4.2. In addition, the
enantiomeric excess increased up to 56%, but no significant difference between WT and I91A
was observed (entries 5 and 8).
76
2.4. Catalysis
Table 2.10. Results for the transfer hydrogenation of substrate 39 at room temperature.a
Entry Complex Substrate Protein equivalent
of complex
Conv.b TON ee (%)
1 17 39 - 0.8 12 7 0
2 17 39 - 0.6 10 8 0
3 17 39 - 0.4 9 9 0
4 17 39 WT 0.8 39 22 52 (S)
5 17 39 WT 0.6 53 39 56 (S)
6 17 39 WT 0.4 30 34 57 (S)
7 17 39 I91A 0.8 59 33 49 (S)
8 17 39 I91A 0.6 75 56 54 (S)
9 17 39 I91A 0.4 74 82 58 (S)
10 - 39 WT - 0 0 0
11 - 39 I91A - 0 0 0
a Reaction conditions: The reaction was carried out at r.t. for 20 h, 20 mM substrate,
0.35 mM protein, in 0.4 M MOPS buffer (200 µL total volume, 5% DMSO) containing 3 M
formate, pH 7.5.
b Determined by normal phase HPLC after extraction; the relative response was corrected by
the experimentally determined response factor; amine [%] = (amine x 100)/(amine+imine).
The decrease in temperature to 4 ◦C afforded an increase in the selectivity of the transfer
hydrogenation reaction up to 69% ee for compound 38. This increase was achieved by using
[(cp∗)Ir(6)Cl]Cl ⊂ WT hCA II as a hybrid catalyst. Again, no marked selectivity difference
between WT hCA II and mutant I91A was observed (Table 2.11, entry 3 to 6). In addition,
the activity of the catalyst based on the WT hCA II is lower compared to mutant I91A. By
increasing catalyst loading to 5%, the conversion reached 70% (TON = 16, entry 14).
Furthermore, a decrease in the enantiomeric excess can be expected if the catalyst is no
longer bound to the protein. To prevent the release of metal complex into catalytic buffer,
the addition of Zn(II) to the catalyst solution was considered. Results are presented in
Table 2.10. It should be noted that the addition of zinc does not affect the results obtained
for the reduction of 39.
Finally, hybrid catalyst [(cp∗)Ir(41)Cl]Cl (18) ⊂ hCA II used for NMR solution studies
was tested under the same reaction conditions (Table 2.10, entries 7 to 2). This catalyst
shows a lower activity compared to [(cp∗)Ir(6)Cl]Cl (17) ⊂ WT hCA II. Nevertheless, the
enantiomeric excess observed remains stable for the WT protein (66 % (S, entry 7). We
speculate that the catalyst activity depends on the nature of the sulfonamide attached to the
2-picolylamine part of the ligand.
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Table 2.11. Results for the transfer hydrogenation of substrate 39 at 4 ◦C.a
Entry Complex Substrate Protein equivalent
of complex
Conv.b TON ee (%)
1 17 39 - 0.8 0 0 0 (S)
2 17 39 - 0.6 0 0 0 (S)
3 17 39 WT 0.8 19 10 67 (S)
4 17 39 WT 0.6 19 14 69 (S)
5 17 39 I91A 0.8 15 8 62 (S)
6 17 39 I91A 0.6 19 14 68 (S)
7 - 39 WT - 0 0 0
8 - 39 I91A - 0 0 0
a Reaction conditions: The reaction was carried out at 4 ◦C. for 20 h, 20 mM substrate,
0.35 mM protein, in 0.4 M MOPS buffer (200 µL total volume, 5% DMSO) containing 3 M
formate, pH 7.5.
b Determined by normal phase HPLC after extraction; the relative response was corrected by
the experimentally determined response factor; amine [%] = (amine x 100)/(amine+imine).
Table 2.12. Results for the transfer hydrogenation of substrate 39 at 4 ◦C with addition of zinc in the reaction
buffer.a
Entry Complex Substrate Protein Conv.b TON ee (%)
1 17 39 WT 27 17 68 (S)
2 17 39 I91A 23 14 64 (S)
3 17 39 K170A 18 11 69 (S)
4 17 + Zn 39 WT 35 22 69 (S)
5 17 + Zn 39 I91A 27 17 63 (S)
6 17 + Zn 39 K170A 22 14 66 (S)
7 18 39 WT 7 4 66 (S)
8 18 39 I91A 9 5 23 (S)
9 18 39 K170A 6 4 42 (S)
10 18 + Zn 39 WT 7 5 51 (S)
11 18 + Zn 39 I91A 9 5 21 (S)
12 18 + Zn 39 K170A 6 4 42 (S)
13c 17 39 WT 82 16 70 (S)
14c 17 39 I91A 70 14 66 (S)
a Reaction conditions: The reaction was carried out at 4 ◦C for 44 h using
1.6 mol% complex (0.3 mM final concentration), 20 mM substrate, 0.4 mM
protein, in 0.4 M MOPS buffer (200 µL total volume, 5% DMSO) containing
3 M formate, pH 7.5.
b Determined by normal phase HPLC after extraction; the relative response
was corrected by the experimentally determined response factor; amine [%] =
(amine x 100)/(amine+imine). c 5% catalyst loading.
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2.4.2 Michaelis-Menten kinetic experiments
As previously reported for biotin-streptavidin technology, the host protein is not only responsi-
ble for inducing enantioselectivity, but also for increasing the reaction rate of the catalyst. This
phenomenon is called “protein accelerated catalysis”. [63] The kinetic data were collected for
different hybrid catalysts at given times with different initial concentrations of substrate. Ob-
served reaction velocity for the reduction of 1-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline
(39) are reported in Figure 2.19.
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Figure 2.19. Velocity curves for [(cp∗)Ir(6)Cl]Cl (17) or hCA II artificial metalloenzymes as a function of
1-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline (39) concentration. 1.8 mol% complex (0.35 mM final con-
centration), 0.4 mM protein, in 0.4 M MOPS buffer (200 µL total volume, 5% DMSO) containing 3 M formate,
pH 7.5, 25 ◦C. [(cp∗)Ir(6)Cl]Cl (17) (•), [(cp∗)Ir(6)Cl]Cl (17) ⊂ WT (•), [(cp∗)Ir(6)Cl]Cl (17) ⊂ I91A (•).
The Michaelis-Menten kinetic model is one of the simplest models to describe steady-
state enzyme kinetics (equation 2.4); however, many proteins show significant deviations, for
example due to inhibition. [64] Calculated values Km, Vmax and, if necessary Ki, were obtained
from the iteration procedures of equation 2.4 or 2.5 are compiled in Table 2.13. For reactions
following the Michaelis-Menten kinetic profile, the rate of product formation is given by
v =
Vmax · [S]
Km + [S]
(2.4)
where Vmax is the maximum velocity achieved by the system, and Km the Michaelis
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constant. It follows that kcat = Vmax/[E]0, where [E]0 is the enzyme concentration, i.e. the
catalyst concentration.
For kinetic studies of [(cp∗)Ir(6)Cl]Cl (17)⊂WT, we assume a simple scenario of substrate
inhibition due to a binding event that inhibits the enzyme at high substrate concentration,
which can be described by the following equation: [64]
v =
Vmax · [S]
Km + [S] +
[S]2
Ki
(2.5)
Note that other mechanisms of inhibition should also be considered, [65] requiring much
more detailed kinetic exploration beyond the reach of the current studies.
Table 2.13. Kinetics parameters derived from equation 2.4 and 2.5.
Entry Enzyme Vmax (mM/min) Km (mM) Ki (mM) kcat (1/min) kcat/Km (1/mM*min)
1 17 ⊂ WT 2.31 · 10−2 6.67 45.08 6.60 · 10−2 9.89 · 10−3
2 17 ⊂ I91A 1.85 · 10−2 8.63 - 5.28 · 10−2 6.11 · 10−3
Thus kinetic study shows an increase of reaction rate using artificial metalloenzymes com-
pared to the protein-free catalysis. The presence of a hydrophobic pocket around the catalytic
metal may provide a favorable environment for the transfer of hydride to substrate 39. In
addition, transfer hydrogenation catalyzed by complex 17 could not be fitted using equations
2.4 nor 2.5. Further investigation should be carried out to determine the kinetic profile of
complex 17.
Note, however, that a point mutation of hCA II-WT eliminates any inhibition of the
hybrid catalyst. One possible reason may be the enlargement of the hydrophobic pocket by
substitution of isoleucine by a smaller amino acid (alanine) at position 91. This hypothesis
may be explored in the future by NMR studies on the position and orientation adopted by
the substrate in the catalytic pocket.
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The creative ’act’ is a process, not a moment.
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3
Conclusion and outlook
This study dealt with the development of a new hybrid catalyst based on a human Carbonic
Anhydrase II scaffold for the reduction of cyclic imines. For this purpose, a first generation
of piano-stool hCA II inhibitors incorporating a bidentate ligand bearing an arylsulfonamide
anchor was designed in silico. To further fine-tune the binding affinity of the metal complex
for hCA II, a second recognition motif was developed. X-ray structure analysis revealed a
CH/π interaction between [(η6-C6Me6)Ru(4)Cl]Cl and the amino acid residue phenylalanine,
at position 131 (F131). In parallel with these structural investigations, widely applicable force
field parameters amenable to molecular dynamics simulations of hCA II-inhibitor interactions
(Maurus Schmid and Tristan Bereau) were experimentally validated.
Based on computational results and X-ray information gained during the first part of my
Ph.D., a second generation of catalysts (based on a 2-picolylamine ligand bearing a sulfon-
amide anchor) was designed in silico. Coupled to a second recognition element, which ensures
the precise localization of catalytic metals within the hCA II binding pocket, inhibitors show
improved binding affinities towards wild-type hCA II (down to level of nM). In this way,
a well-defined chiral second coordination sphere was tailored to provide a favorable envi-
ronment for enantioselective catalysis. A chemogenetic strategy allowed the optimization of
[(cp∗)Ir(6)Cl]Cl (17) ⊂ I91A hCA II as a hybrid catalyst for the enantioselective reduction of
prochiral imines. A single point mutation was sufficient to prevent substrate inhibition, and
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an enantiomeric excess of 69 % (S ) was obtained for the synthesis of salsolidine.
A novel artificial metalloenzyme based on hCA II has thus been developed. From this
point onward, the goal is to improve the catalytic performance of the artificial metalloenzyme
(activity and selectivity). For this purpose, further chemogenetic modifications are necessary,
i.e. genetic variation of hCA II combined with chemical fine-tuning of the ligand by modifying
the arylsulfonyl group.
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Experimental
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La première vertu d’une pensée active sera donc de s’attacher
aux problèmes qui se posent et non pas à ceux que l’on sup-
pose.
D. de Rougemont
4
Experimental section
4.1 General experimental conditions
4.1.1 Solvents and reagents
Materials and reagents were purchased at the highest commercially available grade and used
without further purification.
Solvents used for reactions correspond to the quality “puriss”. For analytical and prepara-
tive high performance liquid chromatography (HPLC), HPLC-grade solvents were used. The
water used for reactions was filtered using a Barnstead ultrapure water system.
4.1.2 Separation and purification methods
Reactions were monitored by thin layer chromatography (TLC) using Merck silica gel 60 F254
plates. Flash chromatography was performed using Merck silica gel 60, particle size 40-63 µm.
Compounds were visualized using UV (254 and/or 366 nm) with a UV-lamp from Camag.
High performance liquid chromatography was performed on Agilent 1100 Series with UV-
Vis detection.
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4.1.3 Spectroscopic methods
1H, 13C and 19F-NMR spectra were recorded (295 K) on Bruker Avance DRX-500 or DPX-400
MHz spectrometers. Solvents for NMR were obtained from Cambridge Isotope Laboratories,
Inc. (Andover, MA, USA). Chemical shifts (δ) are reported in ppm using trimethylsilyane or
the residual solvent peaks as a reference and coupling constants (J ) are reported in Hertz (Hz).
The multiplicity’s are abbreviated as: s = singlet, d = doublet, t = triplet, m = multiplet
and br = broad.
The NOESY experiment of [(η6-C6H6)Ru(4)Cl]Cl (9) was carried out at 25
◦C on a Bruker
DRX600 NMR spectrometer, equipped with a z-axis pulsed field gradient dual broadband in-
verse probehead. The temperature was calibrated using a methanol sample. A phase-sensitive
NOESY experiment was performed with 2048 time points in F2 and 512 time increments in
the indirect dimension F1, which corresponds to acquisition times of 190 ms in F2 and 47 ms
in F1. The mixing time was set to 1.2 s, the recycling delay was 1.5 s and the total experiment
time was 1.7 h.
Circular dichroism (CD) spectroscopy analyses were performed on a Chirascan spectropho-
tometer from Applied Photophysics Ltd (United Kingdom).
The esterase activity screening assay (Section 4.4.1) and competitive displacement assay
(Section 4.4.2) were performed using a Tecan Safire spectrophotometer using NUNC 96-well
plates. The data were analyzed with gnuplot [1] (Version 4.2) software using a least-square
fitting.
4.1.4 Spectrometric methods
The mass spectra (MS) were recorded on an Esquire 3000 plus (Bruker) for Electron Spray
Ionisation (ESI) and/or a Finnigan MAT 8400 for Fast Atom Bombardment (FAB) and/or
Voyager-DE PRO bioSpectrometry for Maldi-TOF measurements (matrix: 4-nitroaniline).
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High resolution mass spectrometry (HRMS) was recorded on a Bruker FTMS 4.7T
BioAPEX II.
4.1.5 Other methods
The elementary analysis (EA) was measured on a Analysator 240 from Perkin-Elmer or a
vario MICRO cube from Elementar.
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4.2 Ligand synthesis
4.2.1 2,2’-Bipyridine-5-sulfonamide (1)
2,2’-Bipyridine-5-sulfonic acid (46) [2]
5 6
N
7
8
4
N
3
2
SHO1
O
O
46
2,2’-Bipyridine (25.00 g, 160.0 mmol, 1.0 eq) was added slowly to oleum (60 mL) maintained
at 0 ◦C, followed by addition of HgSO4 (818 mg, 2.8 mmol, 0.01 eq). The mixture was stirred
for 24 h at 220 ◦C. The reaction mixture was allowed to cool to room temperature, and the
remaining sulfuric acid was removed by distillation. The solid was dissolved in water (125 mL),
and activated charcoal (5 g) was added. The solution was refluxed for 15 min, and the mixture
was filtered over celite. The pH of the obtained red solution was adjusted with conc. aqueous
NH3 to pH 12-13. The aqueous solution was then washed three times with CH2Cl2 in order
to remove the starting material. Tetra-n-butylammonium bromide (25.0 g) was added, and
the solution was extracted with CH2Cl2 (3 x 100 mL) and the combined organic layers were
washed with water. Hydrobromic acid (48% in H2O, 5 mL) was added, and the mixture was
shaken, washed with CH2Cl2 and the volume of the aqueous layer was reduced. The solution
was cooled to 0 ◦C, and cooled isopropanol (20 mL) was added to precipitate the product. The
precipitate was filtered and dried to obtain 46 (7.12 g, 29.9 mmol, 19%) as a white powder.
Annex spectra page: 161
1H NMR (400 MHz, D2O, 20
◦C, δ): 8.85 (d, J = 2.2 Hz, 1H, H2), 8.47 (dt, J = 4.9, 1.3 Hz,
1H, H8), 8.19 (dd, J = 8.3, 2.3 Hz, 1H, H3), 7.94 (dd, J = 8.4, 0.8 Hz, 1H, H4), 7.86 (m,
2H, H5,7), 7.41 (ddd, J = 6.9, 4.9, 1.9 Hz, 1H, H6).
13C NMR (101 MHz, D2O, 20
◦C, δ): 157.4, 153.9, 149.4, 146.3, 139.4, 138.8, 135.9, 125.5,
122.8, 122.3.
MS (FAB, pos.) m/z : [M]+ calcd for C10H8N2O3S, 236.0; found, 236.0.
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2,2’-Bipyridine-5-sulfonamide (1) [2]
5 6
N
7
8
4
N
3
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SH2N1
O
O
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Compound 46 (1.51 g, 6.4 mmol, 1.0 eq) was placed in a round-bottom flask and PCl5 (1.47 g,
7.1 mmol, 1.1 eq) was added. The mixture (calcium chloride protected) was heated at 120 ◦C
for 30 min. The reaction mixture was allowed to cool to room temperature, and toluene
(20 mL) was added. The solution was refluxed for 2 h. After cooling, the solution was
filtered. The solvent and phosphorylchloride residues were removed under reduced pressure
(3 h). A conc. aqueous solution of NH3 (50 mL) was added to the solid, and the solution
was stirred overnight. The solution was concentrated, and the solid was filtered, washed with
cooled water and dried under reduced pressure to obtain 1 (0.90 g, 3.8 mmol, 60%) as a pale
brown solid.
Annex spectra page: 163
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 9.07 (d, J = 2.2 Hz, 1H, H2), 8.74 (ddd, J = 4.1,
1.5, 0.8 Hz, 1H, H8), 8.57 (d, J = 8.3 Hz, 1H, H4), 8.44 (d, J = 7.9 Hz, 1H, H5), 8.34 (dd,
J = 8.4, 2.4 Hz, 1H, H3), 8.00 (td, J = 7.8, 1.8 Hz, 1H, H6), 7.65 (s, 2H, H1), 7.53 (ddd,
J = 7.5, 4.7, 1.2 Hz, 1H, H7).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 157.7, 153.8, 149.6, 146.3, 140.1, 137.6, 135.0,
125.1, 121.3, 120.6.
MS (ESI, pos.) m/z (relative intensity): [M+H]+ calcd for C10H10N3O2S, 236.0; found, 236.0
(100) [M+H]+, 258.0 (10) [M+Na]+.
EA Anal. calcd for C10H9N3O2S: C, 51.05%; H, 3.86%; N, 17.86%. Found: C, 50.79%;
H, 4.06%; N, 17.45%.
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4.2.2 4-(Di-2-pyridinylamino)-benzenesulfonamide (2)
N -(4-(Methylthio)phenyl)-N -(pyridin-2-yl)pyridine-2-amine (49)
N
N
N
7
65
4
32
S
1
49
2-Bromopyridine (4.23 mL, 44.2 mmol, 2.2 eq), 4-(methylmercapto)aniline (2.5 mL, 20.1 mmol,
1.0 eq), 1,1-bis(diphenylphosphino)ferrocene (0.83 g, 1.5 mmol, 0.07 eq),
tris(dibenzylideneacetone) dipalladium (0.66 g, 0.7 mmol, 0.07 eq) and sodium tert-butoxide
(5.43 g, 56.5 mmol, 2.8 eq) were dissolved in dry toluene (50 mL). The reaction mixture was
flushed with N2, and heated at 100
◦C for 24 h. The solution was cooled to room temperature,
and CH2Cl2 (50 mL) was added. The solid was removed by filtration and purified by flash
gel chromatography (cyclohexane/EtOAc, 1/1). The solvent was removed under vacuum to
obtain 49 (5.33 g, 18.2 mmol, 90%) as a pale yellow powder.
Annex spectra page: 165
TLC : n-hexane/EtOAC (1/1); Rf = 0.10.
1H NMR (400 MHz, CD3OD, 20
◦C, δ): 8.20 (ddd, J = 5.1, 2.0, 0.9 Hz, 2H, H7), 7.71 (ddd,
J = 8.4, 7.3, 2.0 Hz, 2H, H5), 7.31 (d, J = 8.6 Hz, 2H, H2), 7.07 (m, 4H, H3,6), 6.99 (d,
J = 8.3 Hz, 1H, H4), 2.49 (s, 3H, H1).
13C NMR (101 MHz, CD3OD, 20
◦C, δ): 159.3, 148.9, 143.1, 139.9, 137.7, 129.1, 128.7,
120.0, 118.8, 16.0.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C17H16N3S, 294.1064; found, 294.1053.
EA Anal. calcd for C17H15N3S ·
1
5H2O: C, 68.75%; H, 5.23%; N, 14.15%. Found: C, 68.87%;
H, 5.15%; N, 13.99%.
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N -(4-(Methylsulfonyl)phenyl)-N -(pyridin-2-yl)pyridine-2-amine (50)
N
N
N
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4
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O
O
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Compound 49 (500 mg, 1.7 mmol, 1.0 eq) was dissolved in CH2Cl2 (25 mL). Finely ground
KMnO4/MnO2 (4.0 g, 1/1) was added in small portions over a period of 15 min. The mixture
was stirred vigorously overnight at room temperature. The product was filtered through celite
in order to remove spent oxidant. The residue was then washed with CH2Cl2 (2 x 30 mL).
The solvent was dried over Na2SO4, and removed under reduced pressure to yield 50 (270 mg,
0.8 mmol, 49%) as a white solid.
Annex spectra page: 167
TLC : CH2Cl2/MeOH (9/1); Rf = 0.65.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.32 (dd, J = 4.8, 1.2 Hz, 2H, H7), 7.84 (d,
J = 8.7 Hz, 2H, H2), 7.77 (td, J = 8.2, 1.9 Hz, 2H, H5), 7.22 (d, J = 8.7 Hz, 2H, H3), 7.15
(dd, J = 7.0, 5.1 Hz, 2H, H6), 7.04 (d, J = 8.2 Hz, 2H, H4), 3.22 (s, 3H, H1).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 157.0, 149.5, 148.6, 138.5, 135.3, 128.3, 125.0,
119.8, 118.0, 43.7.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C17H16N3O2S, 326.0963; found, 326.0952.
EA Anal. calcd for C17H15N3O2S: C, 61.52%; H, 4.59%; N, 12.59%. Found: C, 62.09%;
H, 4.86%; N, 12.01%.
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N -(Pyridine-2-yl)-N -(4-((2-(trimethylsilyl)ethyl)sulfonyl)phenyl)pyridin-2-amine (51)
N
N
N
9
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To diisopropylamine (156 µL, 1.1 mmol, 1.2 eq) in dry THF (20 mL) at 0 ◦C n-butyllithium
(634 µL, 1.6 M solution in n-hexane, 1.0 mmol, 1.1 eq) was added. The solution was stirred
for 5 min, and then cooled to -70 ◦C with a dry ice/acetone bath. A solution of 50 (300 mg,
0.9 mmol, 1.0 eq) in dry THF (30 mL) was added over 10 min, and the reaction mixture stirred
for 1 h. Chloromethyltrimethylsilane (180 µL, 1.3 mmol, 1.4 eq) was added dropwise, and the
mixture was stirred overnight while allowing to warm to room temperature. The reaction was
quenched with an aqueous solution of 1 M HCl (50 mL), and the aqueous phase extracted with
EtOAc (3 x 60 mL). The combined organic fractions were washed with brine and dried over
Na2SO4. The solvent was removed under reduced pressure to obtain 51 (232 mg, 0.6 mmol,
61%) as a white solid.
Annex spectra page: 169
TLC : CH2Cl2/MeOH (9/1); Rf = 0.82.
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 8.39 (s, 2H, H9), 7.81 (d, J = 7.3 Hz, 2H, H4), 7.66
(s, 2H, H7), 7.24 (d, J = 7.7 Hz, 2H, H5), 7.04 (m, 4H, H6,8), 3.00 (m, 2H, H3), 1.02 (m,
2H, H2), 0.01 (s, 9H, H1).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 157.4, 149.8, 149.2, 138.5, 133.6, 129.7, 124.8, 120.0,
118.6, 53.1, 8.88, -1.87.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C21H26N3O2SSi, 412.1515; found, 412.1501.
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4-(Di-2-pyridinylamino)-benzenesulfonamide (2)
N
N
N
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To a solution of 51 (190 mg, 0.5 mmol, 1.0 eq) in dry THF (5 mL) a 1 M solution of TBAF in
THF (1.38 mL, 1.4 mmol, 3.0 eq) was added. The mixture was refluxed for 1 h, and cooled to
room temperature. A solution of sodium acetate (206 mg, 2.5 mmol, 5.4 eq) in 2 mL of water
and hydroxyl-amine-O-sulfonic acid (281 mg, 2.5 mmol, 5.4 eq) were added sequentially, and
the mixture was stirred overnight at room temperature. The reaction mixture was quenched
by adding H2O (25 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers
were washed sequentially with saturated NaHCO3 solution, water and brine. The organic
layer was dried over Na2SO4, and the solvent was removed under vacuum. The product was
purified by flash gel chromatography (CH2Cl2/MeOH, 5 %) to obtain 2 (71 mg, 0.2 mmol,
47%) as a brown solid.
Annex spectra page: 171
TLC : CH2Cl2/MeOH (9/1); Rf = 0.50.
1H NMR (400 MHz, CDCl3/CD3OD, 20
◦C, δ): 8.32 (d, J = 3.8 Hz, 2H, H7), 7.79 (d,
J = 8.7 Hz, 2H, H2), 7.63 (td, J = 8.2, 1.9 Hz, 2H, H5), 7.16 (d, J = 8.7 Hz, 2H, H3), 7.04
(dd, J = 7.0, 5.3 Hz, 2H, H6), 7.00 (d, J = 8.2 Hz, 2H, H4).
13C NMR (101 MHz, CDCl3/CD3OD, 20
◦C, δ): 157.6, 149.0, 148.9, 138.3, 137.6, 128.0,
125.5, 119.7, 118.2.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C16H15N4O2S, 327.0915; found, 327.0906.
EA Anal. calcd for C16H14N4O2S ·
1
7CH2Cl2: C, 57.28%; H, 4.25%; N, 16.55%. Found:
C, 57.44%; H, 4.33%; N, 16.19%.
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4.2.3 (4-((2,2’-Bipyridine)4-yl)benzenesulfonamide (3)
(E)-3-(4-(Methylthio)phenyl)-1-(pyridin-2-yl)prop-2-en-1-one (55)
2
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To 4-(methylthio)benzaldehyde (5.61 mL, 42.0 mmol, 1.1 eq) in a 1.0 M aqueous solution
of NaOH (30 mL) and MeOH (90 mL), 2-acetylpyridine (4.49 mL, 40.0 mmol, 1.0 eq) was
added. After 3 h of stirring at room temperature, the solution was stored at 4 ◦C overnight.
The yellow precipitate was filtered and washed with H2O and cold MeOH. The solvent was
removed under reduced pressure. The isolated product was recrystallized from MeOH to
obtain 55 (5.30 g, 20.8 mmol, 52%) as a yellow-green solid.
Annex spectra page: 173
TLC : n-hexane/EtOAc (1/1); Rf = 0.51.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.80 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H, H9), 8.22
(d, J = 16.1 Hz, 1H, H4), 8.10 (ddd, J = 7.9, 1.4, 1.0 Hz, 1H, H6), 8.05 (ddd, J = 7.9, 7.4,
1.7 Hz, 1H, H7), 7.82 (d, J = 16.1 Hz, 1H, H5), 7.76 (d, J = 8.3 Hz, 2H, H2), 7.69 (ddd,
J = 7.4, 4.7, 1.4 Hz, 1H, H8), 7.32 (d, J = 8.4 Hz, 2H, H3), 2.53 (s, 3H, H1).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 188.6, 153.5, 149.1, 143.7, 142.4, 137.7, 130.9,
129.2, 127.6, 125.6, 122.4, 119.6, 14.1.
HRMS (ESI, pos.) m/z : [M+H]+ calcd for C15H14NOS, 256.0796; found, 256.0793.
EA Anal. calcd for C15H13NOS: C, 70.56%; H, 5.13%; N, 5.49%. Found: C, 70.30%; H, 5.17%;
N, 5.59%.
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2-(6-Ethoxy-4-(4-(methylthio)phenyl)-5,6-dihydro-2H-pyran-2-yl)pyridine (56)
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Compound 55 (2.0 g, 7.8 mmol, 1.0 eq) and yttrium (III) hexafluoroacetylacetanoate (0.10 g,
0.1 mmol, 0.02 eq) were dissolved in THF (40 mL) and 4 Å molecular sieves (2 g) were added.
Ethyl vinyl ether (7.5 mL, 78.3 mmol, 10.0 eq) was added, and the reaction was stirred under
nitrogen at room temperature for 3 days. The sieves were removed by filtration over celite.
The solvent was removed under reduced pressure, and the brown oil was purified by flash gel
chromatography (n-hexane/EtOAc, 3/1) to obtain 56 (1.87 g, 5.7 mmol, 73%) as a colorless
oil.
Annex spectra page: 175
TLC : n-hexane/EtOAc (1/1); Rf = 0.66.
1H NMR (400 MHz, CD3OD, 20
◦C, δ): 8.46 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H, H13), 7.83
(td, J = 7.8, 1.8 Hz, 1H, H11), 7.69 (dt, J = 8.0, 1.1 Hz, 1H, H10), 7.31 (ddd, J = 7.6, 4.9,
1.2 Hz, 1H, H12), 7.21 (m, 4H, H2,3), 6.02 (dd, J = 2.9, 1.2 Hz, 1H, H6), 5.28 (dd, J = 8.6,
2.0 Hz, 1H, H7), 4.10 (dq, J = 9.6, 7.1 Hz, 1H, H8), 3.82 (ddd, J = 9.9, 6.7, 2.8 Hz, 1H, H5),
3.72 (dq, J = 9.6, 7.1 Hz, 1H, H8
′
), 2.44 (s, 3H, H1), 2.32 (dddd, J = 13.2, 6.8, 2.1, 1.3 Hz,
1H, H4), 1.84 (ddd, J = 13.2, 10.3, 8.6 Hz, 1H, H4
′
), 1.25 (t, J = 7.1 Hz, 3H, H9).
13C NMR (101 MHz, CD3OD, 20
◦C, δ): 153.9, 150.0, 149.8, 142.7, 138.6, 137.9, 129.1,
128.0, 124.4, 120.3, 105.6, 101.8, 65.7, 38.9, 38.4, 16.0, 15.7.
MS (ESI, pos.) m/z (relative intensity): [M+H]+ calcd for C19H22NO2S, 328.1; found, 328.2
(100) [M+H]+, 350.0 (6) [M+Na]+.
EA Anal. calcd for C19H21NO2S: C, 69.69%; H, 6.46%; N, 4.28%. Found: C, 69.79%;
H, 6.51%; N, 4.29%.
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(4-(4-(Methylthio)phenyl)-2,2’-bipyridine (52)
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Compound 56 (1.50 g, 4.5 mmol, 1.0 eq) was dissolved in ACN (10 mL) and H2NOH ·HCl
(3.18 g, 45.7 mmol, 10.4 eq) was added. The mixture was refluxed for 6 h, during which
time a yellow precipitate formed. The solution was allowed to cool to room temperature,
and the ACN was removed under reduced pressure to give an orange solid. A saturated
aqueous solution of NaOH/NaCl (30 mL) and CH2Cl2 (30 mL) were added to the solid, and
the mixture was stirred vigorously until all the solid had dissolved. The organic layer was
extracted with CH2Cl2 (3 x 20 mL), dried over Na2SO4, and the solvent was removed under
reduced pressure. The resulting solid was washed with MeOH to yield 52 (583 mg, 2.1 mmol,
46%) as a white powder.
Annex spectra page: 177
TLC : CH2Cl2/MeOH (9/1); Rf = 0.77.
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 8.72 (m, 3H, H5,6,10), 8.53 (d, J = 8.0 Hz, 1H, H7),
7.88 (td, J = 7.8, 1.8 Hz, 1H, H8), 7.73 (d, J = 8.5 Hz, 2H, H3), 7.57 (dd, J = 5.2, 1.9 Hz,
1H, H4), 7.37 (m, 3H, H2,9), 2.54 (s, 3H, H1).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 156.5, 156.0, 149.6, 149.3, 149.0, 140.5, 137.2, 134.6,
127.5, 126.7, 124.0, 121.5, 121.3, 118.7, 15.9.
HRMS (ESI, pos.) m/z : [M+H]+ calcd for C17H15N2S, 279.0955; found, 279.0951.
EA Anal. calcd for C17H14N2S ·
1
6H2O: C, 72.57%; H, 5.13%; N, 9.96%. Found: C, 72.50%;
H, 5.23%; N, 10.19%.
100
4.2. Ligand synthesis
(4-(4-(Methylsulfonyl)phenyl)-2,2’-bipyridine (57)
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Compound 52 (249 mg, 0.9 mmol, 1.0 eq) was dissolved in CH2Cl2 (20 mL). Finely ground
KMnO4/MnO2 (4.0 g, 1/1) was added to the solution over a period of 0.5 h. The mixture
was stirred at room temperature for 3 days. After completion of the reaction, the product
was filtered through celite and CH2Cl2 was removed under reduced pressure to obtain 57
(220 mg, 0.7 mmol, 79%) as a white powder which was used with no further purification.
Annex spectra page: 179
TLC : CH2Cl2/MeOH (9/1); Rf = 0.83.
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 8.79 (d, J = 5.1 Hz, 1H, H5), 8.72 (m, 2H, H6,10),
8.50 (d, J = 8.0 Hz, 1H, H7), 8.08 (d, J = 8.4 Hz, 2H, H2), 7.96 (d, J = 8.4 Hz, 2H, H3),
7.88 (td, J = 7.8, 1.8 Hz, 1H, H8), 7.55 (dd, J = 5.1, 1.8 Hz, 1H, H4), 7.38 (ddd, J = 7.6,
4.8, 1.2 Hz, 1H, H9), 3.11 (s, 3H, H1).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 156.8, 155.4, 150.1, 149.1, 147.6, 143.9, 141.0, 137.6,
128.4, 128.3, 124.4, 121.9, 121.7, 119.5, 44.7.
HRMS (ESI, pos.) m/z : [M+H]+ calcd for C17H15N2O2S, 311.0854; found, 311.0850.
EA Anal. calcd for C17H14N2O2S ·
1
3H2O: C, 64.54%; H, 4.67%; N, 8.85%. Found: C, 64.40%;
H, 4.42%; N, 8.81%.
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(4-(4-((2-(Trimethylsilyl)ethyl)sulfonyl)phenyl)-2,2’-bipyridine (58)
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Diisopropylamine (0.89 mL, 6.3 mmol, 1.3 eq) in THF (5 mL) was cooled to 0 ◦C and
n-butyllithium (2.2 M solution in cyclohexane) (2.6 mL, 5.8 mmol, 1.2 eq) was added. The
solution was stirred at 0 ◦C for 5 min, and cooled to -70 ◦C with a dry ice/acetone bath. A
solution of 57 (1.5 g, 4.8 mmol, 1.0 eq) in dry THF (5 mL) was added dropwise over a period
of 10 min. The reaction mixture was stirred for 1 h. Chloromethyltrimethylsilane (0.94 mL,
6.8 mmol, 1.4 eq) was added dropwise and the reaction was stirred at room temperature for
2 d. The reaction was quenched with a 1 M aqueous solution of HCl (2 mL), and the aqueous
phase extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with
brine and dried over MgSO4, and the solvent was removed under reduced pressure to obtain
58 (1.61 g, 4.0 mmol, 84%) as a red-brown solid.
Annex spectra page: 181
TLC : CH2Cl2/MeOH (9/1); Rf = 0.74.
1H NMR (500 MHz, CDCl3, 20
◦C, δ): 8.79 (d, J = 5.1 Hz, 1H, H7), 8.73 (b, 2H, H8,12),
8.48 (d, J = 7.9 Hz, 1H, H9), 8.03 (d, J = 8.4 Hz, 2H, H4), 7.95 (d, J = 8.4 Hz, 2H, H5),
7.90 (td, J = 7.7, 1.8 Hz, 1H, H10), 7.58 (dd, J = 5.1, 1.8 Hz, 1H, H6), 7.39 (ddd, J = 7.4,
4.8, 1.2 Hz, 1H, H11), 3.04 (m, 2H, H3), 0.94 (m, 2H, H2), 0.01 (s, 9H, H1).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 156.3, 155.1, 149.9, 148.9, 147.8, 143.5, 139.2, 137.9,
129.2, 128.2, 124.5, 122.1, 121.9, 119.7, 53.0, 9.3, -1.9.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C21H25N2O2SSi, 397.1406; found, 397.1398.
EA Anal. calcd for C21H24N2O2SSi ·
2
3H2O: C, 61.73%; H, 6.25%; N, 6.86%. Found: C, 61.36%;
H, 6.14%; N, 6.56%.
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(4-((2,2’-Bipyridine)4-yl)benzenesulfonamide (3)
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To a solution of 58 (262 mg, 0.7 mmol, 1.0 eq) in dry THF (5 mL) a 1 M solution of TBAF in
THF (3.87 mL, 3.9 mmol, 4.3 eq) was added. The mixture was refluxed for 1 h, and cooled to
room temperature. A solution of sodium acetate (523 mg, 6.4 mmol, 9.7 eq) in 2 mL of water
and hydroxyl-amine-O-sulfonic acid (729 mg, 6.5 mmol, 9.8 eq) were added sequentially, and
the mixture was stirred overnight at room temperature. The reaction mixture was quenched
by adding H2O (10 mL), and extracted with EtOAc (3 x 30 mL). The organic fractions were
washed sequentially with saturated NaHCO3 solution, water and brine. The organic layer was
dried over Na2SO4, and the solvent was removed under reduced pressure. The product was
purified by flash chromatography (CH2Cl2/MeOH, gradient 0 to 5 %) to obtain 3 (149 mg,
0.5 mmol, 72%) as a white solid.
Annex spectra page: 183
TLC : CH2Cl2/MeOH (9/1); Rf = 0.38.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.81 (d, J = 5.1 Hz, 1H, H5), 8.74 (d, J = 4.0 Hz,
1H, H10), 8.71 (d, J = 1.5 Hz, 1H, H6), 8.45 (d, J = 8.0 Hz, 1H, H7), 8.08 (d, J = 8.5 Hz,
2H, H2), 7.99 (m, 3H, H3,8), 7.85 (dd, J = 5.1, 1.9 Hz, 1H, H4), 7.51 (m, 3H, H1,9).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 156.2, 154.9, 150.2, 149.4, 146.9, 144.7, 140.5,
137.5, 127.6, 126.6, 124.5, 121.9, 120.7, 117.9.
HRMS (ESI, pos.) m/z : [M+H]+ calcd for C16H14N3O2S, 312.0806; found, 312.0803.
EA Anal. calcd for C16H13N3O2S ·
1
3EtOAc: C, 61.11%; H, 4.63%; N, 12.34%. Found:
C, 61.02%; H, 4.69%; N, 12.34%.
103
Chapter 4. Experimental section
4.2.4 N -(Di(2-pyridyl)methyl)-amidobenzene-4-sulfonamide (4)
Bis(pyridine-2-yl)methanamine (60) [3]
NH2
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Di-2-pyridyl ketoxime (507 mg, 2.5 mmol, 1.0 eq) was dissolved in a mixture of H2O (7.5 mL),
EtOH (12.5 mL) and NH3 (25% in water, 10.5 mL). Ammonium acetate (369 mg, 4.8 mmol,
1.8 eq) was added and the solution was heated to 80 ◦C. Zn powder (753 mg, 11.5 mmol,
4.5 eq) was added portionwise over a period of 0.5 h. The reaction mixture was stirred for
5 h at 80 ◦C. The mixture was allowed to cool and residual Zn powder was removed by
filtration. All volatiles were removed under reduced pressure. The solution was basified with
a 10 M aqueous solution of NaOH (10 mL) . The aqueous layer was extracted with CH2Cl2
(3 x 30 mL). The combined organic layers were washed with brine, dried over Na2SO4 and
the solvent was removed under reduced pressure to afford 60 (340 mg, 1.8 mmol, 72%) as an
oil.
Annex spectra page: 185
1H NMR (400 MHz, CDCl3, 20 ◦C, δ): 8.54 (ddd, J = 4.8, 1.7, 0.9 Hz, 2H, H6), 7.60 (td,
J = 7.7, 1.8 Hz, 2H, H4), 7.36 (dt, J = 8.0, 1.1 Hz, 2H, H3), 7.11 (ddd, J = 7.5, 4.8, 1.2 Hz,
2H, H5), 5.30 (s, 1H, H2), 2.43 (s, 2H, H1).
MS (ESI-MS, pos.) m/z (relative intensity): [M+H]+ calcd for C11H12N3, 186; found, 186
(100) [M+H]+, 208 (10) [M+Na]+.
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2,5-Dioxopyrrolidin-1-yl-4-sulfamoylbenzoate (61) [4]
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4-Carboxybenzenesulfonamide (5.02 g, 24.9 mmol, 1.0 eq) was dissolved in DMF (100 mL) and
N -hydroxysuccinimide (3.26 mg, 28.4 mmol, 1.1 eq) was added. The mixture was cooled to
0 ◦C and N,N ’-dicyclohexylcarbodiimide (5.0 g, 24.2 mmol, 1.0 eq) was added. The solution
was stirred at room temperature overnight. The solvent was removed under reduced pressure.
The white solid was washed with cooled isopropanol (2 x 50 mL) and dried under reduced
pressure to obtain 61 (6.63 g, 22.2 mmol, 89%) as a white powder.
Annex spectra page: 186
TLC : CH2Cl2/MeOH (9/1); Rf = 0.78.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.30 (d, J = 8.5 Hz, 2H, H3), 8.08 (d, J = 8.5 Hz,
2H, H2), 7.71 (s, 2H, H1), 2.91 (s, 4H, H4).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 170.2. 161.0, 149.8, 130.9, 127.2, 126.7, 25.6.
MS (FAB-MS, pos.) m/z (relative intensity): [M]+ calcd for C11H10N2O6S, 298; found, 184
(100) [M-(N -Hydroxysuccinimide)]+, 299 (52) [M+H]+, 452 (27) [M+H+NBA]+, 597 (10)
[2M+H]+.
EA Anal. calcd for C11H10N2O6S: C, 44.29%; H, 3.38%; N, 9.39%. Found: C, 44.10%;
H, 3.62%; N, 9.52%.
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N -(Di(2-pyridyl)methyl)-amidobenzene-4-sulfonamide (4)
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Compound 61 (1.09 g, 5.9 mmol, 1.0 eq) was dissolved in acetone (1 mL), H2O (2 mL), and
a 1 M aqueous solution of H2KPO4 (4 mL). Compound 60 (1.87 mg, 6.3 mmol, 1.1 eq) was
added. The solution was stirred overnight at room temperature. EtOH (10 mL) was added to
allow product precipitation, and the mixture was stored in the fridge for 3 d. The solvent was
removed by decantation, and the solid was purified by flash chromatography (CH2Cl2/MeOH,
gradient 1 to 5 %). The solvent was removed under reduced pressure to obtain 4 (2.01 g,
5.4 mmol, 92%) as a white powder.
Annex spectra page: 188
TLC : CH2Cl2/MeOH (9/1); Rf = 0.50.
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 9.43 (d, J = 7.9 Hz, 1H, H4), 8.53 (dd, J = 4.8,
1.6 Hz, 2H, H9), 8.10 (d, J = 8.3 Hz, 2H, H3), 7.93 (d, J = 8.4 Hz, 2H, H2), 7.79 (td,
J = 7.7, 1.7 Hz, 2H, H7), 7.54 (b, 4H, H1,6), 7.30 (dd, J = 7.5, 4.8 Hz, 2H, H8), 6.47 (d,
J = 7.9 Hz, 1H, H5).
13C NMR (126 MHz, DMSO-d6, 20 ◦C, δ): 165.1, 159.5, 148.9, 146.5, 137.0, 136.9, 128.3,
125.7, 122.6, 122.2, 60.1.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C18H17N4O3S, 369.1021; found, 369.1016.
EA Anal. calcd for C18H16N4O3S ·
1
2H2O ·MeOH: C, 55.73%; H, 5.17%; N, 13.68%. Found:
C, 55.70%; H, 4.99%; N, 13.87%.
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N -Benzyl-4-sulfamoylbenzamide (40)
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Benzylamine (202 µL, 1.8 mmol, 1.2 eq) was dissolved in acetone (6 mL), H2O (12 mL), and
a 1 M aqueous solution of H2KPO4 (4 mL). Compound 61 (500 mg, 1.7 mmol, 1.0 eq) was
added. The solution was stirred at room temperature for 2 h. The solid was extracted with
EtOAc (3 x 30 mL). The combined organic layers were washed with brine and dried over
Na2SO4. The product was purified by flash chromatography (CH2Cl2/MeOH, gradient 1 to
5%). The solvent was removed under reduced pressure to obtain 40 (246 mg, 0.8 mmol, 50%)
as a white powder.
Annex spectra page: 190
TLC : CH2Cl2/MeOH (9/1); Rf = 0.63.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 9.23 (t, J = 5.9 Hz, 1H, H4), 8.04 (d, J = 8.5 Hz,
2H, H3), 7.91 (d, J = 8.4 Hz, 2H, H2), 7.49 (s, 2H, H6), 7.34 (s, 2H, H7), 7.33 (s, 2H, H1),
7.25 (ddd, J = 8.7, 5.1, 3.7 Hz, 1H, H8), 4.50 (d, J = 6.0 Hz, 2H, H5).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 165.2, 146.3, 139.3, 137.2, 128.3, 127.9, 127.2,
126.8, 125.6, 42.7.
MS (FAB-MS, pos.) m/z (relative intensity): [M]+ calcd for C14H14N2O3S, 290.1; found,
290.1 (100) [M]+, 184.0 (65) [M-C7H8N]
+.
EA Anal. calcd for C14H14N2O3S: C, 57.92%; H, 4.86%; N, 9.65%. Found: C, 57.55%;
H, 4.94%; N, 9.66%.
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N -(4-Methylbenzyl)-4-sulfamoylbenzamide (42)
O
N
H
4
3
2
S
O
OH2N1
5
7
6
8
42
4-Methylbenzylamine (320 µL, 2.5 mmol, 1.5 eq) was dissolved in acetone (2 mL), H2O (6 mL),
and a 1 M aqueous solution of H2KPO4 (2 mL). Compound 61 (500 mg, 1.7 mmol, 1.0 eq)
was added. The solution was stirred at room temperature for 2 h. The solid was extracted
with EtOAc (3 x 30 mL). The combined organic layers were washed with brine and dried over
Na2SO4. The product was purified by flash chromatography (CH2Cl2/MeOH, gradient 1 to
5%). The solvent was removed under reduced pressure to obtain 42 (184 mg, 0.6 mmol, 36%)
as a white powder.
Annex spectra page: 192
TLC : CH2Cl2/MeOH (9/1); Rf = 0.51.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 9.17 (t, J = 6.0 Hz, 1H, H4), 8.03 (d, J = 8.4 Hz,
2H, H3), 7.90 (d, J = 8.4 Hz, 2H, H2), 7.47 (s, 2H, H1), 7.22 (d, J = 8.1 Hz, 2H, H6), 7.14
(d, J = 8.0 Hz, 2H, H7), 4.44 (d, J = 5.9 Hz, 2H, H5), 2.27 (s, 3H, H8).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 165.1, 146.2, 137.2, 136.3, 135.8, 128.8, 127.8,
127.2, 125.6, 42.5, 20.6.
MS (FAB-MS, pos.) m/z (relative intensity): [M]+ calcd for C15H16N2O3S, 304.1; found,
304.1 (100) [M]+, 184.0 (99) [M-C8H11N]
+.
EA Anal. calcd for C15H16N2O3S: C, 59.13%; H, 5.33%; N, 9.17%. Found: C, 59.19%;
H, 5.30%; N, 9.20%.
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N -(4-Fluorobenzyl)-4-sulfamoylbenzamide (43)
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4-Fluorobenzylamine (289 µL, 2.5 mmol, 1.5 eq) was dissolved in acetone (2 mL), H2O (6 mL),
and a 1 M aqueous solution of H2KPO4 (2 mL). Compound 61 (500 mg, 1.7 mmol, 1.0 eq)
was added. The solution was stirred at room temperature for 2 h. The solid was extracted
with EtOAc (3 x 30 mL). The combined organic layers were washed with brine and dried
over Na2SO4. The product was purified by flash chromatography (CH2Cl2/MeOH, gradient
5 to 20%). The solvent was removed under reduced pressure to obtain 43 (228 mg, 0.7 mmol,
44%) as a white powder.
Annex spectra page: 194
TLC : CH2Cl2/MeOH (9/1); Rf = 0.65.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 9.22 (t, J = 6.0 Hz, 1H, H4), 8.03 (d, J = 8.4 Hz,
2H, H3), 7.91 (d, J = 8.4 Hz, 2H, H2), 7.48 (s, 2H, H1), 7.37 (dd, J = 8.7, 4.0 Hz, 2H, H6),
7.16 (dd, J = 8.7, 6.8 Hz, 2H, H7), 4.47 (d, J = 5.8 Hz, 2H, H5).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 165.2, 146.3, 137.1, 135.5, 129.3, 127.9, 125.6,
115.1, 114.9, 42.1.
19F NMR (376 MHz, DMSO-d6, 20 ◦C, δ): -116.1.
MS (FAB-MS, pos.) m/z (relative intensity): [M]+ calcd for C14H13FN2O3S, 308.1; found,
308.1 (100) [M]+, 184.0 (84) [M-C7H7NF]
+.
EA Anal. calcd for C14H13FN2O3S ·
2
5H2O: C, 53.29%; H, 4.41%; N, 8.88%. Found: C, 53.08%;
H, 4.25%; N, 9.26%.
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N -(4-(Trifluoromethyl)benzyl)-4-sulfamoylbenzamide (44)
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4-(Trifluoromethyl)benzylamine (359 µL, 2.5 mmol, 1.5 eq) was dissolved in acetone (2 mL),
H2O (6 mL), and a 1 M aqueous solution of H2KPO4 (2 mL). Compound 61 (500 mg,
1.7 mmol, 1.0 eq) was added. The solution was stirred overnight at room temperature. The
solid was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed
with brine and dried over Na2SO4. The product was purified by flash chromatography
(CH2Cl2/MeOH, 10%). The solvent was removed under reduced pressure to obtain 44 (104 mg,
0.3 mmol, 17%) as a white powder.
Annex spectra page: 196
TLC : CH2Cl2/MeOH (9/1); Rf = 0.42.
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 9.34 (t, J = 6.0 Hz, 1H, H4), 8.05 (d, J = 8.4 Hz,
2H, H3), 7.92 (d, J = 8.4 Hz, 2H, H2), 7.71 (d, J = 8.1 Hz, 2H, H7), 7.55 (d, J = 8.0 Hz,
2H, H6), 7.50 (s, 2H, H1), 4.58 (d, J = 5.9 Hz, 2H, H5).
13C NMR (126 MHz, DMSO-d6, 20 ◦C, δ): 165.4, 146.4, 144.2, 136.9, 128.0, 127.9, 125.7,
125.3, 125.2, 42.4.
19F NMR (376 MHz, DMSO-d6, 20 ◦C, δ): -60.8.
MS (FAB-MS, pos.) m/z (relative intensity): [M]+ calcd for C15H13F3N2O3S, 358.0; found,
358.1 (100) [M]+, 184.0 (99) [M-C8H11N]
+.
EA Anal. calcd for C15H13F3N2O3S ·
1
3H2O: C, 49.45%; H, 3.78%; N, 7.69%. Found: C, 49.50%;
H, 3.69%; N, 7.76%.
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N -(2,3-Difluorobenzyl)-4-sulfamoylbenzamide (45) [5]
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2,3-Difluorobenzylamine (470 µL, 4.1 mmol, 1.2 eq) was dissolved in acetone (6 mL), H2O
(12 mL), and a 1 M aqueous solution of H2KPO4 (4 mL). Compound 61 (1.01 mg, 3.4 mmol,
1.0 eq) was added. The solution was stirred overnight at room temperature. The solid
was filtered, and washed with EtOH. The product was purified by flash chromatography
(CH2Cl2/MeOH, gradient 1 to 5%). The solvent was removed under reduced pressure to
obtain 45 (155 mg, 0.5 mmol, 14%) as a white powder.
Annex spectra page: 198
TLC : CH2Cl2/MeOH (9/1); Rf = 0.59.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 9.26 (t, J = 5.7 Hz, 1H, H4), 8.04 (d, J = 8.5 Hz,
2H, H3), 7.91 (d, J = 8.5 Hz, 2H, H2), 7.49 (s, 2H, H1), 7.34 (m, 1H, H8), 7.19 (m, 2H,
H6,7), 4.57 (d, J = 5.6 Hz, 2H, H5).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 165.3, 146.4, 136.8, 128.6, 128.5, 128.0, 125.7,
124.7, 124.6, 116.1, 115.9, 36.5.
19F NMR (376 MHz, DMSO-d6, 20 ◦C, δ): -139.7 (d, J = 21.8 Hz, 1F), -144.6 (d, J =
21.8 Hz, 1F).
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C14H13F2N2O3S, 327.0614; found, 327.0618.
EA Anal. calcd for C14H13F2N2O3S: C, 51.53%; H, 3.71%; N, 8.58%. Found: C, 51.34%;
H, 3.75%; N, 8.48%.
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4.2.5 4-(2-(Aminomethyl)pyridin-4-yl)benzenesulfonamide (5)
N -(tert-Butyl)-4-(2-cyanopyridin-4-yl)benzenesulfonamide (65)
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4-Chloro-2-pyridinecarbonitrile (182 mg, 1.3 mmol, 0.7 eq) and 4-(tert-butylaminosulphonyl)
benzene-boronic acid (496 mg, 1.9 mmol, 1.0 eq) were dissolved in THF (8 mL).
Tetrakis(triphenylphosphine)-palladium (136 mg, 0.1 mmol, 0.06 eq) and an aqueous solu-
tion (2 mL) of Na2CO3 (381 mg, 3.6 mmol, 1.9 eq) were added. The reaction mixture was
heated at 80 ◦C for 6 h. The cooled crude mixture was poured onto water (50 mL), and
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried over Na2SO4.
The product was purified by flash chromatography (n-hexane/EtOAc 1/1). The solvent was
removed under reduced pressure to obtain 65 (325 mg, 1.0 mmol, 80%) as a pale brown
powder.
Annex spectra page: 200
TLC : n-hexane/EtOAc (1/1); Rf = 0.54.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.85 (d, J = 5.2 Hz, 1H, H7), 8.51 (dd, J = 1.9,
0.9 Hz, 1H, H5), 8.15 (ddd, J = 5.2, 1.9, 0.8 Hz, 1H, H6), 8.10 (d, J = 8.2 Hz, 2H, H3), 7.97
(d, J = 8.4 Hz, 2H, H4), 7.69 (s, 1H, H2), 1.12 (s, 9H, H1).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 151.9, 147.1, 145.6, 138.3, 133.5, 127.9, 127.0,
126.8, 125.2, 117.5, 53.5, 29.8.
HRMS (ESI-MS, pos.) m/z : [M+Na]+ calcd for C16H17N3O2SNa, 338.0939; found, 338.0941.
EA Anal. calcd for C16H17N3O2S ·
1
3EtOAc: C, 60.39%; H, 5.75%; N, 12.19%. Found:
C, 60.31%; H, 5.58%; N, 12.30%.
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N -(tert-Butyl)-4-(2-(aminomethyl)pyridin-4-yl)benzenesulfonamide (66)
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LiAlH4 (104 mg, 2.7 mmol, 2.2 eq) was added to dry THF (10 mL). The reaction mixture was
allowed to stir until a homogeneous slurry had formed. AlCl3 (267 mg, 1.6 mmol, 1.6 eq) was
then added, the reaction mixture was cooled to 0 ◦C, and a solution of 65 (382 mg, 1.2 mmol,
1.0 eq) in THF (10 mL) was added dropwise. The reaction was allowed to warm to room
temperature, and was stirred for 2 h. The reaction was quenched with a 2 M aqueous solution
of NaOH (10 mL). The product was extracted with EtOAc (3 x 50 mL), and the combined
organic layers were washed with brine and dried over Na2SO4. The solvent was removed
under reduced pressure, and the obtained orange solid was dissolved in CH2Cl2 (30 mL) and
di-tert-butyl dicarbonate (528 mg, 2.4 mmol, 2.0 eq) was added. The solution was stirred
overnight at room temperature. The solvent was removed, and the product was purified by
flash gel chromatography (n-hexane/EtOAc, 1/1) to obtain 66 (328 mg, 0.8 mmol, 65%) as
a colorless oil.
Annex spectra page: 202
TLC : n-hexane/EtOAc (1/1); Rf = 0.17.
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 8.72m, 8.63M (dd, J = 5.2, 0.8 Hz, 1H, H7), 8.00
(d, J = 8.7 Hz, 2H, H3), 7.72 (d, J = 8.7 Hz, 2H, H4), 7.52m, 7.49M (dd, J = 1.8, 0.8 Hz,
1H, H5), 7.41 (dd, J = 5.2, 1.8 Hz, 1H, H6), 5.57 (s, 1H, H9), 5.30 (s, 1H, H2), 4.62m, 4.52M
(d, J = 5.5 Hz, 2H, H8), 1.62m, 1.47M (s, 9H, H10), 1.26 (s, 9H, H1).
13C NMR (126 MHz, DMSO-d6, 20 ◦C, δ): 158.7, 156.2, 150.6, 149.9, 147.6, 144.1, 141.9,
127.8, 127.7, 121.9, 120.5, 119.8, 79.8, 54.9, 45.9, 30.3, 28.5.
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MS (ESI-MS, pos.) m/z : [M+H]+ calcd for C21H30N3O4S, 420.2; found, 420.2.
EA Anal. calcd for C21H29N3O4S ·
1
4CH2Cl2: C, 57.81%; H, 6.82%; N, 9.26%. Found:
C, 57.87%; H, 6.72%; N, 9.22%.
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4-(2-(Aminomethyl)pyridin-4-yl)benzenesulfonamide (5)
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A few drops of anisole were added to a solution of compound 66 (410 mg, 1.3 mmol, 1.0 eq)
in TFA (5 mL). The solution was stirred overnight at room temperature. After removal of
TFA under a gentle stream of N2, the product was dissolved in a mixture of CH2Cl2/MeOH,
and precipitated with diethyl ether. The solvent was removed by filtration and 5 (545 mg,
1.0 mmol, 76%) was obtained as a pale brown solid.
Annex spectra page: 204
TLC : n-hexane/EtOAc (1/1); Rf = 0.17.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.73 (d, J = 5.2 Hz, 1H, H6), 8.39 (b, 3H, H8),
8.02 (d, J = 8.6 Hz, 2H, H2), 7.98 (d, J = 8.6 Hz, 2H, H3), 7.92 (s, 2H, H4), 7.82 (dd,
J = 5.3, 1.8 Hz, 1H, H5), 7.50 (s, 2H, H1), 4.29 (d, J = 5.8 Hz, 2H, H7).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 154.2, 149.7, 146.5, 144.8, 139.8, 127.5, 126.5,
120.9, 120.2, 42.8.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C12H14N3O2S, 264.0806; found, 264.0802.
EA Anal. calcd for C12H13N3O2S · 2TFA: C, 39.11%; H, 3.08%; N, 8.55%. Found: C, 39.30%;
H, 3.24%; N, 8.62%.
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4.2.6 N -((4-(4-Sulfamoylphenyl)pyridin-2-yl)methyl)benzenesulfonamide (6)
4-Bromo-2-methylpyridine-N -oxide (68)
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4-Bromo-2-methylpyridine (3.00 mg, 17.4 mmol, 1.0 eq) and 3-chloroperoxybenzoic acid
(4.80 mg, 27.8 mmol, 1.6 eq) in CH2Cl2 (20 mL) were stirred overnight at room temper-
ature. A 2 M aqueous solution of Na2CO3 (20 mL) was added, and the reaction mixture was
stirred for 1 h. The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), and the combined
organic layers were washed with brine and dried over Na2SO4. The solvent was removed under
reduced pressure to obtain 68 (2.40 g, 12.8 mmol, 73%) as a yellow oil.
Annex spectra page: 205
TLC : CH2Cl2/MeOH (9/1); Rf = 0.72.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.16 (d, J = 6.9 Hz, 1H, H1), 7.79 (d, J = 2.9 Hz,
1H, H3), 7.51 (dd, J = 6.9, 3.0 Hz, 1H, H2), 2.32 (s, 3H, H4).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 149.6, 139.8, 129.2, 126.9, 116.3, 16.9.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C6H7BrNO, 187.9711; found, 187.9704.
EA Anal. calcd for C6H6BrNO ·
1
4H2O: C, 37.43%; H, 3.40%; N, 7.28%. Found: C, 37.51%;
H, 3.57%; N, 6.96%.
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4-Bromo-2-hydroxymethylpyridine (69)
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Compound 68 (2.40 g, 12.8 mmol, 1.0 eq) was dissolved in dry CH2Cl2 (10 mL) and the
solution was cooled to 0 ◦C. Trifluoroacetic acid anhydride (15 mL) was added. When the
vigorous thermal reaction had ceased, the orange mixture was stirred at room temperature
for 30 min and then refluxed for 3 h. An aqueous saturated solution of NaHCO3 was carefully
added. The aqueous layer was extracted with CH2Cl2 (3 x 30 mL), and the combined organic
layers were washed with brine, and dried over Na2SO4. The solvent was removed under
reduced pressure to obtain 69 (1.90 g, 10.1 mmol, 79%) as a brown oil.
Annex spectra page: 207
TLC : n-hexane/EtOAc (1/1); Rf = 0.25.
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 8.37 (d, J = 5.3 Hz, 1H, H1), 7.49 (d, J = 1.1 Hz,
1H, H3), 7.38 (dd, J = 5.4, 1.7 Hz, 1H, H2), 4.75 (s, 2H, H4).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 161.1, 149.5, 133.7, 125.9, 124.1, 64.1.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C6H7BrNO, 187.9711; found, 187.9704.
EA Anal. calcd for C6H6BrNO ·
1
4H2O: C, 37.43%; H, 3.40%; N, 7.28%. Found: C, 37.28%;
H, 3.18%; N, 7.13%.
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4-Bromo-2-pyridine aldehyde (73)
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To compound 69 (1.90 g, 10.1 mmol, 1.0 eq) in chloroform (15 mL), MnO2 (8.78 g, 101.0 mmol,
10.0 eq) was added. The reaction mixture was refluxed for 2 h. Then the solid material was
removed by filtration over celite, and the solvent was removed under reduced pressure to
obtain 73 (1.07 g, 5.75 mmol, 57%) as a brown oil.
Annex spectra page: 209
TLC : n-hexane/EtOAc (1/1); Rf = 0.58.
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 10.04 (s, 1H, H4), 8.61 (d, J = 5.3 Hz, 1H, H1),
8.12 (s, 1H, H3), 7.70 (d, J = 3.7 Hz, 1H, H2).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 192.1, 153.7, 151.0, 134.3, 131.8, 125.3.
MS (FAB-MS, pos.) m/z (relative intensity): [M]+ calcd for C6H4BrNO, 184.9; found, 157.0
(100) [M-COH]+, 185.0 (12) [M]+.
EA Anal. calcd for C6H4BrNO ·
1
2CHCl3: C, 36.96%; H, 2.62%; N, 6.63%. Found: C, 37.27%;
H, 2.39%; N, 6.63%.
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4-Bromo-2-pyridine ketoxime (72)
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To compound 73 (1.07 g, 5.8 mmol, 1.0 eq) in MeOH (15 mL), NaHCO3 (0.77 g, 9.2 mmol,
1.6 eq) and NH2OH ·HCl (1.40 g, 20.1 mmol, 3.5 eq) were added. The reaction mixture was
stirred overnight at room temperature before diluting with EtOAc (30 mL), and washing with
NaHCO3 solution and brine. The organic layer was dried over Na2SO4, and the solvent was
removed under reduced pressure to obtain 72 (0.98 g, 4.9 mmol, 85%) as a yellow solid.
Annex spectra page: 211
TLC : n-hexane/EtOAc (1/1); Rf = 0.50.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 11.90 (s, 1H, H4), 8.47 (dd, J = 5.4, 0.6 Hz, 1H,
H1), 8.07 (s, 1H, H5), 7.93 (dd, J = 2.0, 0.6 Hz, 1H, H3), 7.66 (dd, J = 5.3, 1.9 Hz, 1H, H2).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 153.6, 150.8, 147.7, 132.4, 126.8, 122.5.
MS (FAB-MS, pos.) m/z : [M]+ calcd for C6H5BrN2O, 199.9; found, 200.0.
EA Anal. calcd for C6H5BrN2O ·
1
10EtOAc: C, 36.63%; H, 2.79%; N, 13.35%. Found: C, 36.50%;
H, 2.77%; N, 13.06%.
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N -[(4-Bromopyridin-2-yl)methyl]benzenesulfonamide (70)
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Zinc dust (1.37 g, 21.0 mmol, 6.0 eq) was added in several portions to a solution of compound
72 (700 mg, 3.5 mmol, 1.0 eq) in TFA (15 mL) at 0 ◦C. The reaction mixture was stirred for
15 min, and added to a mixture of a 2 M aqueous solution of NaOH (20 mL) and CH2Cl2
(20 mL). The insoluble material was removed by filtration, and the organic layer was sepa-
rated. The organic layer was washed with water, brine and dried over Na2SO4. The solvent
was removed under reduced pressure. The reduced product was dissolved in CH2Cl2 (15 mL)
and DIPEA (0.70 mL, 4.2 mmol, 1.2 eq) was added. The reaction mixture was stirred at 25 ◦C
for 10 min. It was then cooled to 0 ◦C, and benzenesulfonyl chloride (0.29 mL, 2.2 mmol,
0.7 eq) was added dropwise. The resulting solution was allowed to warm up to 25 ◦C, and
was stirred overnight. The reaction mixture was diluted with CH2Cl2 (20 mL), washed with
water and brine before drying over Na2SO4. The product was purified by flash chromatogra-
phy (n-hexane/EtOAc, 1/1) to afford 70 (280 mg, 0.9 mmol, 25%) as a pale yellow solid.
Annex spectra page: 213
TLC : n-hexane/EtOAc (1/1); Rf = 0.32.
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 8.25 (d, J = 5.2 Hz, 1H, H1), 7.84 (dt, J = 7.2,
1.4 Hz, 2H, H6), 7.53 (t, J = 7.4 Hz, 1H, H8), 7.46 (t, J = 7.5 Hz, 2H, H7), 7.34 (d,
J = 1.4 Hz, 1H, H3), 7.31 (dd, J = 5.3, 1.7 Hz, 2H, H2), 4.25 (s, 2H, H4).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 156.7, 149.9, 139.7, 132.9, 129.2, 127.3, 126.2, 125.4,
100.1, 47.3.
MS (ESI-MS, pos.) m/z (relative intensity): [M+H]+ calcd for C12H12BrN2O2S, 326.9;
found, 327.0 (100) [M+H]+, 349.0 (37) [M+Na]+.
EA Anal. calcd for C12H11BrN2O2S: C, 44.05%; H, 3.39%; N, 8.56%. Found: C, 44.15%;
H, 3.47%; N, 8.61%.
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N -((4-(4-Sulfamoylphenyl)pyridin-2-yl)methyl)benzenesulfonamide (6)
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A mixture of 4-sulfamoylphenylboronic acid pinacol ester (207 mg, 0.7 mmol, 1.2 eq), 70
(200 mg, 0.6 mmol, 1.0 eq), tetrakis(triphenylphosphine)palladium (40 mg, 0.03 mmol, 0.05 eq),
Na2CO3 (191 mg, 1.8 mmol, 2.9 eq), water (1.5 mL) and 1,4-dioxane (1.5 mL) were heated
in a sealed vial in a microwave reactor at 150 ◦C for 15 min. The reaction mixture was di-
luted with CH2Cl2 (30 mL), and washed with water and brine. The organic layer was dried
over Na2SO4 and the solvent was removed under reduced pressure. The product was purified
by flash chromatography (CH2Cl2/MeOH, 3%) to obtain 6 (160 mg, 0.4 mmol, 64%) as a
colorless solid.
Annex spectra page: 215
TLC : CH2Cl2/MeOH (9/1); Rf = 0.51.
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 8.52 (d, J = 6.1 Hz, 1H, H6), 8.35 (t, J = 6.3 Hz,
1H, H8), 7.96 (d, J = 8.5 Hz, 2H, H2), 7.86 (d, J = 8.4 Hz, 2H, H3), 7.79 (d, J = 6.9 Hz,
2H, H9), 7.55 (m, 1H, H1,4,5,10,11), 4.22 (d, J = 6.1 Hz, 2H, H7).
13C NMR (126 MHz, DMSO-d6, 20 ◦C, δ): 157.8, 149.6, 146.1, 144.6, 140.7, 140.3, 132.3,
129.1, 127.4, 126.5, 126.4, 120.1, 119.3, 48.1.
MS (ESI-MS, pos.) m/z : [M]+ calcd for C18H18N3O4S2, 404.1; found, 404.1.
EA Anal. calcd for C18H17N3O4S2 ·
1
3H2O: C, 52.80%; H, 4.35%; N, 10.26%. Found: C, 52.61%;
H, 4.23%; N, 10.42%.
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N -[(4-Bromopyridin-2-yl)methyl]-2,6-difluorobenzene-1-sulfonamide (71)
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Zinc dust (1.93 g, 29.5 mmol, 6.0 eq) was added in several portions to a solution of com-
pound 72 (987 mg, 4.9 mmol, 1.0 eq) in TFA (15 mL) at 0 ◦C. The reaction mixture was
stirred for 15 min, and added to a mixture of a 2 M aqueous solution of NaOH (20 mL) and
CH2Cl2 (20 mL). The insoluble material was removed by filtration, and the organic layer was
separated. The organic layer was washed with water, brine and dried over Na2SO4. The
solvent was removed under reduced pressure. The reduced product was dissolved in CH2Cl2
(15 mL) and DIPEA (0.59 mL, 4.3 mmol, 0.9 eq) was added. The reaction mixture was
stirred at 25 ◦C for 10 min. It was then cooled to 0 ◦C, and 2,6-difluorobenzenesulfonyl
chloride (917 mg, 7.3 mmol, 1.1 eq) was added dropwise. The resulting solution was allowed
to reach 25 ◦C, and was stirred overnight. The reaction mixture was diluted with CH2Cl2
(20 mL), washed with water and brine before drying over Na2SO4. The product was purified
by flash chromatography (n-hexane/EtOAc, 1/1) to afford 71 (698 mg, 1.9 mmol, 39%) as a
pale yellow solid.
Annex spectra page: 217
TLC : n-hexane/EtOAc (1/1); Rf = 0.27.
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 8.32 (d, J = 5.5 Hz, 1H, H1), 7.61 (d, J = 1.9 Hz,
1H, H3), 7.47 (m, 2H, H2,7), 6.98 (t, J = 8.5 Hz, 1H, H6), 6.49 (t, J = 5.9 Hz, 1H, H5), 4.52
(d, J = 5.8 Hz, 2H, H4).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 156.1, 149.7, 134.5, 134.4, 134.1, 126.5, 125.7, 113.2,
113.0, 47.5.
19F NMR (376 MHz, CDCl3, 20
◦C, δ): -107.2.
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MS (ESI-MS, pos.) m/z (relative intensity): [M+H]+ calcd for C12H10BrF2N2O2S, 363.0;
found, 363.0 (100) [M+H]+, 385.0 (100) [M+Na]+.
EA Anal. calcd for C12H9BrF2N2O2S: C, 39.69%; H, 2.50%; N, 7.71%. Found: C, 39.44%;
H, 2.65%; N, 7.63%.
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2,6-Difluoro-N -((4-(4-sulfamoylphenyl)pyridin-2-yl)methyl)benzenesulfonamide (41)
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A mixture of 4-sulfamoylphenylboronic acid pinacol ester (147 mg, 0.5 mmol, 1.2 eq), 71
(160 mg, 0.4 mmol, 1.0 eq), tetrakis(triphenylphosphine)palladium (20 mg, 0.02 mmol, 0.05 eq),
Na2CO3 (136 mg, 1.3 mmol, 2.9 eq), water (1.2 mL) and 1,4-dioxane (1.2 mL) were heated in
a sealed vial in a microwave reactor at 150 ◦C for 15 min. The reaction mixture was diluted
with CH2Cl2 (30 mL), and washed with water and brine. The organic layer was dried over
Na2SO4, and the solvent was removed under reduced pressure. The product was purified
by flash chromatography (CH2Cl2/MeOH, 3%) to obtain 41 (82 mg, 0.2 mmol, 42%) as a
colorless solid.
Annex spectra page: 219
TLC : CH2Cl2/MeOH (9/1); Rf = 0.45.
1H NMR (400 MHz, CD3OD, 20
◦C, δ): 8.47 (d, J = 5.3 Hz, 1H, H6), 8.03 (d, J = 8.5 Hz,
2H, H2), 7.80 (d, J = 8.5 Hz, 2H, H3), 7.74 (d, J = 1.3 Hz, 1H, H4), 7.52 (dd, J = 5.3,
1.9 Hz, 1H, H5), 7.47 (t, J = 8.5 Hz, 1H, H10), 6.98 (d, J = 8.6 Hz, 2H, H9), 4.47 (s, 2H,
H7), 1.19 (s, 2H, H1),
19F NMR (376 MHz, CD3OD, 20
◦C, δ): -108.9.
MS (ESI-MS, pos.) m/z : [M+H]+ calcd for C18H16F2N3O4S2, 440.0; found, 440.1.
EA Anal. calcd for C18H15F2N3O4S2 · 2H2O: C, 45.47%; H, 4.03%; N, 8.84%. Found:
C, 45.67%; H, 3.86%; N, 8.45%.
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4.2.7 1,3-Dimesityl-5-((4-sulfamoylbenzamido)methyl)-4,5-dihydro-1H -imidazol-
3-ium (7)
4-(N -(tert-Butyl)sulfamoyl)benzoic acid (79)
S
O
O
HN
2
1 43
O
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A solution of tert-butylamine in MeOH (50 mL, 3/1) was cooled to 0 ◦C and
4-(chlorosulfonyl)benzoic acid (2.58 g, 11.7 mmol, 1.0 eq) was slowly added. The reaction
mixture was stirred overnight. A 2 M aqueous solution of NaOH (50 mL) was added, and
the aqueous layer was washed with CH2Cl2 (4 x 100 mL) in order to remove the excess
tert-butylamine. The aqueous layer was acidified with a 2 M aqueous solution of HCl until
pH 1. The product was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers
were washed with brine, and dried over Na2SO4 to obtain 79 (1.58 g, 6.2 mmol, 53%) as a
white powder.
Annex spectra page: 221
TLC : CH2Cl2/MeOH (10%); Rf = 0.25.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 13.38 (s, 1H, H5), 8.09 (d, J = 8.4 Hz, 2H, H4),
7.93 (d, J = 8.6 Hz, 2H, H3), 7.72 (s, 1H, H2), 1.09 (s, 9H, H1).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 166.3, 147.9, 133.6, 129.9, 126.5, 53.5, 29.7.
HRMS (ESI-MS, pos.) m/z : [M+Na]+ calcd for C11H15NO4SNa, 280.0619; found, 280.0618.
EA Anal. calcd for C11H15NO4S: C, 51.35%; H, 5.88%; N, 5.44%. Found: C, 51.36%;
H, 5.65%; N, 5.45%.
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2,5-Dioxopyrrolidin-1-yl-4-(N-(tert-butyl)sulfamoyl)benzoate (78)
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Compound 79 (5.02 g, 25.0 mmol, 1.0 eq) was dissolved in DMF (50 mL) and
N -hydroxysuccinimide (3.26 g, 28.4 mmol, 1.1 eq) was added. The reaction mixture was
cooled to 0 ◦C, and DCC (5.0 g, 25.0 mmol, 1.0 eq) was added. The solution was stirred
overnight at room temperature. The solvent was then removed under reduced pressure, and
the white solid was washed with isopropanol (2 x 50 mL). The solid was dried to afford
78 (6.63 g, 22.2 mmol, 89%) as a white powder.
Annex spectra page: 223
TLC : CH2Cl2/MeOH (10%); Rf = 0.25.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.28 (d, J = 8.6 Hz, 2H, H4), 8.08 (d, J = 8.6 Hz,
2H, H3), 7.89 (s, 1H, H2), 2.91 (s, 4H, H5), 1.12 (s, 9H, H1).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 170.1, 160.9, 150.2, 130.9, 127.3, 127.1, 53.7,
29.7, 25.5.
HRMS (ESI-MS, pos.) m/z : [M+Na]+ calcd for C15H18N2O6SNa, 377.0783; found, 377.0783.
EA Anal. calcd for C15H18N2O6S: C, 50.84%; H, 5.12%; N, 7.91%. Found: C, 50.85%;
H, 4.98%; N, 7.87%.
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N,N ’-Dimesitylpropane-1,2,3-triamine (77) [6]
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A round-bottom flask equipped with a magnetic stir-bar was charged with 2,3-dibromopropane-
1-ammonium bromide (4.20 g, 14.1 mmol, 1.0 eq) and 2,4,6-trimethylaniline
(20 mL, 141.0 mmol, 10 eq). After purging with nitrogen, the reaction mixture was stirred
overnight at 120 ◦C. It was then allowed to cool to room temperature, and was dissolved
with a 2 M aqueous solution of NaOH (50 mL) and Et2O (50 mL). The organic and aque-
ous layers were separated, and the organic layer was washed with water, and brine before
drying over Na2SO4. The solvent was removed under reduced pressure, and the excess
2,4,6-trimethylaniline was removed by distillation at 100 ◦C and 0.1 mmHg. The product was
purified by flash chromatography (CH2Cl2/MeOH 9/1, with 0.1% Et3N) to obtain 77 (2.00 g,
6.3 mmol, 44%) as a brown oil.
Annex spectra page: 225
TLC : CH2Cl2/MeOH (10%), with 0.1% Et3N; Rf = 0.37.
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 6.72 (s, 2H, H7), 6.70 (s, 2H, H7
′
), 3.73 (d,
J = 10.9 Hz, 1H, H3), 3.06 (dd, J = 11.9, 6.8 Hz, 1H, H4), 2.77 (d, J = 5.2 Hz, 1H, H4
′
),
2.74 (d, J = 4.7 Hz, 1H, H2), 2.65 (dd, J = 12.5, 5.4 Hz, 1H, H2
′
), 2.17-2,12 (m, 18H, H6,8).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 143.9, 142.4, 129.4, 129.2, 129.1, 129.0, 128.9,
128.8, 58.3, 50.0, 48.6, 43.5, 20.2, 20.1, 18.8, 18.2.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C21H32N3, 326.2596; found, 326.2598.
EA Anal. calcd for C21H31N3 ·
3
4H2O: C, 74.40%; H, 9.66%; N, 12.39%. Found: C, 74.33%;
H, 9.49%; N, 12.35%.
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N -(2,3-Bis(mesitylamino)propyl)-4-(N -(tert-butyl)sulfamoyl)benzamide (83)
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Compound 78 (300 mg, 0.8 mmol, 1.0 eq) was dissolved in DMF (5 mL) and compound 77
(304 g, 0.9 mmol, 1.1 eq) was added. The reaction mixture was stirred over the weekend at
room temperature, and then the DMF was removed under reduced pressure. The product
was purified by flash chromatography (EtOAc/Hexane 1/1) to obtain 83 (415 mg, 0.7 mmol,
87%) as a white powder.
Annex spectra page: 229
TLC : CH2Cl2/MeOH (10%); Rf = 0.49.
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 8.67 (t, J = 5.7 Hz, 1H, H5), 7.89 (s, 4H, H3,4),
7.66 (s, 1H,H2), 6.74 (s, 2H,H12), 6.69 (s, 2H,H12
′
), 3.91 (m, 1H,H10), 3.79 (d, J = 10.8 Hz,
1H, H7), 3.47 (m, 2H, H6,8), 3.36 (m, 1H, H6
′
), 3.05 (m, 1H, H9), 2.82 (m, 1H, H9
′
), 2.18
(m, 18H, H11,13), 1.09 (s, 9H, H1).
13C NMR (126 MHz, DMSO-d6, 20 ◦C, δ): 165.7, 146.4, 143.7, 141.8, 137.4, 129.5, 129.4,
129.3, 129.1, 129.0, 128.8, 127.8, 126.2, 56.6, 53.4, 50.1, 41.9, 29.7, 20.2, 18.8, 18.1.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C32H45N4O3S, 565.3212; found, 565.3202.
EA Anal. calcd for C32H44N4O3S: C, 68.05%; H, 7.85%; N, 9.92%. Found: C, 68.21%;
H, 7.81%; N, 9.84%.
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5-((4-(N -(tert-Butyl)sulfamoyl)benzamido)methyl)-1,3-dimesityl-4,5-dihydro-1H-
imidazol-3-ium chloride (74)
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Compound 83 (197 mg, 0.3 mmol, 1.0 eq) was dissolved in triethylorthoformate (5 mL) and
NH4Cl (21 g, 0.4 mmol, 1.1 eq) was added. The mixture was purged with N2 prior to heating
to 120 ◦C for 48 h. The reaction mixture was allowed to cool to room temperature, and the
product precipitated from Et2O. The white-brown solid was washed three times with Et2O,
and dried under reduced pressure to obtain 74 (121 mg, 0.2 mmol, 57%) as white powder.
Annex spectra page: 229
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 9.41 (t, J = 5.4 Hz, 1H, H), 9.14 (s, 1H, H), 7.91
(d, J = 8.6 Hz, 1H, H), 7.86 (s, 4H, H), 7.71 (d, J = 8.0 Hz, 1H, H), 7.09 (d, J = 10.8 Hz,
1H, H), 7.06 (s, 1H, H), 5.19 (dt, J = 18.8, 7.5 Hz, 1H, H), 4.70 (t, J = 11.8 Hz, 1H, H),
4.48 (dd, J = 12.7, 7.6 Hz, 1H, H), 3.67 (dd, J = 12.3, 5.7 Hz, 2H, H), 3.49 (q, J = 7.1 Hz,
6H, H), 2.43 (s, 3H, H), 2.39 (s, 3H, H), 2.35 (s, 3H, H), 2.32 (s, 3H, H), 2.29 (s, 3H, H),
2.24 (s, 3H, H), 1.07 (s, 9H, H).
13C NMR (126 MHz, DMSO-d6, 20 ◦C, δ): 165.6, 160.4, 146.8, 139.8, 139.4, 136.4, 135.4,
135.3, 130.7, 129.9, 129.8, 129.7, 129.5, 128.0, 126.1, 125.4, 61.5, 58.9, 54.6, 53.4, 53.1, 41.1,
29.7, 20.6, 20.5, 18.2, 17.8, 17.4, 17.1, 15.0.
HRMS (ESI-MS, pos.) m/z : [M+H]+ calcd for C33H44N4O3S, 575.3055; found, 575.3050.
EA Anal. calcd for C33H43ClN4O3S · 3NH4Cl ·H2O: C, 50.19%; H, 7.27%; N, 12.42%. Found:
C, 50.59%; H, 7.09%; N, 12.13%.
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4.3 Complex synthesis
4.3.1 General procedure for complex synthesis
Procedure 1
Bipyridine derivative complexes were synthesized according a modification of the procedure
published by Mann. [7] The ligand (0.28 mmol, 2.0 eq) and the metal dimer (0.14 mmol, 1.0 eq)
were dissolved in ACN (5 mL). The resulting solution was purged with nitrogen for 20 min,
and then refluxed for 4 h. The volume of the reaction was reduced to 2 mL, and the resulting
solid was filtered and washed with a small amount of cold ACN. The solid was dried under
vacuum to afford the desired complex.
Procedure 2
The picolylamine-derivative complexes were synthesized according a modification of the pro-
cedure published by Çetinkaya. [8] The ligand (0.28 mmol, 2.0 eq) and the metal dimer
(0.14 mmol, 1.0 eq) were dissolved in EtOH (5 mL), and the resulting solution was purged
with nitrogen for 20 min. The reaction mixture was refluxed for 2 h and the solvent was
removed under reduced pressure. The solid was washed with a small amount of CH2Cl2, and
dried to afford the desired complex.
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[(η6-C6Me6)RuCl2]2 (92)
Ru
Cl
1
Cl
Ru
Cl
Cl
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According to the published protocol, [9] a mixture of di-µ-chlorobis(p-cymene)chlororuthenium(II)
(0.80 g, 1.3 mmol, 1.0 eq) and hexamethylbenzene (8.75 g, 53.9 mmol, 41.2 eq) were heated
to 185 ◦C for 6 h. The crystals of hexamethylbenzene, which formed on the upper walls of
the flask due to sublimation, were periodically melted down with a heat gun. The reaction
mixture was cooled to room temperature, and the solid was broken up and transferred to a
glass filter containing celite. p-Cymene and the excess of hexamethylbenzene were removed
by washing with Et2O. The product was recovered from the celite with CH2Cl2 (100 mL).
The product was dried under reduced pressure to afford 92 (0.35 g, 0.5 mmol, 40%) as an
orange-red solid.
Annex spectra page: 231
1H NMR (400 MHz, CDCl3, 20
◦C, δ): 2.02 (s, 36H, H1).
13C NMR (101 MHz, CDCl3, 20
◦C, δ): 89.1. 16.1.
MS (Maldi-TOF, pos.) m/z : [M-Cl]+ calcd for C24H36Cl3Ru2, 632.9; found, 633.4.
EA Anal. calcd for C24H36Cl4Ru2: C, 43.12%; H, 5.43%; N, 0%. Found: C, 43.11%; H, 5.46%;
N, 0.39%.
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[(η6-C6H6)Ru(1)Cl]Cl (8)
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Following procedure 1 (section 4.3.1), compound 8 was obtained as a yellow solid (372 mg,
0.7 mmol, 89%).
Annex spectra page: 233
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 9.95 (d, J = 1.9 Hz, 1H, H2), 9.70 (d, J = 5.6,
1.4 Hz, 1H, H8), 8.85 (d, J = 8.5 Hz, 1H, H4), 8.74 (d, J = 8.0 Hz, 1H, H5), 8.60 (dd,
J = 8.4, 2.0 Hz, 1H, H3), 8.34 (m, 3H, H1,6), 7.85 (t, J = 6.4 Hz, 1H, H7), 6.33 (s, 6H, H9).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 156.6, 156.3, 153.3, 152.6, 142.8, 140.2, 136.8,
128.2, 125.0, 124.1, 87.2.
MS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C16H16ClN3O2RuS, 450.9; found, 450.0.
EA Anal. calcd for C16H16Cl2N3O2RuS ·
1
5H2O ·
3
20ACN: C, 39.17%; H, 3.42%; N, 9.14%.
Found: C, 39.29%; H, 3.24%; N, 9.03%.
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[(η6-C6H6)Ru(4)Cl]Cl (9)
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Following procedure 1 (section 4.3.1), compound 9 was obtained as a yellow solid (112 mg,
0.2 mmol, 67%).
Annex spectra page: 235
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 10.77 (d, J = 9.9 Hz, 1H, H4), 9.13 (dd, J = 5.7,
1.5 Hz, 2H, H9), 8.40 (d, J = 8.5 Hz, 2H, H2), 8.12 (td, J = 7.6, 1.3 Hz, 2H, H6), 8.02 (m,
4H, H3,7), 7.63 (s, 2H, H1), 7.58 (ddd, J = 7.4, 5.7, 1.5 Hz, 2H, H8), 6.98 (d, J = 9.9 Hz,
1H, H5), 6.20 (s, 6H, H10).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 166.4, 157.6, 157.5, 147.3, 140.3, 135.9, 128.9,
125.8, 124.5, 122.1, 86.9, 59.2.
HRMS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C24H22ClN4O3RuS, 583.0144; found, 583.0139.
EA Anal. calcd for C24H22Cl2N4O3RuS ·
5
4H2O: C, 44.97%; H, 3.85%; N, 8.74%. Found:
C, 44.73%; H, 3.76%; N, 9.28%.
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[(η6-p-Cymene)Ru(4)Cl]Cl (10)
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Following procedure 1 (section 4.3.1), compound 10 was obtained as a yellow solid (122 mg,
0.2 mmol, 64%).
Annex spectra page: 237
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 10.89 (d, J = 9.9 Hz, 1H,H4), 9.02 (d, J = 5.8 Hz,
2H, H9), 8.43 (d, J = 8.2 Hz, 2H, H2), 8.12 (t, J = 7.8 Hz, 2H, H7), 8.04 (d, J = 8.2 Hz,
4H, H6,3), 7.60 (m, 4H, H1,8), 6.89 (d, J = 9.5 Hz, 1H, H5), 6.10 (d, J = 6.1 Hz, 2H, H12),
5.95 (d, J = 6.1 Hz, 2H, H11), 2.99 (q, J = 6.9 Hz, 1H, H13), 2.08 (d, J = 5.1 Hz, 3H, H10),
1.18 (d, J = 6.8 Hz, 6H, H14).
13C NMR (126 MHz, DMSO-d6, 20 ◦C, δ): 166.5, 157.2, 147.3, 140.3, 135.8, 129.1, 125.8,
124.7, 122.3, 106.1, 100.0, 85.0, 84.9, 58.9, 30.4, 22.1, 17.5.
HRMS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C28H30ClN4O3RuS, 639.0770; found, 639.0767.
EA Anal. calcd for C28H30Cl2N4O3RuS ·
3
2H2O: C, 46.73%; H, 4.90%; N, 7.79%. Found:
C, 46.81%; H, 4.71%; N, 8.18%.
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[(η6-C6Me6)Ru(4)Cl]Cl (11)
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Following procedure 1 (section 4.3.1), compound 11 was obtained as a yellow solid (125 mg,
0.2 mmol, 66%).
Annex spectra page: 239
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 10.68 (d, J = 10.0 Hz, 1H, H4), 8.79 (d,
J = 5.0 Hz, 2H, H9), 8.40 (d, J = 8.4 Hz, 2H, H2), 8.12 (t, J = 7.8 Hz, 2H, H7), 8.04
(d, J = 8.4 Hz, 2H, H3), 7.98 (d, J = 8.1 Hz, 2H, H6), 7.63 (s, 2H, H1), 7.59 (t, J = 6.6 Hz,
2H, H8), 6.34 (d, J = 9.6 Hz, 1H, H5), 2.05 (s, 18H, H10).
13C NMR (125 MHz, DMSO-d6, 20 ◦C, δ): 166.6, 156.9, 156.6, 147.3, 140.1, 135.7, 129.1,
125.8, 125.1, 122.5, 94.8, 57.7, 15.2.
HRMS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C30H34ClN4O3RuS, 667.1083; found, 667.1080.
EA Anal. calcd for C30H34Cl2N4O3RuS: C, 51.28%; H, 4.88%; N, 7.97%. Found: C, 51.19%;
H, 4.86%; N, 8.05%.
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[(η6-Biphenyl)Ru(4)Cl]Cl (12)
Ru
Cl
Cl
O
HN
4
5
N
9
87
6
N
32
S
O
O
H2N1
biph
12
Following procedure 1 (section 4.3.1), compound 12 was obtained as a brown-yellow solid
(10 mg, 0.01 mmol, 21%).
Annex spectra page: 241
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 10.59 (d, J = 9.8 Hz, 1H, H4), 8.92 (dd, J = 5.8,
1.6 Hz, 2H, H2), 8.37 (d, J = 8.4 Hz, 2H, H3), 8.04 (m, 4H, H7+biph), 7.89 (d, J = 8.1 Hz,
2H, H2), 7.78 (dd, J = 7.2, 1.7 Hz, 2H, H6), 7.62 (s, 2H, H1), 7.47 (m, 3H, Hbiph), 7.37 (dd,
J = 8.3, 6.9 Hz, 2H, H8), 6.86 (d, J = 9.6 Hz, 1H, H5), 6.68 (d, J = 6.1 Hz, 2H, Hbiph), 6.52
(t, J = 6.0 Hz, 2H, Hbiph), 6.29 (t, J = 5.9 Hz, 1H, Hbiph).
HRMS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C30H26ClN4O3RuS, 659.0457; found, 659.0441.
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[(cp*)Ir(2-picolylamine)Cl]Cl (13)
1
2
3
4
N
5
NH2 6
Ir Cl
Cl
7
13
Following procedure 2 (section 4.3.1), compound 13 was obtained as a pale orange-yellow
solid (24 mg, 0.05 mmol, 42%).
Annex spectra page: 243
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.65 (d, J = 5.4 Hz, 1H, H1), 8.03 (td, J = 7.7,
1.5 Hz, 1H, H3), 7.74 (d, J = 7.9 Hz, 1H, H4), 7.53 (d, J = 6.4 Hz, 1H, H2), 6.76 (s, 1H,
H6), 5.45 (q, J = 8.7 Hz, 1H, H6
′
), 4.47 (dd, J = 16.4, 3.4 Hz, 1H, H5), 4.12 (dd, J = 16.2,
8.4 Hz, 1H, H5
′
), 1.68 (s, 15H, H7).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 162.5, 151.4, 139.4, 125.9, 121.7, 86.6, 52.1, 8.4.
MS (ESI-MS, pos.) m/z (relative intensity): [M-Cl]+ calcd for C16H23ClIrN2, 471.1; found,
471.2 (100) [M-Cl]+, 435.2 (83) [M-2Cl-H]+.
EA Anal. calcd for C16H23Cl2IrN2 · 2H2O: C, 35.42%; H, 5.02%; N, 5.16%. Found: C, 35.37%;
H, 4.73%; N, 5.44%.
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[(cp*)Ir(4)Cl]Cl (14)
8
7
6 N
9
Ir
Cl
Cl
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5 N
N
H
4
O
3
2
S
OH2N1
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Following procedure 1 (section 4.3.1), compound 14 was obtained as a yellow solid (45 mg,
0.06 mmol, 49%).
Annex spectra page: 245
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 11.00 (d, J = 9.9 Hz, 1H, H4), 8.87 (m, 2H, H9),
8.43 (d, J = 8.5 Hz, 2H, H2), 8.17 (m, 4H, H6,7), 8.03 (d, J = 8.5 Hz, 2H, H3), 7.66 (m, 4H,
H1,8), 6.27 (d, J = 9.7 Hz, 1H, H5), 1.62 (s, 15H, H10).
13C NMR (100 MHz, DMSO-d6, 20 ◦C, δ): 166.5, 155.5, 155.4, 147.3, 141.1, 135.6, 129.1,
126.2, 125.7, 122.9, 88.8, 59.8, 8.34.
HRMS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C28H31ClIrN4O3S, 731.1; found, 731.2.
EA Anal. calcd for C28H31Cl2IrN4O3S · 2.1H2O: C, 41.80%; H, 4.41%; N, 6.96%. Found:
C, 41.43%; H, 3.97%; N, 7.06%.
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[(cp∗)Ir(3)Cl]Cl (15)
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N Ir Cl
Cl
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Following procedure 1 (section 4.3.1), compound 15 was obtained as a yellow solid (37 mg,
0.05 mmol, 54%).
Annex spectra page: 247
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 9.18 (d, J = 1.3 Hz, 1H, H6), 9.10 (d, J = 8.1 Hz,
1H, H7), 9.03 (t, J = 5.9 Hz, 2H, H4,10), 8.40 (t, J = 7.8 Hz, 1H, H8), 8.31 (d, J = 8.4 Hz,
1H,H2), 8.21 (dd, J = 6.0, 1.7 Hz, 1H,H5), 8.06 (d, J = 8.4 Hz, 2H,H3), 7.90 (t, J = 6.5 Hz,
1H, H9), 7.58 (s, 2H, H1), 1.69 (s, 15H, H11).
HRMS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C26H28ClIrN3O2S, 674.1220; found, 674.1198.
EA Anal. calcd for C26H28Cl2IrN3O2S · 2H2O: C, 41.88%; H, 4.33%; N, 5.63%. Found:
C, 41.54%; H, 4.33%; N, 5.69%.
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[(cp∗)Ir(5)Cl]Cl (16)
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5
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N
7
NH2 8
Ir Cl
Cl
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OH2N1
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Following procedure 2 (section 4.3.1), 16 was obtained as a pale orange-yellow solid (24 mg,
0.05 mmol, 42%).
Annex spectra page: 248
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.73 (d, J = 6.1 Hz, 1H, H6), 8.22 (d, J = 2.1 Hz,
1H, H4), 8.09 (d, J = 8.6 Hz, 2H, H2), 8.01 (d, J = 8.5 Hz, 2H, H3), 7.90 (dd, J = 6.2,
2.1 Hz, 1H, H5), 7.56 (b, 1H, H8), 5.53 (q, J = 9.3 Hz, 1H, H8
′
), 4.54 (dd, J = 16.2, 2.9 Hz,
1H, H7), 4.20 (dt, J = 15.2, 6.5 Hz, 1H, H7
′
), 1.72 (s, 15H, H9).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 163.3, 151.7, 148.1, 145.5, 138.3, 127.8, 126.6,
123.3, 119.2, 90.1, 86.8, 52.1, 8.4.
HRMS (ESI-MS, pos.) m/z (relative intensity): [M-Cl]+ calcd for C22H27ClIrN3O2S, 625.1;
found„ 590.2 (100) [M-2Cl-H]+, 626.2 (81) [M-Cl]+.
EA Anal. calcd for C22H27Cl2IrN3O2S · 3.3H2O: C, 36.69%; H, 4.70%; N, 5.84%. Found:
C, 36.57%; H, 4.32%; N, 5.45%.
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[(cp∗)Ir(6)Cl]Cl (17)
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Following procedure 2 (page: 130), 17 was obtained as a pale orange-yellow solid (24 mg,
0.05 mmol, 42%).
Annex spectra page: 250
1H NMR (500 MHz, DMSO-d6, 20 ◦C, δ): 8.53 (m, 1H, H4), 8.36 (t, J = 6.3 Hz, 1H, H11),
7.96 (d, J = 8.4 Hz, 2H, H2), 7.86 (d, J = 8.4 Hz, 2H, H3), 7.79 (d, J = 6.9 Hz, 2H, H9),
7.54 (m, 8H, H1,5,6,10), 4.22 (d, J = 6.2 Hz, 2H, H7), 1.63 (s, 15H, H12).
13C NMR (101 MHz, DMSO-d6, 20 ◦C, δ): 157.8, 149.6, 146.1, 144.6, 140.6, 140.3, 132.3,
129.1, 127.4, 126.5, 126.4, 120.1, 119.2, 92.1, 48.0, 8.3.
HRMS (ESI-MS, pos.) m/z : [M-2Cl-H]+ calcd for C28H31IrN3O4S2, 730.1; found, 730.2.
EA Anal. calcd for C28H31Cl2IrN3O4S2 ·
1
4CH2Cl2: C, 41.28%; H, 3.86%; N, 5.11%. Found:
C, 40.95%; H, 3.69%; N, 5.44%.
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[(cp∗)Ir(41)Cl]Cl (18)
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Following procedure 2 (section 4.3.1), K2CO3 (13 mg, 0.1 mmol, 1.0 eq) was added in the
reaction mixture, compound 18 was obtained as a pale orange-yellow solid (24 mg, 0.05 mmol,
42%).
Annex spectra page: 252
1H NMR (400 MHz, DMSO-d6, 20 ◦C, δ): 8.27 (d, J = 6.1 Hz, 1H, H6), 7.81 (s, 1H, H1),
7.67 (m, 1H, H10), 7.29 (b, 6H, H2,3,9), 6.84 (d, J = 6.8 Hz, 1H, H5), 5.14 (d, J = 16.7 Hz,
1H, H7), 4.45 (d, J = 16.6 Hz, 1H, H7
′
), 4.05 (s, 1H, H8), 1.51 (s, 15H, H11).
19F NMR (376 MHz, DMSO-d6, 20 ◦C, δ): 106.8.
HRMS (ESI-MS, pos.) m/z : [M-Cl]+ calcd for C28H29ClF2IrN3O4S2, 766.1; found, 766.1.
EA Anal. calcd for C28H30Cl2F2IrN3O4S2 · 3H2O ·K2CO3: C, 33.65%; H, 3.50%; N, 4.05%.
Found: C, 33.82%; H, 3.52%; N, 4.08%.
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4.4 General procedure for hCA II inhibition profiling
4.4.1 Esterase activity screening assay
All steady-state measurements [10,11] were performed in Tris-sulfate buffered solution (25 mM,
pH 8.0) in the presence of 5% DMSO at 25 ◦C. [12] The organic solvent ensures the solubility
of the substrate (p-nitrophenyl acetate) as well as of the molecule used as inhibitor. The
initial rates of the enzyme-catalyzed activity were measured by following the hydrolysis of the
chromogenic substrate, p-nitrophenyl acetate, at 348 nm (25 measurements over a period of
35 minutes). Experiments were carried out in triplicate for each inhibitor. Kinetic measure-
ments were performed in a total reaction volume of 300 µL (in Tris-sulfate buffered solution),
containing 0.5 mM p-nitrophenyl acetate and different concentrations of inhibitors.
The initial rates of enzyme catalysis were determined using the linear maximum slopes
(first 10 min, 5 points) of the reaction traces measured by the plate reader. For comparison
of the inhibition data, the initial rates were translated into % activity as a function of the
inhibitor concentration. The inhibition data were analyzed via equation 4.1 [10]
v =
voKi
Ki + {[I]t − 0.5(A −
√
A2 − 4[I]t[E]t)}
(4.1)
A = [I]t + [E]t +Ki
with vo being the initial velocity of the enzyme-catalyzed reaction in the absence of in-
hibitor, Ki the inhibition constant, [E]t the total concentration of the enzyme and [I]t the
total concentration of the inhibitor.
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4.4.2 Competitive displacement assay
Competitive displacement of fluorescent hCA II inhibitor, dansylamide (DNSA), was used
to determine the dissociation constant of strong inhibitors. DNSA is “nonfluorescent” in
aqueous solution but in the presence of hCA II an increase of fluorescence signal can be
observed at 470 nm. The dissociation constant (Kd) of screening hits were determined using a
modification of the method proposed by Tripp. [13–15] Black flat-bottom 96-well plates (NUNC
F96 MicroWell Plates) with excitation at 280 nm, and detection at 470 nm were used. The Kd
for DNSA was determined by titrating hCA II (100 nM) with DNSA (between 100 and 0.05
µM) in a total volume of 208 µL. The equilibrium dissociation constant for DNSA (KDNSA)
was then determined by fitting data to equation 4.2
Ftot =
Fobs − Fini
Fend − Fini
=
1
1 + (KDNSA/[DNSA])
(4.2)
where Ftot is the total fluorescence, Fini is the initial fluorescence of hCA II in the absence
of DNSA and Fend is the end point of fluorescence. The equilibrium dissociation constants for
inhibitors were determined by competitive displacement of DNSA. A fixed concentration of
DNSA (2.25 µM) and hCA II (100 nM) was titrated against different inhibitor concentrations
(from 100 µM to 25 nM). Then the Kd value for each inhibitor was determined by fitting data
to equation 4.3
Ftot =
Fobs − Fini
Fend − Fini
=
1
1 + (KDNSA/[DNSA])(1 + [I]/Kd)
(4.3)
were Ftot is the fraction of total fluorescence, Fobs is the fluorescence signal at each con-
centration of inhibitor, Fini is the initial fluorescence of hCA II without DNSA and Fend is
the end point of fluorescence.
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4.5 General procedure for circular dichroism measurements
4.5.1 Sample preparation and data analysis
Each measurement were obtained at 25 ◦C with a time constant of 2.5 s and a step resolution
of 1 nm. The ellipticity was reported as mean residue molar ellipticity ([Θ], deg cm2 dmol−1)
calculated from equation 4.4
[Θ]mrv = [Θ]obs/10crln (4.4)
were [Θ]obs is the measured ellipticity in degrees, cr is the protein concentration (in mol/L,
hCA II=29098 g/mol), l is the optical path length of the cell (in cm) and n is the number
of protein residues (259 amino acids for hCA II). For the analysis of hCA II scaffold stability
in the presence of organic solvent, a quartz cell with a path length of 1 cm was used. A
solution containing approximately 1 mg/mL of hCA II in 50 mM phosphate buffer (pH 7.4),
with different DMSO percentages (0 to 50% (v/v)) was measured.
Circular dichroism spectra were also measured under catalysis conditions. hCA II (1 mg/mL)
was dissolved (cell path length = 0.1 cm) in MOPS 1.2 mM buffer and 3 M sodium formate
(pH 7.5 and 5% DMSO (v/v)).
145
Chapter 4. Experimental section
4.6 Catalytic experiments: transfer hydrogenation
Lyophilized hCA II corresponding to 0.4 mM final concentration of free binding sites (2.5 mg)
was weighed into vials. The reaction buffer (MOPS 1.2 mM buffer, 3 M sodium formate,
pH 7.5, 200 µL) was added, and the mixture was stirred until all the protein was dissolved.
The metal complex stock solution was added (final concentration 0.3 mM; 0.8 equivalents [Ru]
or [Ir] vs. hCA II free binding sites), and the mixture was stirred for 30 minutes. Finally,
the substrate stock solution was added (4 µL, final concentration 20 mM). The tubes were
placed in a magnetically stirred multireactor, and were heated up to 40 ◦C if required. [16]
4.7 Sample work up and analysis
4.7.1 1-Methyl-6,7-dimethoxy-3,4-dihydroisoquinoline
To the catalysis reaction an aqueous solution of NaOH (60 µL, 20%) was added, before extrac-
tion with CH2Cl2 (2 x 1 mL). The extracts were dried over Na2SO4, and analyzed by chiral
HPLC (Daicel IC 250 x 4.6 mm, 5 µm; CH2Cl2/iPrOH/HNEt2, 98/2/0.06, 1 mL/min, 25
◦C,
280 nm). TR 9.6 min (R)-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, 11.9 min
1-Methyl-6,7-dimethoxy-3,4-dihydroisoquinoline, 15.4 min (S )-6,7-dimethoxy-1-methyl-1,2,3,4-
tetrahydroisoquinoline. The response factor used for the conversion determination is 1.9 at
280 nm. [16]
4.7.2 1-Methyl-3,4-dihydroisoquinoline
To the catalysis reaction an aqueous solution of NaOH (60 µL, 20%) was added, before extrac-
tion with CH2Cl2 (2 x 1 mL). The extracts were dried over Na2SO4, and analyzed by chiral
HPLC (Daicel IC 250 x 4.6 mm, 5 µm; n-hexane/iPrOH/HNEt2, 97/3/0.06, 1 mL/min, 25
◦C,
265 nm). TR 11.0 min (R)-1-methyl-1,2,3,4-tetrahydroisoquinoline, 12.0 min
(S )-1-methyl-1,2,3,4-tetrahydroisoquinoline, 18.9 min 1-methyl-3,4-dihydridoisoquinoline.
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4.7.3 Phenylpyrroline
To the catalysis reaction an aqueous solution of NaOH (60 µL, 20%) was added, before extrac-
tion with CH2Cl2 (2 x 1 mL). The extracts were dried over Na2SO4, and analyzed by chiral
HPLC (Daicel IC 250 x 4.6 mm, 5 µm; n-hexane/iPrOH/HNEt2, 98/2/0.06, 1 mL/min,
25 ◦C, 260 nm). TR 8.9 min 1-phenylpyrrolidine, 10.0 min 1-phenylpyrrolidine, 11.2 min
1-phenylpyrroline. The response factor used for the conversion determination is 31.6 at
260 nm.
4.7.4 2-Cyclohexylpyrrolidine
To the catalysis reaction aq. NaOH (60 µL, 20%) was added, before extraction with CH2Cl2
(1 x 1 mL). The extracts were dried over Na2SO4, and the conversion was determined in the
crude extracts by GC-FID (Agilent J&W, 30 m x 0.32 mm, 0.25 µM, 135 ◦C, isothermal,
1.7 mL/min He; injector: 250 ◦C; split 100; detector 240 ◦C). TR 4.46 min amine, 5.06 min
imine.
For ee-determination trifluoroacetic anhydride (TFAA, 200 µL) was added to the GC-
sample used for conversion determination, and volatiles were removed to near dryness in a
gentle stream of N2. The residue was dissolved in a small amount of CH2Cl2 (300 µL), and
analyzed by GC-FID on chiral stationary phase (Supelco β-DEX 325, 30 x 0.25 mm, 0.25 µm;
115 ◦C isothermal; 1.7 mL/min He; injector 250 ◦C; split 10; detector 250 ◦C) TR 44.1 (S ),
45.6 (R). [17]
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4.8 Michaelis-Menten experiments
Reaction setup [17]
Human Carbonic Anhydrase II (∼2.5 mg, final concentration: 0.4 mM hCA II) was dissolved
in a MOPS/formate solution (100 µL, pH 7.5, 0.4 mM and 3 M respectively) and [Ir] catalyst
(8.75 µL of DMSO stock solution, final concentration: 0.35 mM [Ir]) was added. The resulting
ATHase solution was mixed for 15 min at 25 ◦C (100 rpm).
Reactions were started by adding an appropriate volume of the substrate stock solution
(100 µL, final concentration between 150 and 1 mM) to the tubes. After 20, 40 and
60 minutes, respectively, reaction aliquots (50 µL) were removed and added to a gluthathione
solution (40 µL, 0.25 M) to stop the catalytic reaction.
Work up and analysis
Water (300 µL) was added to aliquots, and HPLC sample were prepared by adding 200 µL of
the previous solution in water (500 µL). Conversions were determined using an Eclipse XDB-
C18 column (5 µm, 4.6 x 150 mm) and water/MeOH/TFA 87:13:0.1 as an eluent at a flow
of 1 ml/min and 25◦C (tR 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline = 11.9 min,
tR 1-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline = 16.3 min,). The response factor used
for the conversion determination is 1.26 at 280 nm.
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4.9 Protein purification: resin preparation
The sulfonamide ligand 4-aminomethylbenzenesulfonamide (1.5 g) was dissolved in 100 mL
of 50% acetone, and added to 125 mL of CM-BioGel A that had been washed in 50% acetone.
The pH was adjusted to 4.8 with HCl. EDAC (2.5 g in 5 mL of 50% acetone) was added
dropwise with gentle stirring. The pH was monitored during the addition and adjusted to 4.8
as necessary during the first two hours. (The pH change is rapid at first and stabilizes after
about 2 hours.) The mixture was then stirred overnight to allow coupling to complete. The
coupled gel was washed thoroughly with 50% acetone to remove excess ligand, then several
times with distilled water. After the final wash, the gel was resuspended in an equal volume
25 mM Tris, 0.25 M Na2SO4 and pH 8.3. For prolonged storage, the gel was placed at 4
◦C,
and NaN3 was added to a final concentration of 0.02%. The gel was washed, and resuspended
in azide free buffer before use. [18]
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4.10 Table of molecules
Number Structure Name
1
NN
SH2N
O
O
2,2’-bipyridine-5-sulfonamide
2 N
N
N
SH2N
O
O
4-(di-2-pyridinylamino)-
benzenesulfonamide
3
SH2N
N
N
O
O
(4-((2,2’-bipyridine)4-
yl)benzenesulfonamide
4 HN
O
S
O
O
H2N N
N
N -(di(2-pyridyl)methyl)-amidobenzene-4-
sulfonamide
5
S
O
OH3N
N
NH3
F
F
O
OF
F
F
O
OF
4-(2-(aminomethyl)pyridin-4-
yl)benzenesulfonamide, TFA salt
6
N H
N S
O
O
S
O
OH2N
N -((4-(4-sulfamoylphenyl)pyridin-2-
yl)methyl)benzenesulfonamide,
7
S
O
O
H2N
O
HN
N
N
Cl
1,3-dimesityl-5-((4-
sulfamoylbenzamido)methyl)-4,5-dihydro-
1H -imidazol-3-ium
8
NN
S
O
O
H2N
Ru
Cl Cl
[(η6-C6H6)Ru(1)Cl]Cl
9
Ru
Cl
Cl
O
HN
N
NS
O
O
H2N
[(η6-C6H6)Ru(4)Cl]Cl
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10 Ru
Cl
Cl
O
HN
N
NS
O
O
H2N
[(η6-p-cymene)Ru(4)Cl]Cl
11 Ru
Cl
Cl
O
HN
N
NS
O
O
H2N
[(η6-C6Me6)Ru(4)Cl]Cl
12 Ru
Cl
Cl
O
HN
N
NS
O
O
H2N
[(η6-biphenyl)Ru(4)Cl]Cl
13
N
NH2
Ir Cl
Cl
[(cp*)Ir(2-picolylamine)Cl]Cl
14
N Ir
Cl
Cl
N
N
H
O
S
OH2N
O
[(cp*)Ir(4)Cl]Cl
15
N Ir Cl
Cl
S
O
OH2N
N
[(cp∗)Ir(3)Cl]Cl
16
N
NH2
Ir Cl
Cl
S
O
OH2N
[(cp∗)Ir(5)Cl]Cl
17
N
NH
Ir Cl
Cl
S
O
OH2N
S
O
O [(cp
∗)Ir(6)Cl]Cl
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18
N
NH
Ir Cl
Cl
S
O
OH2N
S
O
O F
F
[(cp∗)Ir(41)Cl]Cl
19 N
NH
O
O
O
O
(R)-thalidomide
20 N
NH
O
O
O
O
(S)-thalidomide
21 Rh
Cl
Ph3P
PPh3
PPh3
Wilkinson’s catalyst
22
P
PH3CO
OCH3 DIPAMP
23
N
NN
N
O NH2
F3C
F
F
F
3-amino-1-[5,6-dihydro-3-
(trifluoromethyl)-1,2,4-triazolo[4,3-
a]pyrazin-7(8H )-yl]-4-(2,4,5-
trifluorophenyl)-2-buten-1-one
24
N
NN
N
O NH2
F3C
F
F
F
sitagliptin
25
N
NN
N
O O
F3C
F
F
F
prositagliptin ketone
26
Ru
OC CO
Ph
Ph
Ph
OPh H
Ru
COOC
Ph
Ph
Ph
O Ph
H
Shvo’s diruthenium catalyst
27
N
RO2S
N
RuII Cl
H
H
Rn
Noyori’s ruthenium (II) based catalyst
28 N
MeO
MeO
R
-
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29 ∗ NH
MeO
MeO
R
-
30
TsHN NH2
SO3NaNaO3S
2,2’-[(1R,2R)-1-amino-2-[[(4-
methylphenyl)sulfonyl]amino]-1,2-
ethanediyl]bis-benzenesulfonic acid
disodium salt
31
TsHN NH2
OO
= polymer support
-
32
SHN
OO
H
N
N -(2-pyrrolidinylmethyl)-
benzenesulfonamide
33
NN
2,2’-bipyridine
34
N NH
N
N -2-pyridinyl-2-pyridinamine
35 N
HN S
OO
N -(2-pyridinylmethyl)-
benzenesulfonamide
36 NH2
NH M
Ts
L O
Arene
H
O
-
37 NH2
MN O
AreneTs
O
H -
39 N
MeO
MeO
6,7-diethoxy-1-methyl-3,4-
dihydroisoquinoline
38 ∗ NH
MeO
MeO
racemic salsolidine
40
O
N
H
S
O
OH2N
N -benzyl-4-sulfamoylbenzamide
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41
N H
N S
O
O F
FS
O
OH2N
2,6-difluoro-N -((4-(4-
sulfamoylphenyl)pyridin-2-
yl)methyl)benzenesulfonamide
42
O
N
H
S
O
OH2N
N -(4-methylbenzyl)-4-
sulfamoylbenzamide
43
O
N
H
S
O
OH2N
F
N -(4-fluorobenzyl)-4-sulfamoylbenzamide
44
O
N
H
S
O
OH2N F
F
F
N -(4-(trifluoromethyl)benzyl)-4-
sulfamoylbenzamide
45
O
N
H
S
O
OH2N
F
F
N -(2,3-difluorobenzyl)-4-
sulfamoylbenzamide
46
NN
SHO
O
O
2,2’-bipyridine-5-sulfonic acid
47
N
Br
2-bromopyridine
48 S NH2 4-(methylmercapto)aniline
49 N
N
N
S N -(4-(methylthio)phenyl)-N -(pyridin-2-
yl)pyridine-2-amine
50 N
N
N
S
O
O
N -(4-(methylsulfonyl)phenyl)-N -(pyridin-
2-yl)pyridine-2-amine
51 N
N
N
S
O
O
Si
N -(pyridine-2-yl)-N -(4-((2-
(trimethylsilyl)ethyl)sulfonyl)phenyl)pyridin-
2-amine
52
S N
N
O
O
(4-(4-(methylthio)phenyl)-2,2’-bipyridine
53 N
O
2-acetylpyridine
54
S
O
H 4-(methylthio)benzaldehyde
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55
S
O
N
(E )-3-(4-(methylthio)phenyl)-1-(pyridin-
2-yl)prop-2-en-1-one
56
S
O
N
O
2-(6-ethoxy-4-(4-(methylthio)phenyl)-5,6-
dihydro-2H-pyran-2-yl)pyridine
57
S N
N
(4-(4-(methylsulfonyl)phenyl)-2,2’-
bipyridine
58
S N
N
O
OSi
(4-(4-((2-(trimethylsilyl)ethyl)sulfonyl)phenyl)-
2,2’-bipyridine
59 S
O
OH
O
O
H2N 4-carboxybenzenesulfonamide
60
NH2
NN
bis(pyridine-2-yl)methanamine
61 O
O
S
O
O
H2N
N
O
O
2,5-dioxopyrrolidin-1-yl-4-
sulfamoylbenzoate
62
N N
N OH
di-2-pyridyl ketoxime
63 S B
O
O
H2N
OH
OH
4-aminosulfonylphenylboronic acid
64
N
Cl
4-chloro-2-pyridinecarbonitrile
65
S
O
OHN
N
N
N -(tert-butyl)-4-(2-cyanopyridin-4-
yl)benzenesulfonamide
66
S
O
OHN
N H
N
O
O
N -(tert-butyl)-4-(2-
(aminomethyl)pyridin-4-
yl)benzenesulfonamide
67
N
Br
4-bromo-2-methylpyridine
68
N O
Br
4-bromo-2-methylpyridine-N -oxide
155
Chapter 4. Experimental section
69
N
OH
Br
4-bromo-2-hydroxymethylpyridine
70
N HN
Br
S
O
O
N -[(4-bromopyridin-2-
yl)methyl]benzenesulfonamide
71 N HN
Br
S
O
O
F
F
N -[(4-bromopyridin-2-yl)methyl]-2,6-
difluorobenzene-1-sulfonamide
72
N
NBr OH
4-bromo-2-pyridine ketoxime
73
N
O
Br
4-bromo-2-pyridine aldehyde
74
S
O
O
HN
O
HN
N
N
Cl
5-((4-(N -(tert-
butyl)sulfamoyl)benzamido)methyl)-1,3-
dimesityl-4,5-dihydro-1H-imidazol-3-ium
chloride
75
N N
Ru
NHBoc
Cl
Cl
O
-
76
N N
Ru
NH
Cl
Cl
O
O
S
O
O NH2
-
77
H2N
HN
H
N
N,N ’-dimesitylpropane-1,2,3-triamine
78
S
O
O
HN
O
O N
O
O
2,5-dioxopyrrolidin-1-yl-4-(N -(tert-
butyl)sulfamoyl)benzoate
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79 S
O
O
HN
O
OH
4-(N -(tert-butyl)sulfamoyl)benzoic acid
80
Br
H3N
Br
Br
1,2-dibromo-ethanamine
81 H2N 2,4,6-trimethylaniline
82 SCl
O
O O
OH
4-(chlorosulfonyl)benzoic acid
83
S
O
O
HN
O
HN
NH
NH
N -(2,3-bis(mesitylamino)propyl)-4-(N -
(tert-butyl)sulfamoyl)benzamide
84 S
O
O
H2N benzenesulfonamide
85 S
O
O
H2N p-toluenesulfonamide
86 S
O
O
H2N F 4-fluorobenzenesulfonamide
87 S
O
O
H2N
F
F
F 4-(trifluoromethyl)benzenesulfonamide
88
O
O N 3,4-dihydro-6,7-dimethoxy-1-phenyl-
isoquinoline
89 N 3,4-dihydro-1-methyl-isoquinoline
90 N 5-cyclohexyl-3,4-dihydro-2H -pyrrole
91
N
NH2 2-picolylamine
92 Ru
Cl
Cl
Ru
Cl
Cl
[(η6-C6Me6)RuCl2]2
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2,2’-Bipyridine-5-sulfonic acid (46)
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4 Origin Bruker Analytik GmbH
5 Owner icon
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8 Author
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10 Temperature 300.0
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14 Receiver Gain 16384
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2,2’-Bipyridine-5-sulfonamide (1)
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N -(4-(Methylthio)phenyl)-N -(pyridin-2-yl)pyridine-2-amine (49)
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N -(4-(Methylsulfonyl)phenyl)-N -(pyridin-2-yl)pyridine-2-amine (50)
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11 Pulse Sequence zg30
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15 Relaxation Delay 2.2000
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17 Acquisition Time 1.3042
18 Acquisition Date 2010-03-13T03:20:17
19 Modi,cation Date 2010-03-13T03:20:19
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1582.9
23 Nucleus 13C
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25 Spectral Size 65536
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N -(Pyridine-2-yl)-N -(4-((2-(trimethylsilyl)ethyl)sulfonyl)phenyl)pyridin-2-amine (51)
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19 Modication Date 2010-04-09T19:12:36
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1677.3
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 32768
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Parameter Value
1 Data File Name / home/ fabien/ Documents/ 
nmr/ fabien.194/ 2/ d
2 Title fabien.194/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM174
_C13cpd CDCl3 uicon fabien 
50
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 8192
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-04-09T21:09:12
19 Modication Date 2010-04-09T22:09:15
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1529.6
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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4-(Di-2-pyridinylamino)-benzenesulfonamide (2)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.320/ 1/ d
2 Title fabien.320/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM176
_Proton CDCl3ME uicon 
fabien 38
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3ME
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2011-01-24T13:40:06
19 Modication Date 2011-01-24T13:40:09
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1677.3
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 32768
0102030405060708090100110120130140150160170
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.195/ 3/ d
2 Title fabien.195/ 3
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM176
_C13cpd CDCl3 uicon 
fabien 50
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 16384
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-04-20T00:07:58
19 Modication Date 2010-04-20T01:08:01
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1495.9
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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(E )-3-(4-(Methylthio)phenyl)-1-(pyridin-2-yl)prop-2-en-1-one (55)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.207/ 1/ 0d
2 Title fabien.207/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM209
_Proton DMSO uicon 
fabien 14
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 128
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2010-06-03T18:10:53
19 Modi0cation Date 2010-06-03T18:10:56
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1670.9
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.207/ 2/ )d
2 Title fabien.207/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM209
_C13cpd DMSO uicon 
fabien 14
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 8192
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-06-04T20:34:22
19 Modi)cation Date 2010-06-04T20:34:26
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1582.6
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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2-(6-Ethoxy-4-(4-(methylthio)phenyl)-5,6-dihydro-2H-pyran-2-yl)pyridine (56)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.307/ 1/ 3d
2 Title fabien.307/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM309
_Proton MeOH uicon fabien 
27
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent MeOH
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 128
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2010-11-25T15:54:43
19 Modi3cation Date 2010-11-25T15:54:46
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1675.7
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.307/ 2/ )d
2 Title fabien.307/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM309
_C13cpd MeOH uicon 
fabien 27
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent MeOH
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 8192
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-11-27T02:01:48
19 Modi)cation Date 2010-11-27T02:01:52
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1395.8
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 06/14/10 17:01:36FM000171.d
AdministratorOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name FM196
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
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(4-(4-(Methylthio)phenyl)-2,2’-bipyridine (52)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.212/ 1/ ,d
2 Title fabien.212/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM212-cris
_Proton CDCl3 uicon fabien 
22
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2010-06-10T04:31:07
19 Modi,cation Date 2010-06-10T04:31:11
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1677.7
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.213/ 1/ 'd
2 Title fabien.213/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM212
_C13cpd CDCl3 uicon 
fabien 21
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 8192
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-06-11T04:13:43
19 Modi'cation Date 2010-06-11T04:13:45
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1523.0
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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(4-(4-(Methylsulfonyl)phenyl)-2,2’-bipyridine (57)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.216/ 1/ -d
2 Title fabien.216/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Experiment FM213
_Proton CDCl3 uicon 
fabien 49
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2010-06-11T11:41:47
19 Modi-cation Date 2010-06-11T11:41:50
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1678.1
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.221/ 1/ 'd
2 Title fabien.221/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM213
_C13cpd CDCl3 uicon 
fabien 49
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 1024
14 Receiver Gain 11585
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-06-13T15:51:15
19 Modi'cation Date 2010-06-13T15:51:19
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1522.8
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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(4-(4-((2-(Trimethylsilyl)ethyl)sulfonyl)phenyl)-2,2’-bipyridine (58)
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
44-17-08-zimbron/ 1/ 1d
2 Title 44-17-08-zimbron
3 Comment FM252
PROTON CDCl3 u500 
zimbron 44
4 Origin Bruker BioSpin GmbH
5 Owner start
6 Site
7 Spectrometer drx500
8 Author
9 Solvent CDCl3
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 45
15 Relaxation Delay 1.0000
16 Pulse Width 6.5000
17 Acquisition Time 3.1720
18 Acquisition Date 2010-08-17T08:33:00
19 Modi1cation Date 2010-08-17T08:36:17
20 Spectrometer 
Frequency
500.13
21 Spectral Width 10330.6
22 Lowest Frequency -2100.2
23 Nucleus 1H
24 Acquired Size 32768
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.249/ 2/ 'd
2 Title fabien.249/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM252
_C13cpd CDCl3 uicon 
fabien 59
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 11585
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-08-17T03:39:36
19 Modi'cation Date 2010-08-17T03:39:39
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1525.3
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
181
Annexes
182
(4-((2,2’-Bipyridine)4-yl)benzenesulfonamide (3)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.267/ 1/ /d
2 Title fabien.267/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM261
_Proton DMSO uicon fabien 
6
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2010-09-14T00:04:20
19 Modi/cation Date 2010-09-14T00:04:23
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1670.9
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.267/ 2/ )d
2 Title fabien.267/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM261
_C13cpd DMSO uicon fabien 
6
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 1024
14 Receiver Gain 10321
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-09-14T01:07:37
19 Modi)cation Date 2010-09-14T01:07:39
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1581.7
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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184
Bis(pyridine-2-yl)methanamine (60)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.115/ 2/ d
2 Title fabien.115/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM34
Experiment extraction
_Proton CDCl3 uicon 
fabien 23
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 128
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2009-01-08T19:08:01
19 Modication Date 2009-01-08T20:08:04
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest 
Frequency
-1677.7
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 32768
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N -(Di(2-pyridyl)methyl)-amidobenzene-4-sulfonamide (61)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.185/ 1/ d
2 Title fabien.185/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM24
_Proton DMSO uicon fabien 
51
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 128
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2010-02-02T03:38:10
19 Modication Date 2010-02-02T03:38:13
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1670.5
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 32768
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P aram eter Value
1 Data File Nam e / hom e/ fabien/ 
Docum ents/ nm r/ 
fabien.185/ 2/ fid
2 Tit le fabien.185/ 2
3 Com m ent U ser/ Group 
Fabien_Monnard/ Ward
Sam ple FM24
_C13cpd DMSO uicon 
fabien 51
4 Origin Bruker Analytik Gm bH
5 Owner icon
6 Site
7 Spectrom eter dpx400
8 Author
9 Solvent DMSO
10 Tem perature 300.0
11 P ulse Sequence zgdc30
12 Experim ent 1D
13 Num ber of Scans 384
14 Receiver Gain 8192
15 Relaxation Delay 2.2000
16 P ulse Width 9.9000
17 Acquisit ion Tim e 1.3042
18 Acquisit ion Date 2010-02-02T04:02:21
19 Modification Date 2010-02-02T04:02:25
20 Spectrom eter 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1579.0
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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N -(Di(2-pyridyl)methyl)-amidobenzene-4-sulfonamide (4)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
16-09-07-zimbron/ 1/ fid
2 Title 16-09-07-zimbron
3 Comment FM229
PROTON DMSO u500 
zimbron 16
4 Origin Bruker BioSpin GmbH
5 Owner start
6 Site
7 Spectrometer drx500
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 81
15 Relaxation Delay 1.0000
16 Pulse Width 6.5000
17 Acquisition Time 3.1720
18 Acquisition Date 2010-07-09T10:28:00
19 Modification Date 2010-07-09T11:35:35
20 Spectrometer 
Frequency
500.13
21 Spectral Width 10330.6
22 Lowest Frequency -2082.3
23 Nucleus 1H
24 Acquired Size 32768
25 Spectral Size 32768
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
16-09-07-zimbron/ 2/ d
2 Title 16-09-07-zimbron
3 Comment FM229
C13CPD DMSO u500 
zimbron 16
4 Origin Bruker BioSpin GmbH
5 Owner start
6 Site
7 Spectrometer drx500
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 1024
14 Receiver Gain 10321
15 Relaxation Delay 2.0000
16 Pulse Width 15.0000
17 Acquisition Time 1.0912
18 Acquisition Date 2010-07-09T11:26:00
19 Modication Date 2010-07-09T11:35:36
20 Spectrometer 
Frequency
125.77
21 Spectral Width 30030.0
22 Lowest Frequency -2496.6
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 32768
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13 march SN 6181
D:\giese\user\Ward\Fabien\fm229_0001.dat
Acquired: 10:18:00, July 09, 2010 Printed: 10:21, July 09, 2010
Mode of operation: Reflector
Extraction mode: Delayed
Polarity: Positive
Acquisition control: Manual
Accelerating voltage: 20000 V
Grid voltage: 75%
Mirror voltage ratio: 1.12
Guide wire 0: 0.1%
Extraction delay time: 50 nsec
Acquisition mass range: 200 -- 800 Da
Number of laser shots: 200/spectrum
Laser intensity: 1730
Laser Rep Rate: 20.0 Hz
Calibration type: External -- D:\giese\user\Calibration\porph_pos.cal
Calibration matrix: 2,5-Dihydroxybenzoic acid
Low mass gate: Off
Timed ion selector: Off
Digitizer start time: 14.3005
Bin size: 0.5 nsec
Number of data points: 28303
Vertical scale 0: 500 mV
Vertical offset: 0.5%
Input bandwidth 0: 500 MHz
Sample well: 34
Plate ID: PLATE1
Serial number: 6181
Instrument name: Voyager-DE PRO
Plate type filename: C:\VOYAGER\100 well plate.plt
Lab name: Dep. Chemie
Absolute x-position: 17934
Absolute y-position: 33060.5
Relative x-position: 1106.48
Relative y-posititon: 992.96
Shots in spectrum: 200
Source pressure: 8.146e-007
Mirror pressure: 2.583e-007
TC2 pressure: 0.006484
TIS gate width: 8
TIS flight length: 687.7
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N -Benzyl-4-sulfamoylbenzamide (40)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.540/ 1/ /d
2 Title fabien.540
3 Comment FM522
_Proton_16 DMSO / opt/ 
topspin fabien 47
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.1
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-03-15T08:59:00
19 Modi/cation Date 2012-03-15T08:59:29
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.5
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.545/ 1/ )d
2 Title fabien.545
3 Comment fm522
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 43
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 298.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-03-17T10:49:00
19 Modi)cation Date 2012-03-17T10:49:10
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2009.2
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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N -(4-Methylbenzyl)-4-sulfamoylbenzamide (42)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.542/ 1/ /d
2 Title fabien.542
3 Comment fm518
_Proton_16 DMSO / opt/ 
topspin fabien 42
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-03-16T09:30:00
19 Modi/cation Date 2012-03-16T09:30:17
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.5
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.546/ 1/ )d
2 Title fabien.546
3 Comment FM518
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 37
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-03-22T04:32:00
19 Modi)cation Date 2012-03-22T04:32:53
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2007.5
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Annexes
N -(4-Fluorobenzyl)-4-sulfamoylbenzamide (43)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.544/ 2/  d
2 Title fabien.544.2. d
3 Comment FM519
_1H{19F} DMSO / opt/ 
topspin fabien 20
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 298.0
11 Pulse Sequence zgh gqn
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 179
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9661
18 Acquisition Date 2012-03-16T15:21:00
19 Modi cation Date 2012-03-16T15:21:25
20 Class
21 Spectrometer 
Frequency
400.13
22 Spectral Width 8333.3
23 Lowest 
Frequency
-1668.4
24 Nucleus 1H
25 Acquired Size 16384
26 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.544/ 5/ )d
2 Title fabien.544
3 Comment FM519
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 20
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 298.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-03-16T21:16:00
19 Modi)cation Date 2012-03-16T21:16:34
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2007.2
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ Documents/ 
nmr/ fabien.544/ 3/ &d
2 Title fabien.544
3 Comment FM519
_19F{1H} DMSO / opt/ 
topspin fabien 20
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 298.1
11 Pulse Sequence zgfhigqn.2
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.5000
16 Pulse Width 13.0000
17 Acquisition Time 1.3982
18 Acquisition Date 2012-03-16T15:23:00
19 Modi&cation Date 2012-03-16T15:23:30
20 Spectrometer 
Frequency
376.46
21 Spectral Width 93750.0
22 Lowest Frequency -84524.8
23 Nucleus 19F
24 Acquired Size 131072
25 Spectral Size 262144
195
Annexes
N -(4-(Trifluoromethyl)benzyl)-4-sulfamoylbenzamide (44)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
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Parameter Value
1 Data File Name / home/ fabien/ Servers/ 
nmr/ ward/ data/ zimbron/ 
nmr/ zimbron-.079/ 1/ 1d
2 Title zimbron-.079
3 Comment User zimbron
Group ward
FM520
H1 DMSO / opt/ topspin 
zimbron 57
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 7.3000
17 Acquisition Time 2.0000
18 Acquisition Date 2012-03-28T08:33:00
19 Modi1cation Date 2012-03-28T08:36:44
20 Spectrometer 
Frequency
500.13
21 Spectral Width 8012.8
22 Lowest Frequency -509.3
23 Nucleus 1H
24 Acquired Size 16025
25 Spectral Size 32768
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Parameter Value
1 Data File Name / home/ fabien/ Servers/ 
nmr/ ward/ data/ zimbron/ 
nmr/ zimbron-.079/ 2/ ,d
2 Title zimbron-.079
3 Comment User zimbron
Group ward
FM520
C13cpd DMSO / opt/ 
topspin zimbron 57
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 14.0000
17 Acquisition Time 1.5000
18 Acquisition Date 2012-03-28T08:46:00
19 Modi,cation Date 2012-03-28T08:49:13
20 Spectrometer 
Frequency
125.77
21 Spectral Width 29761.9
22 Lowest Frequency -2362.3
23 Nucleus 13C
24 Acquired Size 44641
25 Spectral Size 131072
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.552/ 2/ &d
2 Title fabien.552
3 Comment FM520
_19F{1H} DMSO / opt/ 
topspin fabien 4
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgfhigqn.2
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.5000
16 Pulse Width 13.0000
17 Acquisition Time 1.3982
18 Acquisition Date 2012-03-23T15:42:00
19 Modi&cation 
Date
2012-03-23T15:42:35
20 Spectrometer 
Frequency
376.46
21 Spectral Width 93750.0
22 Lowest 
Frequency
-84524.8
23 Nucleus 19F
24 Acquired Size 131072
25 Spectral Size 262144
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Annexes
N -(2,3-Difluorobenzyl)-4-sulfamoylbenzamide (45)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.355/ 1/ fid
2 Title fabien.355
3 Comment FM375
_Proton_16 DMSO / opt/ 
topspin fabien 40
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 297.1
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-05-20T11:01:00
19 Modification Date 2011-05-20T12:01:16
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.5
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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13C NMR (101 MHz, DMSO) δ 165.36, 146.44, 136.84, 128.61, 128.49, 127.98, 125.67, 124.73, 124.69, 124.64, 124.57, 116.11, 115.94, 40.15, 39.94, 39.73, 39.52, 39.31, 39.10, 38.89, 36.46.
Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.355/ 2/ fid
2 Title fabien.355
3 Comment FM375
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 40
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 297.8
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2011-05-21T03:13:00
19 Modification Date 2011-05-21T03:12:54
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest 
Frequency
-2006.4
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
198
-220-200-180-160-140-120-100-80-60-40-20020
f1 (ppm)
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
-1
4
4
.6
0
-1
4
4
.5
4
-1
3
9
.7
5
-1
3
9
.6
9
Parameter Value
1 Data File Name / home/ fabien/ Documents/ 
nmr/ fabien.355/ 4/ fid
2 Title fabien.355
3 Comment FM375
_19F{1H} DMSO / opt/ 
topspin fabien 40
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 297.4
11 Pulse Sequence zgfhigqn.2
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.5000
16 Pulse Width 13.0000
17 Acquisition Time 1.3982
18 Acquisition Date 2011-05-21T03:17:00
19 Modification Date 2011-05-21T04:16:56
20 Spectrometer 
Frequency
376.46
21 Spectral Width 93750.0
22 Lowest Frequency -84524.8
23 Nucleus 19F
24 Acquired Size 131072
25 Spectral Size 65536
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Annexes
N -(tert-Butyl)-4-(2-cyanopyridin-4-yl)benzenesulfonamide (65)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.373/ 1/ fid
2 Title fabien.373
3 Comment Fm395
_Proton_16 DMSO / opt/ 
topspin fabien 6
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 297.2
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-06-15T17:40:00
19 Modification Date 2011-06-15T18:39:55
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.9
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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P aram eter Value
1 Data File Nam e / hom e/ fabien/ 
Docum ents/ nm r/ 
fabien.364/ 2/ fid
2 Tit le fabien.364
3 Com m ent Fm 385
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 1
4 Origin Bruker BioSpin Gm bH
5 Owner icon
6 Site
7 Spectrom eter spect
8 Author
9 Solvent DMSO
10 Tem perature 297.8
11 P ulse Sequence zgpg30
12 Experim ent 1D
13 Num ber of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 P ulse Width 8.5000
17 Acquisit ion Tim e 1.3632
18 Acquisit ion Date 2011-06-01T20:51:00
19 Modification Date 2011-06-01T21:51:09
20 Spectrom eter 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2007.3
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 32768
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Annexes
N -(tert-Butyl)-4-(2-(aminomethyl)pyridin-4-yl)benzenesulfonamide (66)
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Parameter Value
1 Data File Name / home/ fabien/ Servers/ 
nmr/ ward/ data/ zimbron/ 
nmr/ zimbron-.062/ 1/ !d
2 Title zimbron-.062
3 Comment User zimbron
Group ward
FM484
H1 CDCl3 / opt/ topspin 
zimbron 57
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 7.3000
17 Acquisition Time 2.0000
18 Acquisition Date 2012-01-30T10:13:00
19 Modi!cation Date 2012-01-30T10:15:50
20 Spectrometer 
Frequency
500.13
21 Spectral Width 8012.8
22 Lowest Frequency -518.8
23 Nucleus 1H
24 Acquired Size 16025
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
zimbron-.062/ 4/ fid
2 Title zimbron-.062
3 Comment User zimbron
Group ward
FM484
C13cpd CDCl3 / opt/ 
topspin zimbron 57
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 295.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 14.0000
17 Acquisition Time 1.5000
18 Acquisition Date 2012-01-30T10:57:00
19 Modification Date 2012-01-30T10:59:52
20 Spectrometer 
Frequency
125.77
21 Spectral Width 29761.9
22 Lowest Frequency -2306.2
23 Nucleus 13C
24 Acquired Size 44641
25 Spectral Size 32768
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Analysis Info
Analysis Name Acquisition Date 01/25/12 13:43:40FM000013.d
AdministratorOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name fm484
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 47.8  Trap Drive122.4 VoltCapillary Exit
AveragesAccumulation Time off  36 µs 5 Spectra Auto MS/MS
0.025 0.050 0.075 0.100 0.125 0.150 0.175 0.200 Time [min]
3.50
3.75
4.00
4.25
4.50
8x10
Intens.
FM000013.d: TIC ±All
364.2
420.2
861.4
All, 0.0-0.2min (#3-#22)
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6
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Intens.
100 200 300 400 500 600 700 800 900 m/z
420.2
442.2
All, 0.0-0.2min (#3-#22)
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Intens.
400 410 420 430 440 m/z
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Analysis Info
Analysis Name Acquisition Date 06/09/11 17:33:52FM000004.d
CarstenOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name FM393
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 36.1  Trap Drive110.7 VoltCapillary Exit
AveragesAccumulation Time off  1023 µs 5 Spectra Auto MS/MS
0.02 0.04 0.06 0.08 0.10 0.12 0.14 Time [min]
2.02
2.04
2.06
2.08
7x10
Intens.
FM000004.d: TIC ±All
264.1
All, 0.0-0.2min (#2-#17)
0.0
0.5
1.0
1.5
2.0
6x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
264.1
268.1
282.2 286.0
All, 0.0-0.2min (#2-#17)
0.0
0.5
1.0
1.5
2.0
6x10
Intens.
250 255 260 265 270 275 280 285 290 m/z
Display Report
Bruker Daltonics DataAnalysis 3.0 Page 1 of 106/09/11 17:35:58printed:
204
4-Bromo-2-methylpyridine-N -oxide (68)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.583/ 1/ -d
2 Title fabien.583
3 Comment 560
_Proton_16 DMSO / opt/ 
topspin fabien 47
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-05-09T17:43:00
19 Modi-cation Date 2012-05-09T17:43:50
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.5
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ Documents/ 
nmr/ fabien.583/ 2/ )d
2 Title fabien.583
3 Comment 560
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 47
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-05-09T22:22:00
19 Modi)cation Date 2012-05-09T22:22:33
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2009.2
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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4-Bromo-2-hydroxymethylpyridine (69)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
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Parameter Value
1 Data File Name / home/ fabien/ Documents/ 
nmr/ fabien.621/ 1/ *d
2 Title fabien.621
3 Comment FM586
_Proton_16 CDCl3 / opt/ 
topspin fabien 28
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-06-05T16:55:00
19 Modi*cation Date 2012-06-05T16:55:56
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1650.8
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.454/ 2/ fid
2 Title fabien.454
3 Comment FM454
_13Ccpd_ns256 CDCl3 / 
opt/ topspin fabien 45
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2011-12-06T19:19:00
19 Modification Date 2011-12-06T19:20:24
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -1945.1
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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4-Bromo-2-pyridine aldehyde (73)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.590/ 1/ *d
2 Title fabien.590
3 Comment FM564
_Proton_16 CDCl3 / opt/ 
topspin fabien 44
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 295.9
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-05-14T08:45:00
19 Modi*cation Date 2012-05-14T08:45:57
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1650.6
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
0102030405060708090100110120130140150160170180190200
f1 (ppm)
-100
0
100
200
300
400
500
600
700
800
900
1000
7
6
.8
4
 C
D
C
l3
7
7
.1
6
 C
D
C
l3
7
7
.4
8
 C
D
C
l3
1
2
5
.2
8
1
3
1
.0
8
1
3
4
.3
4
1
5
1
.0
1
1
5
3
.7
5
1
9
2
.1
7
Parameter Value
1 Data File Name / home/ fabien/ Documents/ 
nmr/ fabien.588/ 2/ 'd
2 Title fabien.588
3 Comment FM564
_13Ccpd_ns256 CDCl3 / opt/ 
topspin fabien 36
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-05-11T20:25:00
19 Modi'cation Date 2012-05-11T20:25:50
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -1944.1
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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4-Bromo-2-pyridine ketoxime (72)
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Parameter Value
1 Data File 
Name
/ home/ fabien/ 
Documents/ 
university/ unibas/ 
phd/ nmr/ fabien.598/ 
1/ 0d
2 Title fabien.598
3 Comment FM568
_Proton_16 DMSO / 
opt/ topspin fabien 20
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse 
Sequence
zg30
12 Experiment 1D
13 Number of 
Scans
16
14 Receiver Gain 212
15 Relaxation 
Delay
1.0000
16 Pulse Width 8.5000
17 Acquisition 
Time
1.9999
18 Acquisition 
Date
2012-05-15T18:22:00
19 Modi0cation 
Date
2012-05-15T18:22:18
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest 
Frequency
-1644.9
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.598/ 2/ )d
2 Title fabien.598
3 Comment FM568
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 20
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-05-16T00:10:00
19 Modi)cation Date 2012-05-16T00:11:05
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2006.6
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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N -[(4-Bromopyridin-2-yl)methyl]benzenesulfonamide (70)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.659/ 1/ -d
2 Title fabien.659.1.-d
3 Comment FM609b
_Proton_16 CDCl3 / opt/ 
topspin fabien 43
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-06-28T16:49:00
19 Modi-cation Date 2012-06-28T16:49:58
20 Class
21 Spectrometer 
Frequency
400.13
22 Spectral Width 8223.7
23 Lowest Frequency -1651.2
24 Nucleus 1H
25 Acquired Size 16446
26 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.659/ 2/ *d
2 Title fabien.659.2.*d
3 Comment FM609b
_13Ccpd_ns256 CDCl3 / 
opt/ topspin fabien 43
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-06-29T02:01:00
19 Modi*cation Date 2012-06-29T02:02:09
20 Class
21 Spectrometer 
Frequency
100.62
22 Spectral Width 24038.5
23 Lowest Frequency -1944.2
24 Nucleus 13C
25 Acquired Size 32768
26 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 06/28/12 15:25:13FM000038.d
AdministratorOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name fm609
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 41.1  Trap Drive115.7 VoltCapillary Exit
AveragesAccumulation Time off  201 µs 5 Spectra Auto MS/MS
0.02 0.04 0.06 0.08 0.10 Time [min]
0.94
0.96
0.98
1.00
8x10
Intens.
TIC ±All
159.0
329.0
351.0
426.9
467.2 676.9
All, 0.0-0.1min (#1-#13)
0
1
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4
5
6x10
Intens.
200 300 400 500 600 700 800 m/z
327.0 329.0
331.0
349.0 351.0
352.0
All, 0.0-0.1min (#1-#13)
0
1
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4
5
6x10
Intens.
325 330 335 340 345 350 355 m/z
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N -((4-(4-Sulfamoylphenyl)pyridin-2-yl)methyl)benzenesulfonamide (6)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
zimbron-.084/ 1/ 2d
2 Title zimbron-.084
3 Comment User zimbron
Group ward
FM543
H1 DMSO / opt/ topspin 
zimbron 35
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 7.3000
17 Acquisition Time 2.0000
18 Acquisition Date 2012-04-15T14:57:00
19 Modi2cation Date 2012-04-15T15:00:38
20 Spectrometer 
Frequency
500.13
21 Spectral Width 8012.8
22 Lowest Frequency -509.8
23 Nucleus 1H
24 Acquired Size 16025
25 Spectral Size 32768
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Parameter Value
1 Data File 
Name
/ home/ fabien/ 
Documents/ 
university/ unibas/ 
phd/ nmr/ 
zimbron-.084/ 3/ -d
2 Title zimbron-.084
3 Comment User zimbron
Group ward
FM543
C13cpd DMSO / opt/ 
topspin zimbron 35
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse 
Sequence
zgpg30
12 Experiment 1D
13 Number of 
Scans
256
14 Receiver Gain 197
15 Relaxation 
Delay
1.0000
16 Pulse Width 14.0000
17 Acquisition 
Time
1.5000
18 Acquisition 
Date
2012-04-15T15:13:00
19 Modi-cation 
Date
2012-04-15T15:16:50
20 Spectrometer 
Frequency
125.77
21 Spectral Width 29761.9
22 Lowest 
Frequency
-2362.5
23 Nucleus 13C
24 Acquired Size 44641
25 Spectral Size 131072
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N -[(4-Bromopyridin-2-yl)methyl]-2,6-difluorobenzene-1-sulfonamide (71)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.603/ 1/ *d
2 Title fabien.603
3 Comment FM570
_Proton_16 CDCl3 / opt/ 
topspin fabien 35
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-05-18T18:09:00
19 Modi*cation Date 2012-05-18T18:10:12
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1650.8
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.610/ 2/ *d
2 Title fabien.610
3 Comment FM570
_13Ccpd_ns256 CDCl3 / 
opt/ topspin fabien 57
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 512
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-05-24T21:59:00
19 Modi*cation Date 2012-05-24T22:00:00
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -1944.2
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.603/ 3/ )d
2 Title fabien.603
3 Comment FM570
_19F{1H} CDCl3 / opt/ 
topspin fabien 35
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgfhigqn.2
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.5000
16 Pulse Width 13.0000
17 Acquisition Time 1.3982
18 Acquisition Date 2012-05-18T18:14:00
19 Modi)cation Date 2012-05-18T18:14:54
20 Spectrometer 
Frequency
376.46
21 Spectral Width 93750.0
22 Lowest Frequency -84524.8
23 Nucleus 19F
24 Acquired Size 131072
25 Spectral Size 262144
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2,6-Difluoro-N -((4-(4-sulfamoylphenyl)pyridin-2-yl)methyl)benzenesulfonamide (41)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.633/ 2/ 0d
2 Title fabien.633
3 Comment FM595
_1H{19F} MeOD / opt/ 
topspin fabien 59
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent MeOD
10 Temperature 300.0
11 Pulse Sequence zgh0gqn
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9661
18 Acquisition Date 2012-06-09T12:08:00
19 Modi0cation Date 2012-06-09T12:09:10
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8333.3
22 Lowest Frequency -1673.0
23 Nucleus 1H
24 Acquired Size 16384
25 Spectral Size 32768
1H NMR (400 MHz, Methanol­d4) δ 
8.47 (d, J = 5.3 Hz, 1H), 8.03 (d, J = 
8.5 Hz, 2H), 7.80 (d, J = 8.5 Hz, 2H), 
7.75 – 7.72 (m, 1H), 7.52 (dd, J = 5.3, 
1.9 Hz, 1H), 7.49 (t, J = 8.5 Hz, 1H), 
6.98 (d, J = 8.6 Hz, 2H), 4.47 (s, 3H), 
1.19 (s, 2H).
-220-210-200-190-180-170-160-150-140-130-120-110-100-90-80-70-60-50-40-30-20-1001020
f1 (ppm)
-20
0
20
40
60
80
100
120
140
160
180
200
220
240
260
280
- 1
0
8
.6
7
Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.633/ 3/ &d
2 Title fabien.633
3 Comment FM595
_19F{1H} MeOD / opt/ 
topspin fabien 59
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent MeOD
10 Temperature 300.0
11 Pulse Sequence zgfhigqn.2
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.5000
16 Pulse Width 13.0000
17 Acquisition Time 1.3982
18 Acquisition Date 2012-06-09T12:11:00
19 Modi,cation Date 2012-06-09T12:11:26
20 Spectrometer 
Frequency
376.46
21 Spectral Width 93750.0
22 Lowest Frequency -84524.8
23 Nucleus 19F
24 Acquired Size 131072
25 Spectral Size 262144
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Analysis Info
Analysis Name Acquisition Date 06/08/12 11:53:57FM000034.d
AdministratorOperatorMethod Copy of wdw127-4.MS
Instrument esquire3000plus_01096Sample Name FM592
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 49.3  Trap Drive123.9 VoltCapillary Exit
AveragesAccumulation Time off  71 µs 5 Spectra Auto MS/MS
0.02 0.04 0.06 0.08 0.10 0.12 0.14 Time [min]
2.95
3.00
3.05
8x10
Intens.
FM000034.d: TIC ±All
279.1 344.3
440.1
495.2
579.2
718.1
All, 0.0-0.2min (#2-#17)
0.0
0.5
1.0
1.5
2.0
7x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
440.1
All, 0.0-0.2min (#2-#17)
0.0
0.5
1.0
1.5
7x10
Intens.
420 425 430 435 440 445 450 455 m/z
Display Report
Bruker Daltonics DataAnalysis 3.0 Page 1 of 106/08/12 11:56:30printed:
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4-(N -(tert-Butyl)sulfamoyl)benzoic acid (79)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.401/ 1/ d
2 Title fabien.401
3 Comment FM423
_Proton_16 DMSO / opt/ 
topspin fabien 27
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 297.3
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-07-27T12:07:00
19 Modication Date 2011-07-27T12:07:51
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.5
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.401/ 2/ ,d
2 Title fabien.401
3 Comment FM423
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 27
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 298.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2011-07-27T19:18:00
19 Modi,cation Date 2011-07-27T19:18:52
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest 
Frequency
-2005.9
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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2,5-Dioxopyrrolidin-1-yl-4-(N -(tert-butyl)sulfamoyl)benzoate (78)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.403/ 1/ d
2 Title fabien.403
3 Comment FM423
_Proton_16 DMSO / opt/ 
topspin fabien 42
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 297.3
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-07-28T16:43:00
19 Modication Date 2011-07-28T16:43:50
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.5
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.408/ 2/ ,d
2 Title fabien.408
3 Comment FM423
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 48
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 298.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 512
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2011-07-29T21:51:00
19 Modi,cation Date 2011-07-29T21:51:39
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2007.3
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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N,N ’-Dimesitylpropane-1,2,3-triamine (77)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.391/ 1/ d
2 Title fabien.391
3 Comment FM413
_Proton_16 DMSO / opt/ 
topspin fabien 36
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 297.3
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 31
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-07-12T08:33:00
19 Modication Date 2011-07-12T08:33:07
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.9
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.391/ 2/ d
2 Title fabien.391
3 Comment FM413
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 36
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 298.2
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 256
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2011-07-12T22:34:00
19 Modication Date 2011-07-12T22:34:37
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2006.5
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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N -(2,3-Bis(mesitylamino)propyl)-4-(N -(tert-butyl)sulfamoyl)benzamide (83)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
zimbron-.044/ 1/ d
2 Title zimbron-.044
3 Comment User zimbron
Group ward
FM427
H1 DMSO / opt/ topspin 
zimbron 56
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 7.3000
17 Acquisition Time 2.0000
18 Acquisition Date 2011-10-12T11:19:00
19 Modication Date 2011-10-12T11:21:33
20 Spectrometer 
Frequency
500.13
21 Spectral Width 8012.8
22 Lowest Frequency -508.3
23 Nucleus 1H
24 Acquired Size 16025
25 Spectral Size 32768
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
zimbron-.045/ 1/ d
2 Title zimbron-.045
3 Comment User zimbron
Group ward
FM427
C13cpd DMSO / opt/ 
topspin zimbron 59
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 512
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 14.0000
17 Acquisition Time 1.5000
18 Acquisition Date 2011-10-12T14:02:00
19 Modication 
Date
2011-10-12T14:04:30
20 Spectrometer 
Frequency
125.77
21 Spectral Width 29761.9
22 Lowest 
Frequency
-2363.0
23 Nucleus 13C
24 Acquired Size 44641
25 Spectral Size 131072
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5-((4-(N -(tert-Butyl)sulfamoyl)benzamido)methyl)-1,3-dimesityl-4,5-dihydro-1H-imidazol-
3-ium chloride (74)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
zimbron-.044/ 1/ d
2 Title zimbron-.044
3 Comment User zimbron
Group ward
FM427
H1 DMSO / opt/ topspin 
zimbron 56
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 7.3000
17 Acquisition Time 2.0000
18 Acquisition Date 2011-10-12T11:19:00
19 Modication Date 2011-10-12T11:21:33
20 Spectrometer 
Frequency
500.13
21 Spectral Width 8012.8
22 Lowest Frequency -508.3
23 Nucleus 1H
24 Acquired Size 16025
25 Spectral Size 32768
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
zimbron-.047/ 3/ d
2 Title zimbron-.047
3 Comment User zimbron
Group ward
fm443
C13cpd DMSO / opt/ 
topspin zimbron 38
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 1024
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 14.0000
17 Acquisition Time 1.5000
18 Acquisition Date 2011-10-13T19:48:00
19 Modication Date 2011-10-13T19:50:02
20 Spectrometer 
Frequency
125.77
21 Spectral Width 29761.9
22 Lowest Frequency -2362.5
23 Nucleus 13C
24 Acquired Size 44641
25 Spectral Size 131072
229
Annexes
230
[(η6-C6Me6)RuCl2]2 (92)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.178/ 1/ *d
2 Title fabien.178/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM136
_Proton CDCl3 uicon 
fabien 43
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2009-12-08T09:02:52
19 Modi*cation Date 2009-12-08T09:02:55
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1677.3
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.178/ 2/ *d
2 Title fabien.178/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM136
_C13cpd CDCl3 uicon 
fabien 43
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent CDCl3
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 16384
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2009-12-09T06:08:05
19 Modi*cation Date 2009-12-09T06:08:08
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1521.4
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 12/07/09 18:55:16FM000104.d
CarstenOperatorMethod Copy of DEFAULT.MS
Instrument esquire3000plus_01096Sample Name FM134
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 66.1  Trap Drive141.1 VoltCapillary Exit
AveragesAccumulation Time off  706 µs 5 Spectra Auto MS/MS
0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 0.18 Time [min]
2.95
3.00
3.05
3.10
7x10
Intens.
[mAU]
FM000104.d: TIC ±All
141.1
282.4
323.1
405.1 476.1 563.6 604.4 704.1 787.2
All, 0.0-0.2min (#2-#21)
0
2
4
5x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
295.1
304.4
312.1
317.2
323.1
353.3
All, 0.0-0.2min (#2-#21)
0
1
2
3
4
5x10
Intens.
290 300 310 320 330 340 350 360 m/z
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[(η6-C6H6)Ru(1)Cl]Cl (8)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.171/ 1/ 0d
2 Title fabien.171/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM129
_Proton DMSO uicon 
fabien 2
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2009-10-27T18:05:04
19 Modi0cation 
Date
2009-10-27T18:05:07
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest 
Frequency
-1678.1
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.171/ 3/ &d
2 Title fabien.171/ 3
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM129
_C13cpd DMSO uicon fabien 
2
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 384
14 Receiver Gain 16384
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2009-10-27T19:41:34
19 Modi&cation Date 2009-10-27T19:41:37
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest Frequency -1583.5
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 10/26/09 18:36:23FM000098.d
EatonOperatorMethod Copy of DEFAULT.MS
Instrument esquire3000plus_01096Sample Name FM129
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 50.0  Trap Drive124.8 VoltCapillary Exit
AveragesAccumulation Time off  542 µs 5 Spectra Auto MS/MS
0.02 0.04 0.06 0.08 0.10 0.12 0.14 Time [min]
3.6
3.7
3.8
7x10
Intens.
FM000098.d: TIC ±All
282.3 407.0
450.0
All, 0.0-0.2min (#1-#17)
0.0
0.5
1.0
1.5
2.0
6x10
Intens.
200 300 400 500 600 700 m/z
407.0
444.2
450.0
All, 0.0-0.2min (#1-#17)
0.0
0.5
1.0
1.5
6x10
Intens.
400 410 420 430 440 450 460 470 480 m/z
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[(η6-C6H6)Ru(4)Cl]Cl (9)
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.332/ 1/ 3d
2 Title fabien.332
3 Comment FM350_2
_Proton_16 DMSO / opt/ 
topspin fabien 10
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.4
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-02-25T16:14:00
19 Modi3cation Date 2011-02-25T16:14:39
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.5
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.259/ 2/ ,d
2 Title fabien.259/ 2
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM131
_C13cpd DMSO uicon 
fabien 26
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgdc30
12 Experiment 1D
13 Number of Scans 1024
14 Receiver Gain 8192
15 Relaxation Delay 2.2000
16 Pulse Width 9.9000
17 Acquisition Time 1.3042
18 Acquisition Date 2010-08-27T21:18:27
19 Modi,cation Date 2010-08-27T21:18:30
20 Spectrometer 
Frequency
100.62
21 Spectral Width 25125.6
22 Lowest 
Frequency
-1583.1
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 11/04/09 09:24:54FM000099.d
AdministratorOperatorMethod Copy of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name FM131
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 59.4  Trap Drive134.3 VoltCapillary Exit
AveragesAccumulation Time off  544 µs 5 Spectra Auto MS/MS
FM000099.d: TIC ±All
3.6
3.7
3.8
3.9
4.0
7x10
Intens.
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 Time [min]
304.3 353.3 429.3
583.1
701.5
All, 0.0-1.0min (#4-#102)
0.0
0.5
1.0
6x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
547.1 563.6 577.2
583.1
All, 0.0-1.0min (#4-#102)
0.00
0.25
0.50
0.75
1.00
1.25
6x10
Intens.
540 550 560 570 580 590 600 m/z
Display Report
Bruker Daltonics DataAnalysis 3.0 Page 1 of 111/05/09 10:03:31printed:
236
[(η6-p-cymene)Ru(4)Cl]Cl (10)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.177/ 1/ 6d
2 Title fabien.177/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM134
_Proton DMSO uicon 
fabien 31
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2009-11-16T15:00:57
19 Modi6cation 
Date
2009-11-16T15:01:01
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest 
Frequency
-1670.9
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
10-17-11-zimbron/ 2/ -d
2 Title 10-17-11-zimbron
3 Comment FM134
C13CPD DMSO u500 
zimbron 10
4 Origin Bruker BioSpin GmbH
5 Owner start
6 Site
7 Spectrometer drx500
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 1024
14 Receiver Gain 6502
15 Relaxation Delay 2.0000
16 Pulse Width 15.0000
17 Acquisition Time 1.0912
18 Acquisition Date 2009-11-17T09:55:00
19 Modi-cation Date 2010-01-05T15:47:06
20 Spectrometer 
Frequency
125.77
21 Spectral Width 30030.0
22 Lowest Frequency -2496.7
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 11/16/09 08:36:42FM000102.d
SabinaOperatorMethod Copy of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name FM134
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 64.0  Trap Drive138.9 VoltCapillary Exit
AveragesAccumulation Time off  330 µs 5 Spectra Auto MS/MS
FM000102.d: TIC ±All
5.8
6.0
6.2
6.4
7x10
Intens.
0.025 0.050 0.075 0.100 0.125 0.150 0.175 0.200 0.225 Time [min]
282.3 563.6
639.1
All, 0.0-0.2min (#1-#25)
0
1
2
3
6x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
633.4
639.1
641.0
All, 0.0-0.2min (#1-#25)
0.0
0.5
1.0
1.5
2.0
2.5
6x10
Intens.
620 630 640 650 660 670 m/z
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[(η6-C6Me6)Ru(4)Cl]Cl (11)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.327/ 1/ 4d
2 Title fabien.327
3 Comment FM137 lavage
_Proton_128 DMSO / 
opt/ topspin fabien 15
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.2
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of 
Scans
128
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-02-24T13:49:00
19 Modi4cation 
Date
2011-02-24T13:49:12
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest 
Frequency
-1640.9
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ 
university/ unibas/ 
phd/ nmr/ 4-09-12-
zimbron/ 2/ -d
2 Title 4-09-12-zimbron
3 Comment FM137
C13CPD DMSO u500 
zimbron 4
4 Origin Bruker BioSpin GmbH
5 Owner start
6 Site
7 Spectrometer drx500
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse 
Sequence
zgpg30
12 Experiment 1D
13 Number of 
Scans
1024
14 Receiver Gain 13004
15 Relaxation 
Delay
2.0000
16 Pulse Width 15.0000
17 Acquisition 
Time
1.0912
18 Acquisition 
Date
2009-12-09T23:22:00
19 Modi-cation 
Date
2010-01-05T15:47:15
20 Spectrometer 
Frequency
125.77
21 Spectral Width 30030.0
22 Lowest 
Frequency
-2494.4
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 12/08/09 15:26:02FM000105.d
CarstenOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name FM137
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 66.0  Trap Drive141.0 VoltCapillary Exit
AveragesAccumulation Time off  270 µs 5 Spectra Auto MS/MS
0.05 0.10 0.15 0.20 0.25 0.30 Time [min]
7.5
8.0
8.5
7x10
Intens.
FM000105.d: TIC ±All
323.0
667.2
All, 0.0-0.4min (#3-#37)
0
1
2
3
4
6x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
661.4
667.2
669.1
All, 0.0-0.4min (#3-#37)
0
1
2
3
6x10
Intens.
645 650 655 660 665 670 675 680 685 690 695 m/z
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[(η6-biphenyl)Ru(4)Cl]Cl (93)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.327/ 1/ 4d
2 Title fabien.327
3 Comment FM137 lavage
_Proton_128 DMSO / 
opt/ topspin fabien 15
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.2
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of 
Scans
128
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2011-02-24T13:49:00
19 Modi4cation 
Date
2011-02-24T13:49:12
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest 
Frequency
-1640.9
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ 
university/ unibas/ 
phd/ nmr/ 4-09-12-
zimbron/ 2/ -d
2 Title 4-09-12-zimbron
3 Comment FM137
C13CPD DMSO u500 
zimbron 4
4 Origin Bruker BioSpin GmbH
5 Owner start
6 Site
7 Spectrometer drx500
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse 
Sequence
zgpg30
12 Experiment 1D
13 Number of 
Scans
1024
14 Receiver Gain 13004
15 Relaxation 
Delay
2.0000
16 Pulse Width 15.0000
17 Acquisition 
Time
1.0912
18 Acquisition 
Date
2009-12-09T23:22:00
19 Modi-cation 
Date
2010-01-05T15:47:15
20 Spectrometer 
Frequency
125.77
21 Spectral Width 30030.0
22 Lowest 
Frequency
-2494.4
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 12/08/09 15:26:02FM000105.d
CarstenOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name FM137
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 66.0  Trap Drive141.0 VoltCapillary Exit
AveragesAccumulation Time off  270 µs 5 Spectra Auto MS/MS
0.05 0.10 0.15 0.20 0.25 0.30 Time [min]
7.5
8.0
8.5
7x10
Intens.
FM000105.d: TIC ±All
323.0
667.2
All, 0.0-0.4min (#3-#37)
0
1
2
3
4
6x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
661.4
667.2
669.1
All, 0.0-0.4min (#3-#37)
0
1
2
3
6x10
Intens.
645 650 655 660 665 670 675 680 685 690 695 m/z
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[(cp*)Ir(2-picolylamine)Cl]Cl (13)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.509/ 1/ d
2 Title fabien.509
3 Comment FM491
_Proton_16 DMSO / opt/ 
topspin fabien 5
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-02-08T17:24:00
19 Modication Date 2012-02-08T17:24:17
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1644.1
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.509/ 2/ d
2 Title fabien.509
3 Comment FM491
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 5
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 512
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-02-09T01:39:00
19 Modication Date 2012-02-09T01:39:34
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2004.9
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 32768
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Analysis Info
Analysis Name Acquisition Date 02/08/12 17:54:37FM000019.d
AdministratorOperatorMethod Copy of DEFAULT.MS
Instrument esquire3000plus_01096Sample Name FM491
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
2800 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 51.6  Trap Drive126.3 VoltCapillary Exit
AveragesAccumulation Time off  96 µs 5 Spectra Auto MS/MS
0.02 0.04 0.06 0.08 0.10 0.12 0.14 0.16 Time [min]
2.00
2.05
2.10
8x10
Intens.
TIC ±All
471.2
All, 0.0-0.2min (#1-#9)
0.00
0.25
0.50
0.75
1.00
1.25
7x10
Intens.
250 500 750 1000 1250 1500 1750 2000 2250 2500 m/z
435.2
463.2
471.2
499.2
All, 0.0-0.2min (#1-#9)
0.00
0.25
0.50
0.75
1.00
1.25
7x10
Intens.
420 430 440 450 460 470 480 490 m/z
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[(cp*)Ir(4)Cl]Cl (14)
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Parameter Value
1 Data File Name / home/ fabien/ Servers/ 
nmr/ ward/ data/ zimbron/ 
nmr/ zimbron-.066/ 1/  d
2 Title zimbron-.066
3 Comment User zimbron
Group ward
FM157
H1 DMSO / opt/ topspin 
zimbron 15
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 7.3000
17 Acquisition Time 2.0000
18 Acquisition Date 2012-01-31T15:57:00
19 Modi cation Date 2012-01-31T15:59:54
20 Spectrometer 
Frequency
500.13
21 Spectral Width 8012.8
22 Lowest Frequency -510.3
23 Nucleus 1H
24 Acquired Size 16025
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ Servers/ 
nmr/ ward/ data/ zimbron/ 
nmr/ zimbron-.068/ 3/ "d
2 Title zimbron-.068
3 Comment User zimbron
Group ward
FM157
C13cpd DMSO / opt/ 
topspin zimbron 19
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 512
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 14.0000
17 Acquisition Time 1.5000
18 Acquisition Date 2012-01-31T22:59:00
19 Modi"cation Date 2012-01-31T23:02:05
20 Spectrometer 
Frequency
125.77
21 Spectral Width 29761.9
22 Lowest Frequency -2363.0
23 Nucleus 13C
24 Acquired Size 44641
25 Spectral Size 32768
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Analysis Info
Analysis Name Acquisition Date 02/18/10 17:00:39Fm000150.d
SandroOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name 7FM15
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 70.8  Trap Drive145.8 VoltCapillary Exit
AveragesAccumulation Time off  267 µs 5 Spectra Auto MS/MS
0.02 0.04 0.06 0.08 0.10 0.12 0.14 Time [min]
7.5
7.6
7.7
7.8
7x10
Intens.
TIC ±All
363.1 547.2
731.2
All, 0.0-0.1min (#2-#16)
0.0
0.2
0.4
0.6
0.8
7x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
729.6
731.2
733.1
734.1
735.1
All, 0.0-0.1min (#2-#16)
0
1
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3
4
5
6
6x10
Intens.
720 725 730 735 740 745 m/z
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[(cp∗)Ir(3)Cl]Cl (15)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.270/ 1/ 4d
2 Title fabien.270/ 1
3 Comment User/ Group 
Fabien_Monnard/ Ward
Sample FM277
_Proton128 DMSO uicon 
fabien 23
4 Origin Bruker Analytik GmbH
5 Owner icon
6 Site
7 Spectrometer dpx400
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 1024
14 Receiver Gain 256
15 Relaxation Delay 1.2000
16 Pulse Width 9.2000
17 Acquisition Time 2.9688
18 Acquisition Date 2010-09-15T21:41:42
19 Modi4cation Date 2010-09-15T21:41:45
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8278.1
22 Lowest Frequency -1678.1
23 Nucleus 1H
24 Acquired Size 24576
25 Spectral Size 65536
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Annexes
[(cp∗)Ir(5)Cl]Cl (16)
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.547/ 1/ 2d
2 Title fabien.547
3 Comment FM523
_Proton_16 DMSO / opt/ 
topspin fabien 50
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 132
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-03-21T16:59:00
19 Modi2cation Date 2012-03-21T16:59:48
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1640.9
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.548/ 1/ )d
2 Title fabien.548
3 Comment FM523
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 3
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 512
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-03-23T00:19:00
19 Modi)cation Date 2012-03-23T00:19:14
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest Frequency -2005.6
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 03/22/12 08:45:39FM000026.d
MalikaOperatorMethod Copy of DEFAULT.MS
Instrument esquire3000plus_01096Sample Name FM523
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 65.6  Trap Drive140.5 VoltCapillary Exit
AveragesAccumulation Time off  84 µs 5 Spectra Auto MS/MS
0.01 0.02 0.03 0.04 0.05 0.06 Time [min]
2.45
2.50
8x10
Intens.
FM000026.d: TIC ±All
304.3 467.3 511.3 555.4
590.2
626.2
724.9 780.8 844.1 911.1
All, 0.0-0.1min (#1-#8)
0.0
0.2
0.4
0.6
0.8
7x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
588.2
590.2
597.1 609.0
624.2
626.2
628.1
634.1 644.2
All, 0.0-0.1min (#1-#8)
0
2
4
6
8
6x10
Intens.
580 590 600 610 620 630 640 m/z
Display Report
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Annexes
[(cp∗)Ir(6)Cl]Cl (17)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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Parameter Value
1 Data File Name / home/ fabien/ Documents/ 
university/ unibas/ phd/ 
nmr/ zimbron-.086/ 1/ "d
2 Title zimbron-.086.1."d
3 Comment User zimbron
Group ward
FM545
H1 DMSO / opt/ topspin 
zimbron 47
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 197
15 Relaxation Delay 1.0000
16 Pulse Width 7.3000
17 Acquisition Time 2.0000
18 Acquisition Date 2012-04-16T16:43:00
19 Modi"cation Date 2012-04-16T16:46:30
20 Class
21 Spectrometer 
Frequency
500.13
22 Spectral Width 8012.8
23 Lowest Frequency -508.3
24 Nucleus 1H
25 Acquired Size 16025
26 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ university/ 
unibas/ phd/ nmr/ 
fabien.572/ 1/ ,d
2 Title fabien.572
3 Comment FM545
_13Ccpd_ns256 DMSO / 
opt/ topspin fabien 59
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 295.9
11 Pulse Sequence zgpg30
12 Experiment 1D
13 Number of Scans 512
14 Receiver Gain 212
15 Relaxation Delay 2.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.3632
18 Acquisition Date 2012-04-18T00:02:00
19 Modi,cation 
Date
2012-04-18T00:02:20
20 Spectrometer 
Frequency
100.62
21 Spectral Width 24038.5
22 Lowest 
Frequency
-2005.7
23 Nucleus 13C
24 Acquired Size 32768
25 Spectral Size 65536
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Analysis Info
Analysis Name Acquisition Date 04/16/12 17:00:21FM000027.d
AdministratorOperatorMethod Copy(2) of E3Kp Default.ms
Instrument esquire3000plus_01096Sample Name fm545
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1500 m/z50 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 78.9  Trap Drive134.8 VoltCapillary Exit
AveragesAccumulation Time off  72 µs 5 Spectra Auto MS/MS
0.025 0.050 0.075 0.100 0.125 0.150 0.175 0.200 Time [min]
2.80
2.85
2.90
8x10
Intens.
TIC ±All
304.3 404.1 626.2
730.2
All, 0.0-0.2min (#2-#17)
0.0
0.5
1.0
1.5
2.0
7x10
Intens.
200 400 600 800 1000 1200 1400 m/z
730.2
766.1
788.1
804.1
All, 0.0-0.2min (#2-#17)
0.0
0.5
1.0
1.5
7x10
Intens.
720 730 740 750 760 770 780 790 800 m/z
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Annexes
[(cp∗)Ir(41)Cl]Cl (18)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.642/ 1/ 1d
2 Title fabien.642
3 Comment FM596
_Proton_16 DMSO / opt/ 
topspin fabien 6
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zg30
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.0000
16 Pulse Width 8.5000
17 Acquisition Time 1.9999
18 Acquisition Date 2012-06-13T13:28:00
19 Modi1cation Date 2012-06-13T13:29:09
20 Spectrometer 
Frequency
400.13
21 Spectral Width 8223.7
22 Lowest Frequency -1640.9
23 Nucleus 1H
24 Acquired Size 16446
25 Spectral Size 65536
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Parameter Value
1 Data File Name / home/ fabien/ 
Documents/ nmr/ 
fabien.642/ 3/ ,d
2 Title fabien.642
3 Comment FM596
_19F{1H} DMSO / opt/ 
topspin fabien 6
4 Origin Bruker BioSpin GmbH
5 Owner icon
6 Site
7 Spectrometer spect
8 Author
9 Solvent DMSO
10 Temperature 300.0
11 Pulse Sequence zgfhigqn.2
12 Experiment 1D
13 Number of Scans 16
14 Receiver Gain 212
15 Relaxation Delay 1.5000
16 Pulse Width 13.0000
17 Acquisition Time 1.3982
18 Acquisition Date 2012-06-13T13:33:00
19 Modi&cation 
Date
2012-06-13T13:34:01
20 Spectrometer 
Frequency
376.46
21 Spectral Width 93750.0
22 Lowest 
Frequency
-84524.8
23 Nucleus 19F
24 Acquired Size 131072
25 Spectral Size 262144
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Analysis Info
Analysis Name Acquisition Date 06/13/12 14:13:24FM000036.d
AdministratorOperatorMethod Copy of wdw130-1.MS
Instrument esquire3000plus_01096Sample Name FM596
Comment
Acquisition Parameter
off ESI  Ion Polarity Alternating Ion PolarityPositive  Ion Source Type
1000 m/z100 m/zScan BeginMass Range Mode Scan EndStd/Normal  
Skim 1 40.0 Volt 73.5  Trap Drive148.4 VoltCapillary Exit
AveragesAccumulation Time off  162 µs 5 Spectra Auto MS/MS
0.01 0.02 0.03 0.04 0.05 0.06 Time [min]
1.14
1.16
1.18
1.20
1.22
8x10
Intens.
TIC ±All
183.0 483.2 527.3 701.5
766.1
All, 0.0-0.1min (#1-#7)
0.0
0.2
0.4
0.6
0.8
1.0
7x10
Intens.
100 200 300 400 500 600 700 800 900 m/z
764.1
766.1
All, 0.0-0.1min (#1-#7)
0.0
0.2
0.4
0.6
0.8
7x10
Intens.
750 755 760 765 770 775 780 785 m/z
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Annexes
Human Carbonic Anhydrase II isozymes
Analysis Info Acquisition Date 4/27/2012 4:17:12 PM
D:\Data\GrpSchirmer\Till\livia\HCAII WT_33_01_6878.dAnalysis Name
Method Operator Administrator20kda_directtof.m
Instrument micrOTOFSample Name HCAII WT
Comment
Generic Display Report
printed: 1 of 1Page Bruker Daltonics DataAnalysis 3.3 5/4/2012 2:17:53 PM
254
Analysis Info Acquisition Date 5/16/2012 10:12:23 AM
D:\Data\GrpSchirmer\Till\elisa\hCAII H64A_24_01_6896.dAnalysis Name
Method Operator Administrator20kda_directtof.m
Instrument micrOTOFSample Name hCAII H64A
Comment
Generic Display Report
printed: 1 of 1Page Bruker Daltonics DataAnalysis 3.3 5/16/2012 12:15:10 PM
Analysis Info Acquisition Date 5/16/2012 10:29:38 AM
D:\Data\GrpSchirmer\Till\elisa\hCAII I91A_27_01_6899.dAnalysis Name
Method Operator Administrator20kda_directtof.m
Instrument micrOTOFSample Name hCAII I91A
Comment
Generic Display Report
printed: 1 of 1Page Bruker Daltonics DataAnalysis 3.3 5/16/2012 12:34:18 PM
255
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Analysis Info Acquisition Date 5/16/2012 10:47:04 AM
D:\Data\GrpSchirmer\Till\elisa\hCAII F131A_30_01_6902.dAnalysis Name
Method Operator Administrator20kda_directtof.m
Instrument micrOTOFSample Name hCAII F131A
Comment
Generic Display Report
printed: 1 of 1Page Bruker Daltonics DataAnalysis 3.3 5/16/2012 12:27:03 PM
Analysis Info Acquisition Date 5/16/2012 10:52:49 AM
D:\Data\GrpSchirmer\Till\elisa\hCAII K170A_31_01_6903.dAnalysis Name
Method Operator Administrator20kda_directtof.m
Instrument micrOTOFSample Name hCAII K170A
Comment
Generic Display Report
printed: 1 of 1Page Bruker Daltonics DataAnalysis 3.3 5/16/2012 12:59:28 PM
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Curriculum vitae
Nationality: Swiss
Date of birth: 30th of September, 1984
Education
• Oct. 2008 - Sep. 2012: Ph.D. candidate in Inorganic Chemistry, Basel/Switzerland
> Supervisor: Prof. Dr. Thomas R. Ward
• Oct. 2006 - Dec. 2007: M.Sc. in Chemistry, Basel/Switzerland
> Supervisor: Prof. Dr. Helma Wennemers
• Oct. 2003 - Oct. 2006: B.Sc. in Chemistry, Neuchâtel/Switzerland
• June 2003: Certificat de Maturité, La Chaux-de-Fonds/Switzerland
Professional experience
• March 2008: Training Course, Basel/Switzerland
> Supervisor: Dr. Jessica Bernard
Clariant Analytical Services Muttenz, Clariant AG, Basel/Switzerland
• April 2008 - Sep. 2008: Training Course, Basel/Switzerland
> Supervisor: Dr. René Hermatschweiler
Van Bearle AG, Basel/Switzerland
Other skills
• September 2011: 31th REGIO-Symposium, Sornetan/Switzerland
> Main Organiser
• Oct. 2008 - Sep. 2012: Teaching assistant
> First year Pharmaceutical Science students
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Curriculum vitae
The following lecturers contributed to my education:
University of Neuchâtel: Prof. Dr. Robert Deschenaux, Prof. Dr. Reinhard Neier,
Prof. Dr. Thomas R. Ward, Prof. Dr. Georg Süss-Fink, Prof. Dr. Raphael Tabacchi, Prof.
Dr. Thomas Bürgi, Prof. Dr. Fritz Stoeckli, Prof. Dr. Helen Stoeckli-Evans, Prof. Dr.
Piero Martinoli, Prof. Dr. François Sigrist, Prof. Dr. Martin Burkhard, Prof. Dr. Bruno
Betschart, Dr. Claude Saturnin, Dr. Sylvain Burger, M. Marc Heyraud.
University of Basel: Prof. Dr. Helma Wennemers, Prof. Dr. Markus Meuwly, Prof.
Dr. Matthias Hamburger, Prof. Dr. Angelo Vedani, Prof. Dr. Karl Gademann, Prof. Dr.
Edwin Constable, Prof. Dr. Andreas Pfaltz, Prof. Dr. Wolfgang Meier, Prof. Dr. Giese
Bernd, Prof. Dr. Thomas R. Ward, PD Dr. Daniel Häusinger.
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Cover picture: X-ray structure of [(cp∗)Ir(6)Cl]Cl ⊂ WT hCA II, PDB code 3ZP9.
